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ABSTRACT 
THE USE OF NANOPARTICLES AND ELECTROSPUN FIBERS FOR 
INTRAVAGINAL DELIVERY TO TREAT VIRAL AND BACTERIAL INFECTIONS 
AND ELECTROPHYSIOLOGICAL MEASUREMENTS OF SYNTHETIC 
CHLORIDE CHANNELS 
Farnaz Minooei 
October 28, 2020 
Female reproductive viral and bacterial infections affect millions of women 
worldwide. Given the diversity and magnitude of these unmet reproductive health 
challenges, topical administration of antiretrovirals (ARVs) and antibiotics have 
emerged as promising approaches to maintain and restore reproductive health. 
However, currently available intravaginal dosage forms often suffer from low user 
adherence and the need for frequent, daily administration to achieve therapeutic 
effect. To address these challenges, the broad goal of this research was to focus 
on the development of new localized nanoparticle (NP) and electrospun fiber 
dosage forms to prolong the delivery and enhance the efficacy of active agents to 
treat viral and bacterial infections.  
The first goal of this work was to evaluate the synergistic interactions 
between a biologic, Q-Griffithsin (Q-GRFT), and three ARVs − tenofovir 
 vi 
(TFV), raltegravir (RAL), and dapivirine (DAP) − in free and encapsulated forms, 
to identify unique protein-drug synergies to prevent human immunodeficiency virus 
type 1 (HIV-1) infection. Free Q-GRFT and free ARV co-administration resulted in 
strong synergistic interactions, relative to administration of each active agent 
alone. Similarly, Q-GRFT NP and ARV NP co-administration resulted in synergy 
across all formulations, with the most potent interactions between encapsulated 
Q-GRFT and DAP. This work suggests that Q-GRFT and ARV co-administration 
in free or encapsulated forms may improve efficacy and decrease the dose 
required to achieve prophylaxis. Moreover, the encapsulation of different active 
agents in NP-based platforms may provide modest levels of sustained-release with 
utility to a variety of agents and infection types.  
The second part of this dissertation focused on the use of molecular 
dynamics (MD) and molecular mechanics simulations to study the compatibility of 
the mentioned ARVs with PLGA NPs. Solubility parameters were calculated for 
water, polymer, and each drug individually, and were compared with those attained 
from a group-contribution method (GCM). In addition, plots of the radial distribution 
function (RDF) and calculated charges obtained from electrostatic potential (ESP) 
fitting were used to compare the interactions between each drug and the polymer. 
Results indicated stronger hydrogen bonding between RAL and PLGA compared 
to TFV and PLGA. These findings explain the experimental observation that PLGA 
NPs encapsulating RAL have significantly higher encapsulation efficiency relative 
to NPs encapsulating TFV. This result provides important insight into the role of 
 vii 
drug–polymer interactions on the encapsulation efficacy of small molecule 
antiretrovirals in polymeric NPs. 
The third goal of this dissertation was to develop a new electrospun fiber 
dosage form to promote vaginal microbiota health, with the potential to prolong 
probiotic delivery for bacterial vaginosis (BV) treatment. First, we examined the 
initial safety and efficacy of fast-dissolving polyethylene oxide (PEO) fibers 
formulated alone or with an antibiotic in an established murine model of BV 
infection. We then fabricated PEO and polyvinyl alcohol (PVA) fibers containing 
Lactobacillus acidophilus (L. acidophilus) as a model probiotic. In addition, different 
parameters including electrospinning solution, the use of fresh or lyophilized 
bacteria, and extended storage conditions were evaluated for their impact on L. 
acidophilus viability and fiber morphology. Our results show that probiotics are 
highly and viably incorporated in PEO and PVA fibers, and exhibit prolonged 
stability for up to 3 months within -20 or 4°C storage conditions. In addition, this 
study suggests that blank and antibiotic-containing PEO fibers are safe in vivo, 
inert to the vaginal mucosa in the absence and presence of Gardnerella vaginalis 
(G. vaginalis) infection, and capable of delivering effective therapeutics. In 
addition, probiotics were highly and viably incorporated in PEO and PVA fibers, 
and exhibited prolonged stability for up to 3 months within -20 or 4°C storage 
conditions. Furthermore, PEO and PVA fibers inhibited the viability and cell 
adhesion of G. vaginalis, in both soluble and epithelial-based co-culture assays, 
suggesting their ability to exert health-promoting effects against pathogenic 
species involved in BV. 
 viii 
Lastly, we sought to build upon the baseline hydrophilic rapid release fiber 
dosage form to develop a fiber-based sustained-release delivery platform to 
prolong probiotic release for up to 2 weeks. Two different fiber architectures – 
mesh and layered – were developed to incorporate two lactic acid-producing model 
organisms, Lactobacillus crispatus (L. crispatus) and Lactobacillus acidophilus (L. 
acidophilus). In this study, fiber mass loss and morphology were assessed to 
evaluate fiber degradation over 2 wk, followed by the assessment of probiotic 
release and proliferation, lactic acid release, and changes in pH. Lastly, the 
efficacy of these fibers was evaluated in an in vitro soluble co-culture assay against 
G. vaginalis infection. Both fiber architectures prolonged probiotic release for up to 
14 d and produced therapeutically-relevant levels of lactic acid, which correlated 
with a significant reduction in pH. Moreover, probiotic-containing fibers showed 
similar inhibitory properties to free probiotics against G. vaginalis, indicating that 
probiotics maintain their activity after electrospinning and have the potential to fully 
inhibit G. vaginalis infection. This study demonstrated that electrospun fibers 
composed of both hydrophilic and hydrophobic polymers may offer a viable long-
term alternative to daily administration to maintain vaginal health, treat BV, and 
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INTRODUCTION 
Human immunodeficiency virus (HIV) remains a major health challenge, 
impacting over 1.7 million people each year1,2 and over 38 million worldwide. 
Women are disproportionately affected by HIV infections, and more than half of 
the world’s infected population is comprised of women living in sub-Saharan 
Africa3. Currently, there is no cure for or effective vaccine against HIV-11, hence a 
major emphasis has been placed on developing strategies to prevent and treat 
HIV-1 infections. Furthermore, due to the increased risk of viral co-infections in 
HIV-1 infected patients, a primary focus has been to evaluate combinations of 
antiretroviral drugs delivered with multipurpose prevention technologies, to 
simultaneously target multiple sexually transmitted infections (STIs)4, such as 
herpes simplex virus 2 (HSV-2) and HIV-1. 
 Bacterial vaginosis (BV) is the most common vaginal infection in women 
between the ages of 15 to 445, impacting ~30% of women in the U.S. and globally6. 
Furthermore, bacterial vaginosis has been shown to increase the risk of HIV-1 and 
other virus acquisition in women by 60%7. In addition, women co-infected with BV 
and HIV-1 have a higher intravaginal concentration of HIV-1 RNA, relative to HIV-
1–only infected women7. In BV, the normal microbial ecology of the reproductive 
tract is altered, and resident lactobacilli are replaced by an overgrowth of 
pathogenic vaginal anaerobes such as G. vaginalis, as well as Atopobium vaginae, 
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Prevotella, Peptostreptococcus, and Bacteroides spp8-10.  Infections related to BV 
may occur due to the abundance of BV-associated bacteria or other sexually 
transmitted pathogens. Women who are infected with BV are specifically 
susceptible to the acquisition of Trichomonas vaginalis, Neisseria gonorrhoeae, 
Chlamydia trachomatis, herpes simplex virus type 2 (HSV-2), and HIV-1. 
Furthermore, studies have shown that BV can exacerbate the spread of HIV-1 and 
HSV-2 by promoting viral replication and vaginal shedding of these viruses11. 
Intravaginal delivery is an effective strategy to improve the localization of 
antiviral, antibacterial, antifungal, chemotherapeutic, and contraceptive agents 
within the female reproductive tract (FRT)12,13. Relative to oral administration 
routes, intravaginal delivery localizes agents to the FRT, avoiding both the harsh 
gastrointestinal environment and hepatic first-pass effect. This results in an 
increase in active agent bioavailability within the target tissue and corresponding 
functional activity, by decreasing off-target effects and systemic exposure14. The 
inherent characteristics of the FRT, including its large surface area and low 
enzymatic activity, additionally make the FRT a favorable site for localized active 
agent administration and targeting15,16.  
Although intravaginal delivery offers a variety of advantages to enhance the 
delivery of active agents17, challenges unique to the FRT must be overcome to 
provide efficacious prophylaxis and treatment. One of the most important 
components of the FRT is the mucus layer, which protects the epithelium and 
lamina propria from incoming pathogens. However, it can also act as a barrier, 
impeding therapeutic transport to underlying epithelial and immune cells18,19. In 
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addition to these challenges, the frequent shedding and production of 
cervicovaginal mucus can decrease active agent retention, while bacterial flora, 
enzymes, and the acidic environment created by beneficial bacteria can contribute 
to metabolization and degradation of active agents, reducing efficaciousness.  
To address these challenges, intravaginal delivery platforms have been 
formulated as solid or semi-solid dosage forms that include suppositories, tablets, 
capsules, gels, rings, and creams to enhance delivery to and retention in the 
FRT20-24. While these dosage forms have enabled high levels of active agent 
incorporation and localization, these traditionally used delivery platforms still face 
significant challenges, including difficulty of self-administration, economic 
feasibility, poor user compliance, vaginal irritation, the need for frequent 
administration, and low residence times25. Of these platforms, intravaginal rings 
have provided the “gold standard” for long-term delivery due to their ability to 
sustain the release of one or multiple active agents for weeks to months, avoid 
leakage and loss of active agent, and improve drug stability26-30. However, some 
biological agents have difficulty withstanding the high temperature and solvent 
processes often required for fabrication, limiting their incorporation31. 
More recently, nanoparticles (NPs) have been developed for topical 
intravaginal delivery of antivirals and antimicrobials due to their ability to 
encapsulate both hydrophilic and hydrophobic agents and to overcome challenges 
such as agent instability, low cellular internalization, and tissue distribution32-40. 
However, NP administration can result in low intravaginal retention due to mucus 
shedding, or conversely may be immobilized within the mucus layer, resulting in 
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inadequate transport to underlying target tissue40. To improve retention and to 
maximize transport, NPs have been surface-modified41,42, while carrier solutions 
with different osmolarities have been explored to increase retention within and 
penetration of the vaginal lumen43-45. Despite these efforts, hurdles including low 
encapsulation efficiency and rapid release of hydrophilic agents have hindered the 
ability to achieve long-term delivery and retention46. Given these issues, other 
delivery platforms have been investigated that may increase the longevity of active 
agents within the FRT and improve user adherence while also offering a new 
dosage form alternative to women.  
Electrospun fibers have emerged as a relatively new delivery platform to 
improve active agent retention and delivery for intravaginal applications due to their 
ease of use, ability to be fabricated into various geometries and sizes, and tunable 
release properties47,48. They have been considered for sustained-delivery, a 
characteristic that is often desirable for intravaginal applications, due to their high 
surface-area-to-volume ratio, degree of interconnected porosity, tunable pore 
sizes, surface-modification potential, interchangeable polymer options, and 
diverse fiber architectures that enable finer control over the rate, duration, and site 
of agent release49. Electrospun fibers have the additional advantage that they can 
be fabricated using a variety of natural or synthetic polymers to tailor release 
properties50, and these polymer types are typically selected based on their 
biocompatibility, hydrophobicity, and related degradation properties. 
The focus of this work was to develop delivery platforms comprised of 
nanoparticles and/or electrospun fibers to both enhance the efficacy of active 
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agents and provide prolonged release (here defined for durations longer than 1 
week). This dissertation includes 7 chapters that represent manuscripts that have 
been published, submitted, or will be submitted. Some content may naturally 
overlap the content of other chapters; therefore, some descriptions may be 
repeated for the sake of comprehensiveness. CHAPTER 1 comprises a review 
article which was published in Pharmaceutics and I shared co-first authorship with 
Dr. Kevin Tyo on this publication. This chapter reviews different fiber architectures 
that have been useful for active agent delivery and provides guidelines for the 
development of new formulations that exhibit release kinetics relevant to the time 
frames and the diversity of active agents needed in next-generation multipurpose 
applications. CHAPTER 2 discusses findings related to the synergistic interactions 
between ARVs and a biologic, GRFT, for HIV-1 prevention, and is in the process 
of submission. The computational study presented in CHAPTER 3 summarizes the 
study of molecular interactions between ARVs and polymeric nanoparticles and is 
in the process of submission. CHAPTER 4 presents research regarding the 
development of rapid-release probiotic fibers as an alternative dosage form for BV 
treatment. The corresponding manuscript was submitted to Science Advances. 
CHAPTER 5 describes our work to develop probiotic-containing sustained-release 
fibers for BV applications and is in preparation for submission. Lastly, CHAPTER 
6 notes previous work in which the activity of synthetic chloride channels in 
different lipid systems was evaluated. This work was published in Chemical 
Communications. The dissertation concludes with CHAPTER 7 which briefly 
 6 
summarizes the findings of the previous chapters and provides future directions 


















RELATING ADVANCED ELECTROSPUN FIBER ARCHITECTURES TO THE 
TEMPORAL RELEASE OF ACTIVE AGENTS TO MEET THE NEEDS OF 
NEXT-GENERATION INTRAVAGINAL DELIVERY APPLICATIONS 
Electrospun fibers have recently gained attention for intravaginal delivery 
due to their ease of use, ability to be fabricated into various geometries and sizes, 
and tunable release properties47,48. They have been considered for sustained-
delivery, a characteristic that is often desirable for intravaginal applications, due to 
their high surface area-to-volume ratio, degree of interconnected porosity, tunable 
pore sizes, surface-modification potential, interchangeable polymer options, and 
diverse fiber architectures that enable finer control over the rate, duration, and site 
of agent release49. Electrospun fibers have the additional advantage that they can 
be fabricated using a variety of natural or synthetic polymers to tailor release 
properties50, and these polymer types are typically selected based on their 
biocompatibility, hydrophobicity, and related degradation properties.  
One of the most significant factors that contributes to active agent release 
from fibers is the relative hydrophobicity of the selected polymer material51,52. In 
addition to polymer hydrophobicity, the medium (in vitro) or environment (in vivo) 
surrounding the fiber can impact drug release. Simulated vaginal and seminal 
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fluids, often used to preliminarily assess intravaginal release, may alter the release 
of agents relative to testing in water or phosphate buffered saline (PBS) (in vitro) 
or in vivo, due to differences in viscosity, salt, and protein concentrations, as well 
as pH. Therefore, depending on the degree of polymer hydrophobicity and the 
environment release it is tested in, the same encapsulated active agent can have 
distinctly different release profiles, in some cases ranging from hours to 
months53,54. Usually, independent of these conditions, the use of hydrophilic 
polymers often results in the immediate release of both hydrophilic and 
hydrophobic active agents due to the high solubility and degradation rate of 
hydrophilic polymers in aqueous environments55. Natural polymers such as 
collagen, gelatin, chitosan, elastin, and laminin, and synthetic polymers including 
poly(ethylene oxide) (PEO), polyvinyl alcohol (PVA), and polyvinylpyrrolidone 
(PVP) are examples of hydrophilic materials that have been fabricated into fibers 
with micron- and nanometer-scaled properties. In contrast, synthetic hydrophobic 
polymers including polycaprolactone (PCL), poly(lactic-co-glycolic acid) (PLGA), 
and polyurethane (PU) have demonstrated burst or sustained-release kinetics 
depending on the hydrophobicity of the incorporated active agent56-60. Moreover, 
synthetic hydrophobic polymers can also serve as a mechanical and structural 
basis for different fiber architectures in which the release of single or multiple 
encapsulants may be tailored by using more complex fiber designs or composites. 
Fiber release rates can also be optimized by adjusting the polymer molecular 
weight or hydrophilicity, for example, by adding hydrophilic groups such as 
aliphatic poly(phosphoester) to the polymer structure61. Together, these features 
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have enabled the incorporation and release of a variety of antiviral, antimicrobial, 
and biological agents from fiber scaffolds62-64.  
Active agent release from polymeric fibers typically occurs via diffusion, 
polymer degradation, and erosion52. When fibers are first administered, solvent or 
solution diffuses through the porous fiber matrix. Once in contact with the solvent 
or solution, the polymer matrix swells, loosening polymer chains and enabling the 
diffusion of active agents, dependent in part on molecular size. Concurrently, the 
fiber surface may undergo bulk erosion at a rate corresponding to polymer 
hydrophilicity. These features in combination with the large surface-to-volume ratio 
of the fibers allows for the increased diffusion of encapsulants relative to diffusion 
from non-porous bulk materials65. Traditionally, fibers have been electrospun as 
uniaxial fibers or fibers that comprise a single polymer or polymer blend and exhibit 
homogeneous morphology. Diffusion of active agents from more traditional 
uniaxial fibers is dependent upon the compatibility of the encapsulant, polymer, 
and surrounding eluant. In contrast with diffusion, polymer degradation is observed 
when fibers are exposed to aqueous environments, and polymer bonds are 
cleaved by either passive hydrolysis or enzymatic reaction66, resulting in slow 
degradation of the fiber scaffold. This degradation alters the distance between and 
size of interconnected pores, thereby impacting the diffusion and release of 
incorporated active agents. For most synthetic polymers, hydrolysis is the most 
common mechanism of degradation, although hydrolysis-resistant polymers have 
been utilized67, which significantly impact active agent release. As the fibers 
degrade, they can also undergo surface or bulk erosion, which is dependent upon 
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solvent diffusivity into the fiber, polymer solubility, and overall fiber matrix 
dimensions68. 
As a result of these mechanisms and the materials selected, electrospun 
fibers can tailor the release of encapsulated agents within different durations to 
achieve immediate (transient or rapid), short-term, or sustained-release. Within 
this review, we defined release as transient, when the complete release of active 
agents occurs within 24 h of administration; short-term, when the release occurs 
from one day to one week; or sustained, when the release of the active agent 
occurs over a duration of weeks to months. A schematic showing an example of 
these different potential release profiles is provided in Figure 1.1. Factors including 
the electrospinning parameters, polymer materials, fiber architecture, the resulting 
structure and morphology, and the distribution and amount of incorporated active 





Figure 1.1. Schematic depicting examples of transient, short-term, and sustained-
release profiles. 
Traditional uniaxial electrospun fibers in which each individual fiber is 
composed of a single cohesive polymer layer were the first fiber architectures to 
be fabricated69 and have been utilized in a variety of drug delivery applications 
over the past decade47,48,70-72. While uniaxial fibers offer high encapsulation 
efficiencies, cost-effectiveness, and ease of use, they have suffered from burst 
release and challenges in tailoring release properties48,53,73. These challenges are 
most evident in achieving the sustained-release of hydrophilic agents, often 
necessitating hydrophilic polymers to attain high encapsulation efficacy as well as 
hydrophobic polymers for sustained-release. More complex fiber architectures 
offer alternative options to address these limitations by combining different polymer 
types in distinct layers to modulate the release.   
While the release characteristics of traditional uniaxial electrospun fibers 
have been thoroughly reviewed in literature74-79, to our knowledge, there has not 
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yet been a review of the more advanced fiber architectures used to deliver active 
agents, nor a review that considers the impact these architectures may have on 
intravaginal delivery applications. Here, we seek to provide an overview of different 
polymer architectures including coaxial, multilayered, and nanoparticle-fiber 
composites (Figure 1.2) as a function of the materials used to construct these 
architectures that have been utilized in a diversity of health applications. We seek 
to present different material combinations in these architectures to systematically 
relate material type and fiber architecture to active agent release kinetics. Last, we 
explore how lessons derived from these different architectures might be applied in 
the context of intravaginal delivery to address the needs of future topical sustained-
release platforms for a given prophylactic or therapeutic application. The overall 
goal of this review is to provide a summary of different fiber architectures that have 
been useful for active agent delivery and to provide guidelines for the development 
of new formulations based on the knowledge obtained from previous work across 
other applications. While some of these more complex architectures have only 
recently been investigated relative to uniaxial fibers, they have demonstrated 
promise in enabling greater tunability of release and may be useful to apply as new 
dosage forms for intravaginal delivery and other similar applications. 
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Figure 1.2. Schematic of different electrospun fiber composites. Diagrams 
representing (A) traditional uniaxial fibers, (B) coaxial fibers, (C) multilayered 
fibers, and (D) nanoparticle-fiber composites. (A) Uniaxial fibers are comprised of 
a single polymer or polymer blend (shown in blue) that is distributed homogenously 
throughout the fiber structure. (B) In contrast, coaxial fibers contain both core 
(orange) and shell (blue) layers that are chemically distinct. (C) Multilayered fibers 
result from sequentially electrospinning different fiber layers together or integrating 
individual layers post-fabrication. (D) Finally, nanoparticle-fiber composites consist 
of hydrophilic or hydrophobic fibers (orange) that encapsulate nanoparticles 
(green). 
Coaxial Electrospun Fibers  
Coaxial Architectures and Properties 
Coaxial electrospinning, adapted from uniaxial or single axial 
electrospinning, provides a multicomponent fiber scaffold that easily allows the 
tunable release of active agents80,81. Coaxial fibers are usually comprised of two 
parts, an outer protective layer or shell and an inner layer or core82, where 
 14 
encapsulants are typically localized (Figures 1.3B and 1.4). Coaxial fibers can 
provide several advantages relative to uniaxially spun fibers. First, electrospinning 
the core and shell polymer solutions simultaneously through a coaxial spinneret 
allows for the design of unique fiber architectures. The thickness and ratios of the 
core and shell layers can be modulated, providing more reproducible fiber 
properties with a greater ability to alter encapsulant release relative to other 
fabrication methods. Additionally, coaxial electrospinning ensures that the active 
agent in the core phase is protected within harsh physiological environments, such 
as the female reproductive tract 64. Furthermore, a variety of materials can be used 
as either the core or shell to finely regulate encapsulant release (Figure 1.3) 80,83.  
 
Figure 1.3. Schematic of anticipated release profiles from different coaxial fiber 
architectures.  
Despite these advantages, the added complexity of simultaneously 
electrospinning two or more polymer phases and the additional interactions 
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between the core and shell solutions requires additional optimization relative to 
uniaxial electrospinning in terms of selecting compatible polymers and solvents. In 
addition to the core-shell architecture itself, the release profiles of active agents 
from coaxial fibers are impacted by solvent choice, polymer-solvent miscibility, the 
miscibility between core and shell solvents/solutions, solvent volatility, and layer 
thicknesses84,85. Solvent choice has been shown to alter fiber diameter and 
structure86, thereby impacting active agent release87. Additionally, miscible core 
and shell solvents/solutions may lead to the partial dissolution of core 
encapsulants in the shell, whereas, immiscible core and shell solvents may 
promote material delamination at the core-shell interface, facilitating burst release 
of the core encapsulant. Therefore, the polymers and solvents for both core and 
shell layers must be selected based on their individual properties as well as their 
anticipated interactions88,89. In addition, solvent volatility and evaporation rate can 
affect the distribution and subsequent release of active agents, while the thickness 
of the polymer shell, polymer composition, and spinning conditions influence 
encapsulant diffusion rates90. Here, we discuss coaxial fibers as a function of their 
core-shell design, composition, and incorporated active agents to help relate these 
considerations to the resulting transient, short-term, or sustained-release.  
Characteristics Release Kinetics from Coaxial Fibers 
Transient Release (within 24 h) 
Hydrophobic Shell—Hydrophilic Core  
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Electrospun fibers can be designed to release the active agent immediately 
or within 24 h of administration if a rapid onset of action is needed for a given 
application91. Moreover, multiple active agents can be incorporated into different 
layers of a coaxial fiber (core or shell) to provide transient release.  
For application to infectious diseases, coaxially spun fibers that 
demonstrate burst release followed by lower levels of short-term release may 
provide on-demand protection against incoming pathogens, increasing the 
immediate efficaciousness of agents by releasing initially high (burst) 
concentrations. This type of release can be achieved by employing coaxial fibers 
comprised of hydrophobic shells and hydrophilic cores. In one study, coaxial and 
triaxial fiber multi-drug delivery platforms that used PCL as the outermost shell 
released ~15% and ~80% of two different hydrophilic dyes, keyacid blue and 
keyacid uranine (KAB and KAU), from the PVP core and PCL shell fibers, 
respectively, within one hour 80. In both the coaxial and triaxial fibers, the PVP core 
containing KAB was protected by the surrounding PCL layer containing KAU, 
which helped to extend the release of the remaining KAB to 24 h. For the triaxial 
fibers, a blank PCL layer was electrospun between the outer PCL shell and the 
inner PEO core. In both the coaxial and triaxial fibers, KAU was released from the 
shell within 3 h; however, the triaxial fibers better modulated the release of KAB 
from the core, releasing 50% less during the first hour. The burst release of the 
KAU dye, observed from both coaxial and triaxial fibers, was attributed to water 
penetrating the porous fiber shell, allowing transient release. In another example 
of coaxial fiber design, water-soluble PVP was used as a core with a hydrophobic 
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ethyl cellulose (EC) shell to encapsulate hydrophobic compounds of either 
quercetin or ketoprofen. Using this architecture, ~75% of both hydrophobic 
encapsulants were released within 24 h. 
Hydrophilic Shell—Hydrophobic or Hydrophilic Cores 
Similarly, coaxial fibers that have hydrophilic shells can facilitate the rapid 
release of encapsulated agents with an initial burst release of 1 to 4 h followed by 
continued transient release within 24 h of administration. One architecture that has 
been adopted to achieve rapid- or on-demand release from coaxial fibers is a 
hydrophilic shell in combination with a hydrophilic or hydrophobic core. In one 
study, zein-PVP core-shell fibers were developed that incorporated the active 
agent in both the core (zein) and the shell (PVP) layers92. Zein, a natural, 
moderately hydrophobic polymer was used to achieve immediate and transient 
release of the hydrophobic drug, ketoprofen. A burst release of 43% was observed 
within the first hour, followed by transient release of the remaining ketoprofen over 
10 h. The initial burst release was correlated with rapid dissolution of the 
hydrophilic shell, while the more transient 10 h release was attributed to the 
hydrophobic core. In another study, the release profile of a hydrophobic drug, 
asiaticoside, was compared between coaxial fibers composed of chitosan cores 
with either a hydrophilic alginate and PVA-blended polymer shell or a hydrophobic 
centella triterpenes cream shell93. The coaxial fiber with the alginate-PVA shell 
demonstrated 80% more asiaticoside release relative to the centella control within 
10 h, which was attributed to the shell hydrophilicity93. Additionally, the trend of 
burst release followed by more gradual transient release was attributed to rapid 
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degradation of the alginate-PVA shell, followed by subsequent degradation of the 
chitosan core. While this example incorporated a polymer blend (alginate-PVA) as 
the hydrophilic shell, to be considered a core-shell structure, it should be noted 
that the material itself needs to be electrospinnable without other polymers. As this 
example demonstrates, hydrophilic polymers such as PVP, PVA, or PEO can be 
electrospun alone or in blends to create hydrophilic core and shell layers.  
Core-Shell Architectures with Similar Core-Shell Hydrophobicity 
Coaxial fibers comprised of both hydrophilic core and shell layers have also 
been investigated to provide transient release of active agents. For example, 
coaxial fibers fabricated with a hydrophilic PVP shell and hydrophilic cellulose 
acetate core were investigated. These coaxial fibers with both a hydrophilic core 
and shell released 31% of their hydrophobic encapsulant (epicatechin) within 10 
min, followed by 80% release after 4 h94.  
In addition to the utilization of materials with similar hydrophobicities, coaxial 
fibers consisting of identical core-shell materials have been fabricated to provide 
the rapid release of active agents. In one study, fibers with PVP shells and cores 
were investigated to provide rapid release of the hydrophobic drug, quercetin. The 
PVP shell-PVP core fibers released quercetin within one minute95, and this burst 
release was similarly observed in a separate study that used the same fiber 
formulation to deliver acyclovir96. In another study, the hydrophobic antibiotic, 
allyltriphenylphosphonium bromide, was incorporated within the core of coaxial 
fibers, and the volumetric ratios of core-shell solutions were varied to study 
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release. Fibers comprised of zein-zein with core-shell volume ratios greater than 
1:2 were found to suppress the burst release of the antibiotic, only releasing 15% 
within the first hour. In contrast, 35% and 45% of the antibiotic were released from 
fibers with a 1:1 core:shell volumetric ratio or blended fiber controls over the same 
duration97. In a separate study, a triaxial fiber in which all three layers were 
comprised of ethyl cellulose provided zero-order release of ketoprofen over 20 h 
due to the gradual increase in the drug content moving from shell to the core98. 
These studies highlight the role of the active agent distribution within the fiber 
layers, suggesting that encapsulant localization within the fiber core may enhance 
release.  
Finally, the release of fluorescently labeled bovine serum albumin (BSA) 
from core-shell hydrogel nanofilaments composed of a poly(lactide-co-ε-
caprolactone) (PLCL) shell and N,N-isopropylacrylamide (NIPAAm)/N,N′-
methylene bisacrylamide crosslinked core was studied. The crosslinker, N,N′-
methylene bisacrylamide, was used to polymerize NIPAAm during the 
electrospinning process. This study showed that by changing the NIPAAm-
crosslinker (w/w) ratio from 4:1 to 37:1, the release of BSA increased from 0.15 to 
0.7 ug/mg over 24 h. However, in the absence of a hydrogel within the core, BSA 
showed nearly complete release over the same duration. This study demonstrated 
that the mechanical and corresponding drug release properties could be more 
finely tailored by altering the NIPAAm-crosslinker (w/w) ratio 99.  
Stimuli-Responsive Coaxial Architectures 
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Another method to modulate the release of active agents from coaxial fibers 
is to integrate stimuli-responsive layers to precisely release agents in response to 
surrounding physiological conditions100. Unlike stimuli-responsive uniaxial fibers, 
the more complex interactions between the core and shell layers in coaxial fibers 
can provide increased control of active agent release via pH- or other stimuli-based 
mechanisms. A variety of natural and synthetic materials have been investigated 
for their use in pH-responsive applications. In one example, a coaxial fiber 
comprised of a lecithin-diclofenac sodium core and a Eudragit S100 shell provided 
the pH-responsive release of ferulic acid for 10 h101. Ferulic acid release was 
facilitated under conditions of neutral pH (pH 7), with minimal release occurring in 
a more acidic (pH 2) environment. Another pH-sensitive polymethacrylate-based 
copolymer101-103, Eudragit EPO, was used to fabricate pH-responsive antibacterial 
fibers. Here, Eudragit EPO cores, which dissolve below pH 5, were used in 
combination with Eudragit L100 shells, which dissolve at a pH greater than 6. 
These coaxial fibers provided pH-responsive release for an hour under slightly 
acidic conditions (pH 6) while demonstrating attenuated release in very acidic 
conditions (pH 2)104. Additionally, two separate studies investigated coaxial fibers 
comprised of Eudragit S100 shells and PEO cores to stimulate pH-responsive 
release within the gastrointestinal tract105,106. In both studies, the release of 
hydrophobic indomethacin and hydrophilic mebeverine hydrochloride agents was 
minimal (~10%) after 2 h under acidic conditions, followed by rapid release for 6 h 
when switched to neutral conditions (pH 7.4). Coaxial fibers comprised of cellulose 
acetate phthalate shells with polyurethane cores, as well as gelatin-sodium 
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bicarbonate shells with PLCL cores have also been used to provide similarly rapid 
pH-responsive release of ciprofloxacin and rhodamine B (Rhd B). These studies 
demonstrated the potential of coaxial fibers as pH-sensitive delivery systems107,108. 
Coaxial fibers with other stimuli-responsive properties have been 
investigated for on-demand, rapid release applications. Although studies with other 
stimuli-responsive systems have been limited, one study investigated the use of 
self-immolative polymers, or polymers that depolymerize when exposed to specific 
external stimuli, for rapid stimuli-responsive release109. In this study, self-
immolative fibers comprised of dibutyltin dilaurate and phenyl (4-
(hydroxymethyl)phenyl) carbamate were blended with polyacrylonitrile and used 
as shells to surround PVP cores. The fibers provided minimal release of KAB dye 
when incubated in water; however, the fibers depolymerized when exposed to 
trifluoroacetic acid, resulting in zero-order release of ~40% dye within a week.  
Short-Term Release (One Day to One Week) 
Hydrophobic Shell—Hydrophilic Core 
A key advantage of short-term release specifically for intravaginal delivery 
is that the burden of frequent or daily administration may decrease, thereby 
increasing user adherence of prophylactics and therapeutics. Traditionally, 
hydrophobic materials have been well-suited to provide longer durations of release 
(depending on the encapsulant) due to their decreased degradation rates in 
aqueous environments. For more traditional uniaxial hydrophobic fiber platforms, 
most hydrophobic small molecule drugs or larger macromolecules achieve release 
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for up to one week due to the similar hydrophobic properties of the polymer and 
encapsulant17. This compatibility allows for hydrophobic encapsulants to partition 
more evenly within and distribute throughout hydrophobic polymers. However, 
hydrophilic agents, which have low solubility in nonpolar polymers, often partition 
to the fiber surface, resulting in burst release and suboptimal short-term and/or 
sustained-release properties. To address this challenge, coaxial fibers in which 
hydrophilic agents are encapsulated within a hydrophilic core and surrounded by 
a protective hydrophobic shell can prolong and adjust the release of hydrophilic 
molecules.  
The use of coaxial fibers with hydrophobic shells and hydrophilic cores has 
been shown to extend the release of many encapsulants82,110,111. In one study, a 
coaxial fiber comprised of a hydrophobic ethyl cellulose shell with a hydrophilic 
PVP core was investigated for short-term release. These fibers released maraviroc 
over a duration of hours to days depending on the thickness of the hydrophobic 
shell, which was modulated via flow rate and total electrospun volume. The 
increased thickness of the hydrophobic shell extended encapsulant release from 
24 h to five days by increasing the shell-to-core volume ratio from 0.5 to 4110. In 
another study, a PCL fiber shell surrounding a PVP-graphene oxide blended core 
was studied. These fibers released 65% of hydrophilic vancomycin hydrochloride 
within 4 h and attained full release of vancomycin after 96 h112. Although this 
coaxial fiber provided short-term release, the long-term safety of graphene oxide 
within the FRT is unknown, and further studies are required to assess its safety in 
intravaginal delivery applications. Finally, a coaxial fiber composed of a synthetic 
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hydrophilic poly-cyclodextrin core and hydrophobic poly(methacrylic acid) shell 
reduced the burst release of a hydrophilic drug, propranolol hydrochloride, by 50%, 
and extended release to 180 h relative to the 140 hour release obtained from 
uniaxial fibers113.  
Hydrophobic Shell—Hydrophobic Core 
In addition to the widely used hydrophobic shell-hydrophilic core coaxial 
architectures, the use of hydrophobic materials in both the core and the shell layers 
has also been investigated to provide the short-term release of active agents. In 
one study, a PCL core surrounded by an outer PCL shell was used to prolong the 
release of the antibiotic ampicillin. Ampicillin, a hydrophilic compound, normally 
localizes to the surface of PCL when spun as a uniaxial fiber, resulting in burst 
release114. As an alternative, a 4% (w/v) PCL solution was used to fabricate an 
ultra-thin shell to delay release. In addition, the parameters for coaxial 
electrospinning were modified using dilute sheath solutions to improve the control 
of fiber diameter and morphology. The resulting coaxial fiber efficiently 
encapsulated ampicillin and provided short-term release for ~80 h 114. In another 
study, coaxial fibers comprised of a zein shell with a PCL core reduced the burst 
release of the hydrophilic antibiotic, metronidazole, achieving short-term release 
for more than four days89.  
Stimuli-Responsive Coaxial Architectures 
Coaxial fibers exhibiting stimuli-responsive properties have also been 
investigated to provide short-term release of active agents. As one example, 
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poly(N-isopropylacrylamide), a thermoresponsive polymer, was used as a core 
layer in combination with an ethyl cellulose and anhydrous ethanol shell solution. 
At room temperature, poly(N-isopropylacrylamide) exhibits hydrophilic properties; 
however, at temperatures above 32°C, the polymer demonstrates more 
hydrophobic characteristics. At room temperature and after 55 h, the fibers 
released 65% of ketoprofen in PBS, while only 40% of the same drug was released 
at 37°C115.  
Blended Polymers in Coaxial Architectures 
Another method of prolonging release is to use blended polymers to 
formulate coaxial fibers, which can decrease fiber wettability. One study combined 
gelatin, a natural hydrophilic protein, with the hydrophobic polymer, PCL, to create 
coaxial fibers with increased hydrophobicity and mechanical stability relative to 
gelatin alone116. In one study, the release of hydrophilic doxycycline was measured 
from three different fiber architectures—a uniaxial PCL-gelatin blended fiber, 
coaxial fibers with three different cores (PCL, gelatin, or a PCL-gelatin blend) and 
a PCL-gelatin blended shell, and a triaxial fiber with both a PCL-gelatin blended 
core and outer shell and an intermediate gelatin layer. Among these five designs, 
uniaxial PCL-gelatin blended fibers released the most doxycycline within 24 h 
(90%), while coaxial fibers with a PCL-gelatin core and shell released the least 
(50%). Additionally, only coaxial fibers with either a PCL-gelatin or gelatin core 
prolonged release over five days. Furthermore, the other architectures including 
the uniaxial PCL-gelatin blend, coaxial fiber with PCL core, and triaxial fibers failed 
to release doxycycline for more than 30 h. The burst release observed in fibers 
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with PCL cores was attributed to the lack of compatibility between the hydrophobic 
PCL cores and hydrophilic encapsulant, which caused doxycycline to localize on 
the core surface. Additionally, the subsequent suboptimal encapsulant release 
was attributed to low water penetration into the hydrophobic core. These studies 
demonstrate that utilization of both hydrophobic and hydrophilic polymers alone or 
as blends can modulate the short-term release of hydrophilic encapsulants due to 
the variation in the permeability of different layers and core-encapsulant 
interactions. 
Sustained-Release (One Week to Multiple Months) 
Hydrophobic Shell—Hydrophilic Core 
Similar to fibers that provide short-term release, fibers designed for 
sustained release commonly use hydrophobic polymers as the outer shell to 
prevent the fiber from undergoing rapid hydrolysis. Studies have demonstrated that 
the most promising coaxial architecture to achieve sustained-delivery utilizes a 
hydrophobic shell and hydrophilic core17. A polymer that is frequently used in 
coaxial fibers to provide sustained-release is poly(lactic-co-glycolic acid) (PLGA). 
In one study, a coaxial fiber composed of a PLGA shell was used to shield a 
hydrophilic core consisting of tragacanth gum. The encapsulant, tetracycline 
hydrochloride, served as a model hydrophilic agent. Investigators observed that 
PLGA (shell)-tragacanth gum (core) coaxial fibers diminished burst release and 
provided sustained-release of tetracycline hydrochloride for 75 days, releasing 
68% of tetracycline hydrochloride during this period117. In another study, a PLGA 
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(shell)-polyethylenimine (PEI, core) architecture was used to prolong the release 
and stability of bone morphogenetic protein-2 plasmid (pBMP2-2). The hydrophilic 
PEI core was used to encapsulate and retain the bioactivity of pBMP2-2, while the 
hydrophobic PLGA shell was used as a protective barrier to prolong release. When 
compared to uniaxial PLGA-PEI blended fibers, the PLGA (shell)-PEI (core) 
coaxial fiber exhibited both improved bioactivity and prolonged release of the 
pBMP2-2 plasmid. The coaxial fiber released 80% of the plasmid over 20 days, 
while the uniaxial fibers released the same amount over seven days118.  
Polymers other than PLGA have been used as hydrophobic shells to sustain 
the release of active agents from coaxial fibers. One study formulated coaxial 
fibers containing a hydrophilic dextran core and hydrophobic PCL shell. The 
addition of polyethylene glycol (PEG) to the PCL shell increased the release of the 
encapsulated BSA by forming pores in the shell layer. Although all fibers released 
~20% BSA within the first 24 h, increasing the PEG concentration increased the 
amount of BSA released over extended durations. Interestingly, all fibers 
demonstrated sustained-release regardless of PEG concentration; coaxial fibers 
fabricated with 5% PEG shells released ~60% BSA, while fibers containing 40% 
PEG shells released 90% BSA over 27 days119. In another study, the relationship 
between PEG (core):PCL (shell) molar ratio and the release of BSA or lysozyme 
was investigated. The thinnest shell layers with a core:shell molar ratio of 1.59 and 
a core flow rate of 2 mL/h provided complete release of both encapsulants within 
24 days, compared to only 50% release from thicker fibers with a core:shell molar 
ratio of 0.32 and a core flow rate of 0.6 mL/h. Moreover, the fibers preserved the 
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bioactivity of lysozyme and released BSA over 29 days, with no noticeable 
differences between BSA and lysozyme release rates120. In addition to 
conventional coaxial spinning, the use of emulsion electrospinning has also been 
investigated to fabricate coaxial fibers, which can be electrospun using a uniaxial 
spinneret81. One study that used emulsion electrospinning fabricated core-shell 
fibers composed of a PEG-poly(D,L-lactic acid) shell and methyl cellulose core to 
minimize the burst release of lysozyme121. The release of lysozyme from the core 
was achieved over 15 days and was dependent on the percent of lysozyme loaded, 
while the structural integrity and bioactivity of lysozyme was protected by the shell. 
A later study compared these same coaxial fibers to blended uniaxial fibers 
composed of PCL and PEG and showed that the coaxial fibers improved 
sustained-release by releasing ~50% of BSA over 35 days relative to blended 
fibers, which released ~75% BSA122.  
Another study explored the effects of multiple processing parameters, 
including PEG and PCL concentrations, PEG molecular weight, encapsulant 
concentration, and fiber diameter, in modulating the release of plasmid DNA 
(pDNA). Plasmid DNA was encapsulated in a PEI core, and a non-viral gene 
delivery vector (r-PEI-HA) was incorporated within a PCL shell123. An increase in 
fiber diameter was observed with an increase in all of the three other parameters, 
while the loading and release of r-PEI-HA were correlated to pDNA concentration 
in the fiber core and PEG molecular weight. The fibers formulated with high PEG 
molecular weight and low pDNA concentration exhibited ~30% release of r-PEI-
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HA over 60 days, while the fibers with high pDNA concentration and low molecular 
weight PEG completely released pDNA within 60 days. 
Core-Shell Architectures with the Same Core-Shell Hydrophobicity 
Although coaxial architectures with similar core and shell hydrophobicities 
have been utilized to obtain transient and short-term release, coaxial fibers that 
use the same materials have been less frequently investigated to provide 
sustained-release. In one study, PLGA was utilized in both the core and shell 
layers to investigate the effect on vancomycin and ceftazidime delivery124. Both 
hydrophilic drugs were encapsulated within the core PLGA layer and exhibited 
similar burst release kinetics within the first day, followed by a second phase of 
more gradual release over five to ten days. Ninety percent of the antibiotics were 
released after 11 days, followed by complete release after 25 days, with the more 
gradual release attributed to the PLGA barrier layer. 
Applications for Intravaginal Delivery 
The enhanced tunability and versatility provided by the core and shell layers 
of coaxial fibers make them excellent candidates for intravaginal delivery 
applications. While uniaxial fibers have been studied for sustained- and stimuli-
responsive release of active agents in the FRT17,125-130, they have faced challenges 
in providing the sustained-release of therapeutically relevant concentrations of 
individual active agents and effectively modulating the release of multiple agents 
core17. Often, compatibility between the polymer and encapsulant can pose 
challenges to achieving sustained-release with uniaxial fibers, while coaxial fibers 
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may circumvent this issue by integrating two different polymers, enabling the 
separation of agents within a compatible polymer formulation (core or shell). 
Moreover, the additional outer shell can help to modulate release. One can 
envision that with a coaxial architecture, multiple agents may be delivered against 
a particular infection to provide a synergistic effect or to provide protection against 
multiple types of viral or bacterial infections. Together, these features allow for 
enhanced tunability with the option of providing immediate to short-term release 
for on-demand applications while also providing long-term release that may be 
particularly useful in prophylactic or contraceptive applications. 
A variety of release kinetics can be attained from coaxial fibers by using 
different combinations of materials in the core and shell layers. Transient or rapid 
release of active agents is often accomplished with the use of hydrophilic polymers 
due to their rapid dissolution in aqueous environments. To achieve short-term 
release extending to one week, a hydrophilic core in combination with a 
hydrophobic shell is the most frequently used architecture, enabling the slow 
dissolution of the shell layer, which acts as a barrier to encapsulant diffusion from 
the core. For sustained-release applications that require delivery on the order of 
weeks to months, hydrophobic polymers such as PLGA and PCL are often 
selected as shell polymers due to their slower degradation kinetics and 
biocompatibility. Yet, due to the number of parameters involved in the synthesis of 
coaxial fibers, two similar architectures may still be tailored to perform very 
differently by altering physical versus chemical properties. An example may be 
seen in which fibers composed of similar or even the same polymers display very 
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different release rates due to the modulation of shell thickness. In these cases, 
thinner shells have been shown to provide more transient release, while increasing 
the shell thickness delays or alters the trend to more gradual release.  
Coaxial fibers have been investigated previously for intravaginal 
delivery107,110. In one study, maraviroc release from coaxial fibers was adjusted by 
varying the drug loading and solution flow rates to provide release over five 
days110. In addition, pH-responsive coaxial fibers have been fabricated to react in 
the presence of semen by utilizing the pH-sensitive polymer cellulose acetate 
phthalate as a shell. The outer shell dissolved immediately after exposure to PBS, 
promoting pH-responsive release of Rhd B107. 
Although coaxial fibers have shown promise in general drug and initial 
intravaginal delivery applications, further refinements are required to expand their 
overall utility. First, compatibility between the solvents of the two polymer 
electrospinning solutions may limit the potential combinations of core-shell 
materials and encapsulated agents to achieve successful electrospinning. 
Additionally, residual solvents from the electrospinning process may interact with 
and inactivate encapsulated active agents in the core layer. Therefore, while 
research in coaxial fiber design is still ongoing, other fiber architectures such as 
multilayered fibers may offer additional advantages to advance intravaginal 
delivery. 
Multilayered Electrospun Fibers 
Multilayered Fiber Architectures and Properties 
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Multilayered fibers can provide layer-by-layer delivery platforms that are 
relatively simple and inexpensive to fabricate while allowing for the encapsulation 
of different active agents within the individual layers. The topology, thickness, and 
composition of each individual layer can be easily tuned to provide different release 
properties based on the envisioned application. Moreover, multilayered fibers have 
been shown to have increased mechanical stability and flexibility compared to 
coaxial fibers131. While the interactions between two or more polymer solution 
interfaces must be considered for coaxial fibers, multilayered fibers can be 
fabricated from normally incompatible polymers due to their sequential versus 
simultaneous fabrication process.  
Electrospun multilayered fibers can be fabricated by sequential layering, 
stacking, or interweaving fibers132-134. In sequential layering, the first layer of 
polymer is electrospun onto a collector, followed by electrospinning additional 
polymer layers directly onto the same collector. In comparison, “stacking” fibers 
refers to individually electrospinning each layer separately and subsequently 
adhering individual layers together post-spin. Stacked fibers share similar physical 
properties with sequentially-layered fibers, enabling temporally-programmed or 
spatially-specific delivery of active agents135. Finally, the fabrication of interwoven 
fibers utilizes dual or multiple-syringes to simultaneously electrospin two or more 
different polymer solutions (usually one hydrophilic and hydrophobic) onto the 
same collector. In contrast to fibers produced using the sequential layering and 
stacking processes, which have distinct, separate layers of polymeric fibers, 
interwoven fibers result from the blending of these different polymer solutions from 
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syringes placed opposite of or adjacent to each other into one integrated layer136-
138. This technique seamlessly integrates both hydrophilic and hydrophobic 
polymers in a way that prevents unwanted interactions between the electrospun 
polymer solutions138,139 while enabling the porosity of the hydrophilic fibers to be 
altered to more finely tune fiber degradation140. Although interwoven fibers do not 
have a shell layer, the interwoven architecture has been beneficial in promoting 
cell adhesion and growth and has the potential to more finely modulate active 
agent release via porosity-based mechanisms for drug delivery applications141,142. 
Regardless of fabrication technique, multilayered fibers are beneficial in that 
they can temporally modulate the release of multiple agents from a single delivery 
platform and can provide additional tunability by modulating the barrier or discrete 
layers of the multilayered structure (Figure 1.4). In addition, the ability to impart 
spatially-specific release—where specific layers of the multilayered fiber possess 
distinct release profiles—is a key advantage of this architecture. This advantage 
may be envisioned for intravaginal delivery applications where one layer provides 
rapid active agent release to the mucus while another layer enables sustained-
delivery specific to underlying epithelial or immune cells132,134. For interwoven 
multilayered fibers, studies have shown that the incorporation of a hydrophilic 
polymer can alter the overall porosity and wettability140,143,144, while using a 
hydrophobic outer layer in multilayered fibers (similar to coaxial fibers) can 




Figure 1.4. Schematic of anticipated active agent release from multilayered fibers. 
One method to modulate the release of active agents (shown in green) is to vary 
the thickness of the outer layer (shown in blue). (A) A thin outer layer provides both 
rapid burst release and limited sustained-release of encapsulants. (B) In contrast, 
increased outer layer thickness can delay the release of some active agents. 
While the process of creating multilayered fibers is well established, more 
work is required to elucidate how each polymer layer impacts release kinetics. 
Physical properties including the pore size, fiber diameter, and thickness of 
traditional uniaxial fibers are known to impact the delivery kinetics of active agents 
from individual layers. Thus, the presence of one or more fiber layers can 
contribute to the complexity in establishing and predicting the release kinetics of 
diverse active agents from differently layered architectures. Despite these 
considerations and complexities, the adoption of different layering techniques to 
create multilayered fibers can achieve diverse patterns of release for transient, 
short-term, and sustained-release applications. 
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Release Kinetics from Multilayered Fibers 
Transient and Short-Term Release  
Multilayered fibers have shown promise in providing transient and short-
term release of active agents. Conventionally, a hydrophilic layer serves as a 
reservoir for active agents, while hydrophobic materials provide an outer shell layer 
to prolong release. One study utilized a multilayered fabrication approach to 
encapsulate the hydrophobic antibiotic, gentamicin, in a hydrophilic PVA center 
layer and utilized a PU outer layer to envelop the inner PVA fiber 146. Three 
separate fibers were fabricated by altering the thickness of the PU outer layer 
between 3.4 and 8.1 µm. The release of gentamicin was modulated with the 
thinnest PU layer (3.4 µm) demonstrating complete release within 1 h, relative to 
10% release obtained from the thickest layer (8.1 µm). Furthermore, the thickest 
PU layer continued to release gentamicin for 24 h. Another study using interwoven 
electrospun fibers containing PEO and PCL demonstrated that by adjusting the 
ratio of the two polymers, tunable fiber degradation could be achieved from the 
resulting changes in pore size and porosity138. Although this study investigated 
interwoven fibers to enhance cell infiltration through the pores, the use of sacrificial 
fiber layers may be applied to modulate active agent release from the fibers for 
intravaginal delivery applications138. 
In addition to modulating the outer layer thickness and overall fiber 
composition, alterations to the number of layers have been shown to impact active 
agent release. In one study, fibroin-gelatin blended uniaxial fibers exhibited release 
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of trypan blue, fluorescein isothiocyanate (FITC)-inulin, and FITC-BSA within 
minutes147. In contrast, multilayered fibers composed of the same materials 
extended the release of all three model compounds to 28 days147. In another study, 
dual-release, multilayered electrospun fibers containing the model dyes, 
5,10,15,20-tetraphenyl-21H,23H-porphinetetrasulfonic acid disulfuric acid (TPPS) 
and chromazurol B, were encapsulated in four-layered PLCL (75:25) fibers. The 
release rate and duration of the dyes were controlled by the fiber diameter and 
individual fiber layer thicknesses. Minimal release of both dyes was observed for 
the first 15 min, followed by a quasi-linear release profile for up to 4 h. However, 
increasing the thickness of dye-loaded layers resulted in higher quasi-linear 
release rates due to the reduced density of the fiber surface148. In another study, 
the transient release of ketoprofen was achieved using trilayer fibers composed of 
two EC outer layers surrounding a center PVP fiber. These fibers provided nearly 
complete release of ketoprofen within 24 h132. Last, asymmetric multilayered 
polylactide fibers with different designs on each side were fabricated to prevent 
liver cancer recurrence by promoting one-sided prolonged chemotherapeutic 
release149. The fiber was composed of five poly(lactic acid) (PLA) layers, with each 
layer serving as either a barrier to release or a drug encapsulating reservoir. In 
vivo studies in a murine model demonstrated tumor suppression for at least four 
days, indicating that the multilayered fiber may provide localized chemotherapy for 
short-term durations149.  
Multilayered fibers with stimuli-responsive properties have also been 
investigated for transient and short-term release applications. In one of the first 
 36 
studies to investigate multilayered architectures, the pH-responsive polymers, 
poly(acrylic acid) (PAA) and poly(allylamine hydrochloride) (PAH), were 
electrospun together to create a blended fiber. These fibers were loaded with a 
low molecular weight cationic molecule, methylene blue, and demonstrated rapid 
release of methylene blue (~10 min) at a neutral pH (7.4). However, by gradually 
adjusting the pH from 6 to 2 in aqueous solutions, the step-wise pH-responsive 
release of methylene blue was achieved over three and a half days. Building upon 
this work, the effect of coating the fibers with a thermoresponsive polymer blend, 
poly(N-isopropylacrylamide)-PAA, or perfluorosilane was assessed. The addition 
of the thermoresponsive poly(N-isopropylacrylamide)-PAA coating modulated 
methylene blue release via temperature. Above a critical temperature, the 
thermoresponsive polymer became insoluble and formed intramolecular hydrogen 
bonds, which led to the release of methylene blue within 50 min (PBS, pH 7.4). In 
comparison, coating with perfluorosilane modulated release for up to 20 h at 
neutral pH. When both the pH-responsive and multiple layers of thermoresponsive 
polymers were integrated and evaluated at 25 and 40°C, dye released for a 
maximum of 10 h regardless of layer thickness150.  
Sustained-Release  
The ability of multilayered fibers to provide long-term release has been 
demonstrated in a variety of studies77,78,151. In one study, the release of a 
hydrophobic chemotherapeutic agent, 7-ethyl-10-hydroxycamptothecin (SN-38), 
was prolonged to 30 days by using a triple-layered fiber in which SN-38 was 
encapsulated in the center layer and surrounded by two superhydrophobic outer 
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layers consisting of PCL and poly(glycerol monostearate-co-ε-caprolactone) 145. 
Similar to the trends seen for transient and short-term release from multilayered 
fibers, increasing the thickness of the outer fiber substantially improved the 
longevity and amount of drug released. In another study, multilayered fibers 
comprised of a PCL shell and a PEO/Rhd B core were fabricated to assess the 
effect of increasing the outer layer thicknesses between 46.1, 68.9, and 186.1 µm 
152. While the thinnest 46 µm layers released 85% of Rhd B in one day, the 68.9 
and 186.1 µm layers increased release to 15 and 25 days, respectively. Moreover, 
the release from the two fibers with the thicker outer layers demonstrated zero-
order kinetics, producing gradual, even release of drug with respect to time. 
Applications for Intravaginal Delivery 
Multilayered fibers have shown promise as a platform to co-deliver or 
prolong the release of active agents in different environments. The process of 
creating multilayered fibers is relatively simple, eliminating the more complex set-
up and considerations of polymer-solvent interactions between the adjacent, 
simultaneously spun layers present in coaxial spinning. By removing this 
complexity of interactions, multilayered fibers can achieve “programmed release” 
by simply modulating the thickness of each layer. 
Multilayered fibers possess other unique features that make them excellent 
candidates for intravaginal delivery applications. One of the unique strengths of 
multilayered fibers is that they can provide spatially-specific release in that, unlike 
other architectures, the individual layers of multilayered fibers can be designed for 
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specific and discrete purposes. For example, one layer may be designed to 
improve mucoadhesion for enhanced longevity and biocompatibility within the 
FRT, while another layer may provide release of active agents dependent on its 
location within the multilayered matrix. Compared to coaxial fibers, the optimization 
of multilayered fibers is not limited by solvent compatibility, as they can be 
sequentially spun and assembled post-fabrication. Moreover, multiple individually 
spun layers can increase the ease of encapsulating multiple types of active agents, 
which serve mechanistically different roles against a single type of viral infection 
or as a multipurpose viral-contraceptive or viral-bacterial dosage form. Finally, 
each fiber layer can be adjusted to have distinct mechanical properties that include 
tensile strength, porosity, and elasticity, important for comfort and user 
preference153. 
To date, the use of multilayered fibers for intravaginal delivery has been 
briefly explored67,110,134. In one study, circular sheets of pre-spun PVP and PVP-
EC fibers were stacked and annealed via a pressed metal die that was dipped in 
solvent. The die annealed the edges of the stacked fibers, creating a multilayered 
fiber with a PVP inner layer surrounded by blended PVP-EC sheaths. Other 
multilayered fibers were also constructed by folding the outer layers and pressing 
the seams. Both types of multilayered fibers encapsulated the hydrophilic 
compound maraviroc and provided biphasic release, exhibiting an initial burst 
release followed by short-term release for up to five days. Another study from the 
same group examined tenofovir (TFV) localization within stacked PCL/PLGA 
fibers. It was found that TFV localization within the multilayered fiber could be 
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predicted by considering the changes in polymer crystalline structure caused by 
encapsulant-polymer interactions and correlating drug-polymer hydrophilicity67. 
Both multilayered and coaxial fibers have the potential to provide tunable 
and sustained-release; however, each architecture still faces the challenges 
surrounding FRT delivery. For example, the interplay between two polymer 
solutions still needs to be considered for interwoven multilayered (and coaxial) 
fibers, which may result in challenges to altering active agent release. Additionally, 
as stated previously, the most significant obstacles to intravaginal delivery are 
providing a dosage form that can facilitate active agent penetration of mucus and 
retention and release of therapeutically relevant agent concentrations within the 
FRT. To improve retention, fibers can be fabricated using polymers or polymer 
blends that have mucoadhesive properties. However, this longevity is rarely 
translated to active agents once they have been released from fibers. Thus, new 
measures may be considered to provide efficacious and sustained-delivery from 
fibers. 
Composite Nanoparticle-Fiber Delivery Vehicles 
Nanoparticle-Fiber Architectures and Properties 
Over the past two decades, polymeric NPs have been extensively studied 
as efficacious drug delivery platforms for a variety of applications. Polymeric 
nanoparticles are an attractive option for intravaginal delivery relative to traditional 
delivery platforms such as gels and films due to the tunability of active agent 
release, ability for surface modification, potential for targeted delivery, enhanced 
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distribution potential, and the often resulting enhanced efficacy of encapsulated 
agents. Additionally, polymeric NPs have been shown to elicit minimal immune 
response and to improve the delivery and bioactivity of biologics40,154,155. Although 
metallic nanoparticles have also been explored for use in many drug delivery 
applications, they have been less commonly administered within the FRT, hence, 
a more comprehensive review of their applications may be found in156,157. 
Many physicochemical characteristics of NPs can be altered, such as 
particle size, surface charge, and hydrophobicity, which contribute to their success 
in achieving sustained-release and localization to target sites158. Although NPs 
have proven to be effective delivery platforms, as discussed in previous 
reviews159,160, achieving the prolonged release of active agents can be difficult due 
to the natural clearance mechanisms of the FRT. In particular, NPs are challenged 
with retention in the vaginal cavity due to mucus clearance and transport through 
mucus to underlying tissue39,161,162. These challenges may be overcome by 
incorporating NPs into electrospun fibers, thereby creating a composite delivery 
vehicle that complements the capabilities of both technologies. One might envision 
that fibers may act as a reservoir for NPs, improving NP and active agent retention, 
while the innate fiber porosity can help to more finely tune encapsulant release 
from NPs relative to the release observed from freely administered NPs or fibers.  
Nanoparticle-fiber composites are dual-component systems that have the 
ability to alter the release kinetics of active agents from NPs or NPs 
themselves163,164. Often, the active agent of interest is encapsulated within the 
NPs, which are then preloaded into polymer solutions for subsequent 
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electrospinning. While a variety of inorganic NPs have been incorporated into 
fibers165-167, concerns still persist regarding the safety of their use relative to 
polymeric NPs, particularly for intravaginal applications. By utilizing biocompatible 
polymeric materials for both nanoparticles and fibers, composites may provide safe 
and prolonged release for clinical applications.  
Release Kinetics from Nanoparticle-Fiber Composites 
Transient Release 
Nanoparticle-fiber composites have been used to rapidly release NPs and 
their encapsulated agents. A study was conducted with hydrophilic PVA and PEO 
fibers that incorporated PLGA NPs that contained the dye, Coumarin 6168. PEO 
fibers released 90% of NPs within 30 min when immersed in a 50:50 ethanol:PBS 
solution, followed by additional release (5%) after 3.5 h. In comparison, PVA fibers 
released approximately 70% of PLGA NPs within 30 min, followed by a decrease 
in NP release (15%) over 8 h. Slightly slower release over 24 h was observed when 
PVA fibers were crosslinked prior to NP incorporation. This study highlights that 
nanoparticle-fiber composites can be used to successfully incorporate NPs and to 
modulate the transient release of NPs from these composites within aqueous 
solutions168.  
Short-Term Release  
Several studies have utilized nanoparticle-fiber composites to provide the 
short-term release of active agents. One group explored a composite drug delivery 
system that encapsulated the antibiotic, erythromycin, in gelatin NPs and free 
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lidocaine hydrochloride within PVA-chitosan blended fibers169. Eighty percent of 
the lidocaine hydrochloride was released from the fibers within 54 h, while 70% of 
the erythromycin was released after 70 h. In contrast, free gelatin NPs released 
90% of erythromycin within the same duration. In a separate study, chitosan-PEO 
blended fibers containing methoxypolyethylene glycol (mPEG)-b-PLA micelles 
demonstrated a low initial burst release (15%) of 5-fluorouracil (5-FU), followed by 
prolonged release (91%) for 109 h170. In another study, the release of free 
hydrophobic naproxen and chitosan nanoparticles containing Rhd B was studied 
from PCL fiber scaffolds171. Rhodamine B exhibited low levels (5%) of burst 
release, while 30–40% of naproxen was released within the first 2 h. Moreover, 
after 72 h, only 20% of Rhd B was released, while 60% of naproxen was released. 
The rapid release of naproxen was achieved via incorporation within the fiber 
scaffold, while the extended release of Rhd B was obtained and enhanced through 
nanoparticle-fiber encapsulation. These results demonstrate the utility of 
nanoparticle-fiber composites in providing the short-term release of multiple 
agents.  
Sustained-Release 
Nanoparticle-fiber composites have also demonstrated long-term release 
capabilities in several studies. In one study, dual-release nanoparticle-fiber 
composites were used to mend and treat critically sized calvarial defects in rats172. 
These composites, consisting of PCL-co-PEG fibers encapsulating 
dexamethasone and BSA NPs and loaded with bone morphogenic protein-2 (BMP-
2), demonstrated sustained-release of both molecules over 35 days. Another study 
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explored the incorporation of siRNA into chitosan NPs and PLGA fiber 
composites164. In these composites, the release of active siRNA was sustained in 
vitro, with 95% of siRNA released from the fibers over 32 days, while gene 
silencing activity was maintained. Sustained-release from nanoparticle-fiber 
composites was also demonstrated in another study with chitosan-PEO 
electrospun fibers that were loaded with PLGA NPs encapsulating phenytoin. 
Nearly complete release of phenytoin from the composite scaffold was achieved 
over nine days173. Lastly, PLA fibers encapsulating chitosan particles provided 
sustained-release of BSA (45%) for 27 days, while chitosan particles alone 
released 80% BSA in 14 days174.  
In addition to NP incorporation within traditional uniaxial or blended fibers, 
NPs have been incorporated in more complex fiber architectures to prolong the 
release of active agents. For instance, the effect of combining a multilayered fiber 
architecture with nanoparticle-fiber composites was investigated by fabricating 
alternating layers of poly-L-lactic acid (PLLA) and PCL fibers with layers of PCL 
fibers encapsulating positively-charged chitosan BSA NPs175. The multilayered 
composite released 80% of the BSA in approximately eight days, whereas the 
monolayer control released the same concentration of BSA within 24 h. 
Applications for Intravaginal Delivery 
Composite delivery vehicles containing nanoparticles and fibers have thus 
far been primarily studied in wound healing and tissue engineering to fabricate 
scaffolds for tissue regeneration and bone remodeling97,176-178. However, these 
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platforms may be promising candidates for intravaginal delivery applications due 
to their structural stability and ability to sustain the release of active agents. In such 
systems, the fibers may be utilized as a reservoir for NPs to aid in intravaginal 
retention by helping to decrease NP clearance during shedding. In addition, it is 
envisioned that, depending on fiber formulation and, importantly, NP size and 
charge, NP (and active agent) release may be modulated, enabling NPs to 
traverse mucus and deliver agents to target cells that reside in the epithelium or 
underlying lamina propria. Similar to other architectures, fiber parameters such as 
polymer composition and size can be tailored to impact release in combination with 
altering NP composition, size, and loading within the fiber.  
For intravaginal delivery applications, NPs can impart cell specificity, cell 
internalization, as well as mucoadhesive or mucopenetrative properties to their 
encapsulated active agents25. Numerous studies have demonstrated the ability of 
NPs to enhance cell targeting via surface modification179,180. Additionally, surface 
modification can increase cell internalization, which may enhance the transport, 
subcellular localization, and corresponding efficacy of drugs like tenofovir 
disoproxil fumarate (TDF), which require cell internalization. Furthermore, the NP 
surface charge can be modulated to provide either mucoadhesive or 
mucopenetrative properties that further enhance active agent delivery. 
Additionally, fibers can be fabricated to encapsulate NPs for sustained-release as 
well as free agents for rapid release, providing both on-demand and sustained-
release in one platform. Finally, nanoparticle-fiber composites, when coupled with 
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coaxial or multilayered fiber architectures, provide an attractive strategy to retain 






Figure 1.5. Schematic of electrospun nanoparticle-fiber composites that integrate 
coaxial and multilayered fiber architectures. (A) Coaxial fibers can be fabricated to 
encapsulate nanoparticles (NPs) within the core fiber, conferring sustained- or 
delayed-release of active agents that are encapsulated in NPs (shown in green). 
(B) Multilayered fibers that encapsulate NPs can also act as reservoirs for either 
NP or active agent release. 
As with multilayered fibers, the use of nanoparticle-fiber composites has 
only recently been investigated for intravaginal delivery. In a proof-of-concept 
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study, rapid-release PEO, PVA, or PVP fibers encapsulated PLGA NPs containing 
C6 dye or etravirine drug34. In this study, composites and free NPs were 
administered within murine FRTs and assessed for retention and release. The 
encapsulated nanoparticles exhibited a 30-fold increase in retention in the mouse 
FRTs relative to free NPs. Furthermore, nanoparticles alone provided transient 
release of etravirine, while all nanoparticle-fiber composites demonstrated release 
for up to seven days. To date, this is the only investigation of nanoparticle-fiber 
composites for use in intravaginal delivery. However, the significant difference in 
retention and release rate achieved with nanoparticle-fiber composites highlights 
the immense potential of this architecture for sustained-delivery in the FRT. 
Although combining nanoparticles and electrospun fibers into one delivery 
vehicle has demonstrated potential, challenges exist for this platform. The major 
concern is related to the concentration of nanoparticles that can be effectively 
encapsulated within fibers without hindering the ability of the polymer solution to 
be electrospun181. Furthermore, the concentration of active agent may decrease 
with the use of a coaxial or multilayered architecture, as only specific layers of the 
fiber will encapsulate NPs. Finally, polymeric NPs are often comprised of the same 
or similar polymers as electrospun fibers, thus care must be taken to prevent 
polymer solvents from dissolving the NPs prior to or during the electrospinning 
process182. Moreover, the morphology of NPs may also be adversely affected by 
electrospinning voltage. These factors limit the combinations of fiber and 
nanoparticle materials available for composite fabrication. Thus, for composite 
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delivery applications to succeed, polymer choice and electrospinning conditions 
must be taken into consideration.  
Future Directions and Discussion 
Within the past decade, electrospun fibers have been explored as a 
multipurpose delivery platform to prevent and treat sexually transmitted infections 
(STIs). For intravaginal applications, fibers have typically been uniaxially 
electrospun to release active agents targeted to HIV-1/HSV-2 infections and 
contraceptive applications. However, other electrospun architectures have been 
developed that may provide more finely-tuned active agent release, the 
encapsulation of multiple agents, and longer release durations, desirable for next-
generation vehicles. Given this, the goal of this review was to summarize the 
advancements in electrospun fiber architectures including coaxial, multilayered, 
and nanoparticle-fiber composites, to meet these needs, and to review their use in 
other drug delivery applications. We sought to relate different temporal regimens 
of delivery, including transient (occurring within hours), short-term (spanning hours 
to one week), and sustained (extending from one week to months), to architectural 
design and materials selection to help guide the design of future platforms that 
meet the unique temporal needs of intravaginal delivery. 
One of the major challenges facing intravaginal delivery is the lack of user 
adherence surrounding the administration of current delivery platforms. Several 
clinical trials have highlighted how a lack of user adherence contributes to 
decreased efficacy in clinical trials. In both the FACTS-001 and VOICE trials, South 
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African women deemed high risk for HIV-1 exposure were given antiretroviral TFV 
gels to administer prior to intercourse104,183. Despite the known efficaciousness of 
TFV, the gels provided suboptimal protection against HIV-1 infection, which was 
attributed to low user adherence of the gels prior to intercourse. Another study 
examined the efficacy of gels that incorporated the antiviral polysaccharide, 
carrageenan, in women in Thailand. This study demonstrated similarly 
disappointing clinical outcomes, with low user adherence considered the most 
significant reason for the lack of clinical efficacy184. Negative outcomes in other 
trials such as PRO-2000 and cellulose sulfate gel studies, which examined the 
efficacy of anti-HIV gels in female populations, further validated these studies, 
highlighting that both user preference and adherence regimens must be 
considered during product design rather than at the clinical trial stage. As a result 
of these studies, there has been an increased emphasis to design vehicles that 
decrease the administration frequency by prolonging active agent release after a 
single topical application. 
In conjunction with improving user adherence, the development of 
multipurpose delivery vehicles that offer long-term protection against the various 
stages of a single infection or a diversity of different types of infections is highly 
desirable185. For single infections, a delivery platform may administer multiple 
agents with different mechanisms of action that target different stages of the viral 
or bacterial life cycle. However, the increased likelihood of viral co-infections, such 
as HSV-2 and HIV, as well as bacterial and fungal infections will likely require co-
administration of antiviral and antimicrobial agents to be successful. Furthermore, 
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applications that seek to meet both antiviral and contraceptive needs in the same 
dosage form will require the incorporation of multiple types of agents to expand a 
platform’s effectiveness. Therefore, a delivery platform that has the capability to 
release multiple active agents, each over time frames relevant to the application 
or active agent, will have greater utility and enable more convenient administration 
schedules based on specific user needs.  
Despite these needs, tailoring the delivery of multiple types of active agents 
for viral, bacterial, fungal, and contraceptive applications is an ambitious goal given 
the unique chemical properties of each agent. For example, the antiretroviral TFV 
and its pro-drug TDF have similar structures and both work as nucleoside reverse 
transcriptase inhibitors yet possess markedly different hydrophobicities. As such, 
a delivery platform designed to prolong TFV release may result in different release 
kinetics of TDF, requiring the formulation of distinct delivery vehicles specific to the 
selected active agents67,127,129,186,187. Furthermore, each active agent may 
necessitate specific temporal dosing regimens to provide protection or treatment. 
For example, it may be desirable to administer viral entry inhibitors, which 
inactivate virions prior to cell entry, over a different time frame than active agents 
that work inside of cells and need to transport through and localize to target tissue. 
Several studies have investigated this and have found that more complex and 
specialized architectures may be useful to achieve temporal delivery goals by 
tuning the release properties of multiple encapsulants for multiple targets188,189. 
Similarly, for contraceptive applications, on-demand and/or zero-order release with 
equivalent daily dosing may be desirable for spermicides and hormonal/non-
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hormonal contraceptives, respectively. Conversely, it may be desirable to deliver 
active agents such as hormones and small hydrophilic drugs (e.g., etonogestrel 
and acyclovir) within the same time frame for simultaneous long-term 
contraception and prevention. However, the drastically different chemical 
properties of these agents will require more complex solutions to achieve similar 
release profiles. Given this, multipurpose intravaginal delivery platforms must be 
tailored to maximize the efficacy of individual active agents, including small 
molecule drugs, proteins, antibiotics, hormones, and live organisms (e.g., 
probiotics), to meet the needs of these diverse applications.  
While providing distinct release profiles of different active agents is an 
important criterion for the development of future intravaginal platforms, to date, 
intravaginal rings (IVRs) are the only platforms that provide delivery over a duration 
of weeks to months190-194. Furthermore, IVR studies indicate that more complex 
dosage forms, such as rings with drug-encapsulating pods, may more likely 
succeed, particularly in challenging delivery scenarios, e.g., achieving the 
sustained-release of small hydrophilic molecules188. These and other 
studies188,189,195,196 emphasize the need to offer alternative delivery vehicles for 
women, with the key lesson that platform architecture must be designed to 
consider the hydrophobicity and chemical compatibility of the encapsulants in 
combination with its surrounding materials.  
In addition to the development of fibers with more complex architectures, 
active agent release and transport from these platforms must be assessed. Tissue 
mimetics and ex vivo tissues have been used to assess these parameters within 
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the context of intravaginal delivery applications127,197-202. One of the most common 
ways in which to assess intravaginal delivery is by using human ectocervical tissue 
explants derived from patients198-202. These explants provide a representative 
environment in which to measure transport by accounting for the three-dimensional 
structure of patient tissue. However, patient-specific variations and tissue 
availability can limit the use of vaginal explants. Given this, organotypic three-
dimensional vaginal tissue models such as EpivaginalTM tissue have been created 
to help evaluate the safety, transport, and efficacy of active agents within an FRT 
mimetic203,204. Other in vitro models have also been developed to explore bacteria 
and host cell interactions in the reproductive environment 205. Moreover, within the 
past decade, new biomarkers and assay endpoints have been identified and 
studied in different models to more fully assess microbicide interactions with the 
FRT206. The use of tissue models promises to streamline the assessment of future 
fiber platforms as viable intravaginal delivery platforms. 
To date, a variety of studies have developed uniaxial electrospun fibers for 
intravaginal applications, including HIV prevention67,126-130,186,187,207-210. In these 
studies, electrospun fibers have demonstrated promising potential for intravaginal 
applications due to their mucoadhesive characteristics, mechanical properties, and 
ability to be fabricated in different shapes and sizes64. Depending upon the polymer 
hydrophilicity, traditional uniaxial fibers have been formulated as transient, short-
term, or long-term delivery platforms. For the purposes of on-demand and short-
term release, many of these studies use hydrophilic fibers, which dissolve or 
degrade quickly. In contrast, fibers consisting of more hydrophobic materials are 
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expected to persist within the FRT, acting as reservoirs to sustain the release of 
active agents. We envision (and have observed) that long-term delivery vehicles 
maintain their structure during the delivery duration of interest and may require 
physical removal from the FRT, similar to current IVRs. However, one of the key 
challenges for intravaginal delivery has been to sustain the release of small 
hydrophilic antiretrovirals due to their rapid diffusion through the porous fiber 
matrix, solubility in aqueous solutions, and chemical incompatibility with 
hydrophobic polymer cores17. Many of these uniaxial fibers demonstrated burst 
release of hydrophilic agents followed by short-term release70,211, partially 
attributed to the localization of hydrophilic agents on the fiber surface. 
Compounding this, concerns exist that the subsequent release of active agents 
may be insufficient to provide complete protection against future infections. While 
blended uniaxial fibers have been moderately successful in addressing these 
challenges, more work is required130. 
The primary parameters that impact release from uniaxial fibers are the 
choice of solvent and polymer. Other factors such as polymer concentration and 
electrospinning parameters also play a role in attaining different release profiles; 
however, it is unlikely that these factors alone are sufficient to overcome the 
challenge of delivering sustained and therapeutically-relevant concentrations of 
hydrophilic agents. Furthermore, it is difficult to utilize traditional uniaxial fibers for 
the encapsulation of multiple diverse agents such as large proteins and small 
drugs. Due to these issues, other electrospinning architectures may be better 
suited to meet the diverse challenges of intravaginal delivery.  
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As discussed previously, coaxial fibers have shown promise for the 
encapsulation and release of small hydrophilic and hydrophobic molecules, which 
may be useful for intravaginal delivery applications. The different goals of transient, 
short-term and long-term release can be achieved by changing the composition 
and hydrophobicity of core and shell materials as well as by modulating the shell 
thickness and core:shell ratio. As described, the shell layer can help regulate active 
agent release, while the core layer is designed to provide optimal compatibility with 
an encapsulant. For instance, by using pH-responsive polymer shells, an 
immediate stimuli-responsive release of agents can be achieved when the fiber is 
in contact with semen. In this scenario, the core layer may be tailored to 
encapsulate multiple agents, while the shell, comprised of pH-sensitive polymers, 
retains encapsulants until needed. Another advantage of coaxial fibers is that they 
can be fabricated to exploit drug-polymer hydrophilicities. For example, a coaxial 
fiber comprised of a hydrophobic shell and hydrophilic core can be utilized to 
provide long-term release of hydrophilic compounds. Agent encapsulation into 
both layers would allow for both transient burst release from the shell due to 
surface localization and high loading and sustained-release from the core layer. 
Finally, coaxial fibers can provide release of biological agents such as large 
proteins. Coaxial cores may be engineered to achieve high protein encapsulation 
and biocompatibility, while shells can be constructed with porous surfaces, 
allowing tunable release. This is particularly significant given that many biologics 
are being investigated as future viral prophylaxes and therapeutics. Although 
coaxial electrospinning is a more complex process that requires additional 
 54 
optimization, relative to uniaxial spinning, it may enable a versatile platform for 
transient, short-term, and long-term release130.  
Multilayered fibers combine different polymer layers via sequential or post-
spinning to incorporate multiple and chemically distinct drugs within specific layers, 
thereby tailoring the release kinetics for each encapsulated agent. Multilayered 
interwoven fibers can be utilized to provide transient release using sacrificial layers 
to encapsulate agents for on-demand applications. The sacrificial layers 
comprised of hydrophilic polymers would provide on-demand release of agents 
based on their immediate degradation when exposed to physiological fluids. Active 
agent release can be further modulated by the number, thickness, and porosity of 
each fiber layer212. Moreover, blank fibers may be incorporated within the 
multilayers to either act as a physical barrier for sustained-release or for 
contraceptive purposes. The layer thickness and level of porosity of blank fibers 
can be conveniently modulated to delay the release of small hydrophilic molecules 
from the drug-loaded layers, serving to prolong release. Additionally, multilayered 
fibers have the potential to deliver biologics and non-hormonal contraceptives. 
These agents, although efficacious, may degrade when exposed to harsh solvents 
during the electrospinning process. By incorporating these active agents in distinct 
layers and integrating barrier layers, multilayered fibers can provide long-term 
release of drugs and biologics while retaining their activities.  
While each of these strategies offers advantages relative to uniaxial 
spinning, the delivery of active agents may be further enhanced by integrating 
nanoparticles with fibers. A composite platform may offer a new alternative to 
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address the challenges of intravaginal delivery, such as the maintaining active 
agent stability, providing cell-specific targeting (via NPs), and enhancing cell 
internalization. Like electrospun fibers, nanoparticles can be designed to 
encapsulate virtually any compound. The limitations of nanoparticle-fiber 
composites mentioned earlier may be overcome by utilizing fibers as a reservoir 
for both active agents and nanoparticles to release multiple therapeutics. 
Furthermore, the release rates of encapsulants from both nanoparticles and fibers 
may be modulated by adjusting the composition of the polymeric scaffold. For on-
demand transient release, hydrophilic polymers may be used to enable rapid 
release of NPs for immediate distribution through and enhanced retention within 
tissue. In contrast, more hydrophobic fibers may be used to delay the release of 
NPs or NP-encapsulated agents. Although drug-polymer hydrophobicity is a major 
contributor to release, other factors such as polymer choice, molecular weight, and 
crystallinity, as well as solvent choice and electrospinning parameters, also affect 
the release of agents from fibers. 
The application of advanced fiber architectures has only recently been 
explored in the context of intravaginal delivery. Advanced fiber architectures 
demonstrate the potential to provide the sustained-release of individual active 
agents in addition to concurrently providing both transient and sustained-delivery 
of multiple active agents. These are key advantages over traditional uniaxial fibers, 
which are challenged with the long-term delivery of small hydrophilic molecules, in 
addition to providing transient and sustained-release simultaneously. We envision 
that future fiber architectures will localize active agents within specific sections of 
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the fiber to tailor the release of individual agents independent of other 
encapsulants. Moreover, we anticipate that future platforms will combine 
architectures to maximize or complement the advantages of individual platforms. 
As previous clinical trials have shown, effective protection will be dependent upon 
fulfilling user preferences, offering convenience, and providing necessary release 













IN VITRO STUDY ON SYNERGISTIC INTERACTIONS BETWEEN FREE AND 
ENCAPSULATED Q-GRIFFITHSIN AND ANTIRETROVIRALS AGAINST HIV-1 
INFECTION 
Introduction 
Human immunodeficiency virus (HIV) remains a major health challenge, 
impacting over 1.7 million people each year1,2 and ~38 million worldwide. Women 
are disproportionately affected by HIV infections, and more than half of the globally 
infected patients are women living in sub-Saharan Africa3. In spite of eradication 
efforts, there is currently no cure or effective vaccine for HIV-11, hence a major 
emphasis has been placed on developing strategies to prevent and treat HIV-1 
infection. Given the diversity and magnitude of these unmet reproductive health 
challenges, one focus has been to evaluate combinations of novel anti-HIV drugs 
delivered with multipurpose prevention technologies, to simultaneously target 
multiple sexually transmitted infections (STIs)4, such as herpes simplex virus 2 
(HSV-2) and HIV-1. 
One of the primary foci in preventing and treating HIV-1 infections, has been 
the development of antiretroviral drugs (ARVs) that inhibit HIV at different stages 
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of the viral infection cycle213-217. Two ARVs currently used in clinical studies, 
Tenofovir (TFV) and Dapivirine (DAP), inhibit HIV-1 by blocking reverse 
transcriptase215, while Raltegravir (RAL), another approved drug for HIV treatment, 
inhibits proviral DNA-strand transfer218. Moreover, combinations of ARVs have 
demonstrated enhanced inhibition via different mechanisms of action219. While 
ARVs are effective in preventing HIV-1 infection, they have been shown to elicit 
adverse effects including bone marrow suppression and hematologic effects220, 
toxicity with long-term use, and an increased risk of antiviral resistance221. These 
adverse effects are often further exacerbated by the poor oral bioavailability and 
frequent dosing required for many of these drugs, which have contributed to 
modest outcomes in clinical trials222.  
To help overcome these challenges, new biological agents have been 
investigated to provide protection via different mechanisms of action223. Antiviral 
lectins such as actinohivin, scytovirin, and microvirin have demonstrated efficacy 
against HIV-1 by binding to oligosaccharides linked to viral envelope glycoproteins; 
however, delivery of these lectins has been challenging due to low bioavailability 
and induction of an immune response224. Furthermore, toxicities arising from acute 
immunological response, due to the administration of foreign proteins, are one of 
the most significant concerns in adopting protein-based active agents225.  
In comparison to these biologics, an antiviral lectin, Griffithsin, originally 
isolated from red alga Griffithsia sp.226, has demonstrated potent anti-HIV activity 
in the picomolar range against both laboratory and primary HIV isolates, and is 
currently being evaluated in clinical trials. Griffithsin inhibits HIV-1 by binding to an 
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envelope glycoprotein (gp120) and inactivating HIV-1 almost immediately upon 
contact. Studies have shown that GRFT is stable and maintains activity in buffered 
solutions (pH 4 to 8) and cervical vaginal lavage fluid at 25°C and 37°C for up to 1 
week227. Additionally, GRFT exhibits excellent safety profiles226,228-231 with 
negligible induction of pro-inflammatory cytokines231 and has demonstrated 
synergy with other antiretrovirals222, suggesting the benefits of future co-
administration strategies. Recently, an oxidation-resistant variant of GRFT, Q-
GRFT, was shown to retain the biophysical, antiviral, and safety properties of wild-
type GRFT, making it an even more suitable HIV microbicide candidate232,233.  
Prophylactic and therapeutic strategies that use a combination of anti-HIV 
drugs to target infection, have been shown to enhance the intracellular efficacy of 
each drug234,235 and decrease the transmission risk of antiviral-resistant viruses222. 
One study demonstrated that a combination of multiple nucleoside reverse 
transcriptase inhibitors (NRTIs) and non-nucleoside reverse-transcriptase 
inhibitors (NNRTIs), such as TFV and Efavirenz (EFV), provided synergistic 
inhibition of HIV-1, as well as an increase in intracellular drug efficacy235. 
Additionally, GRFT has shown synergistic effect in combination with maraviroc, 
TFV, and EFV, requiring lower GRFT doses when used in combination. The 
strongest synergy was observed between GRFT and TFV (CI = 0.34) suggesting 
that a combination of GRFT and other active agents, may provide a promising 
strategy to inhibit virus transmission and replication via different mechanisms of 
action222.  
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Regardless of activity, active agents require formulation into an acceptable 
dosage form that protects agent stability and potentially provides extended 
release. Current ARVs have been incorporated into short-acting or on-demand 
dosage forms such as tablets and gels, and long-acting sustained-release vehicles 
such as intravaginal rings (IVRs). However, oral ARVs incorporated in pre-
exposure prophylaxis (PrEP) regimens have only been moderately successful in 
preventing, and to date do not cure HIV-1 infections. A variety of clinical studies236-
240 have shown that the efficacy of oral PrEP ranges from zero to seventy-five 
percent, depending in large part on user adherence241.  
As an alternative to daily oral PrEP administration, topical intravaginal PrEP 
technologies (e.g., gels, IVRs) have shown success in delivering active agents to 
the female reproductive tract (FRT). While clinical trials have demonstrated 
promising levels of protection for gels, efficacy has been shown to be significantly 
impacted or abbreviated by a lack of user adherence, due to the required frequent 
administration regimens and lack of retention attributed to product leakage242. In 
comparison, IVRs can provide long-term protection against STIs and pregnancy 
(> 1 month) by offering longer delivery durations and high durability in the FRT. 
However, clinical trials have reported some challenges regarding using IVRs such 
as vaginal discomfort, ease of product placement, low pliability, and hygiene 
issues243, further emphasizing the need to design alternative delivery platforms 
with potentially increased convenience and ease of use.   
Thus far, short-term safety studies with GRFT have demonstrated 
outstanding preclinical safety in vitro and in vivo231,244,245; however currently, there 
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are no available delivery vehicles that prolong GRFT (or Q-GRFT) delivery to 
achieve efficacy beyond 72 hr post-administration. To begin to address these 
challenges, we and others have shown that polymeric nanoparticles (NPs) and 
electrospun fibers provide sustained-delivery, with the potential to safely 
incorporate and enhance the transport of biologics40,128,130,246-265. Polymeric NPs 
have been investigated to encapsulate ARVs and biologics for HIV-1 treatment266-
269 and have been shown to improve delivery to vaginal tissue by overcoming 
challenges such as agent instability; low cellular internalization and tissue 
distribution; and frequent dosing; while eliciting minimal immune response in the 
FRT154,268-271. Polymeric fibers that encapsulate active agents have also been 
recently applied to intravaginal drug delivery, demonstrating sustained-delivery 
and the potential to safely incorporate biologics128,272. Despite this, to date, there 
are no food and drug administration (FDA)-approved NP or fiber delivery platforms 
available to provide topical STI prevention128,252,273. Moreover, a platform that 
incorporates the attributes of both platforms, such as NP-fibers, may improve 
delivery by providing a reservoir to retain NPs and decrease NP clearance during 
shedding.  
Despite being well-established technologies used successfully as durable 
stents, scaffolds, and delivery reservoirs for long-term implantation and delivery in 
vivo260,274,275, NP-fiber composites have only recently been explored for sustained-
delivery to the FRT273. Several groups have evaluated multilayered fibers for the 
delivery of active agents276,277, and have shown that nano- (often hydrophilic) and 
micro-scale (often hydrophobic or higher MW polymers) can impart greater 
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mechanical stability and flexibility compared to a single layer of fibers278. Other 
work175,279,280 has investigated multilayered fibers and demonstrated time-
regulated release of active agents. For intravaginal delivery specifically, an 
approach utilizing stacked fibers was evaluated for short-term (60 hr) intravaginal 
delivery, in part to demonstrate how individual layers pressed together post-
spinning may modulate release263. Recently, we developed a multilayered NP-fiber 
composite, that incorporates poly(lactic-co-glycolic) acid (PLGA) NPs, that 
sustains the delivery of GRFT in vitro, relative to sustained-delivery from NPs over 
~7 days. In addition to the potential for sustained-delivery in the order of months, 
this NP-fiber architecture demonstrated efficacy against HIV-1 infections in vitro 
and protection against a lethal dose of HSV-2 in a murine model. Based on these 
studies, NP-fiber composites can be used to tailor the release of active agents and 
provide long-term efficacy.  
In this work, we sought to examine the delivery of Q-GRFT and three 
different ARVs (e.g., TFV, RAL, and DAP) to identify unique protein-drug synergies 
between Q-GRFT and these active agents delivered in free or encapsulated forms. 
We selected these ARVs due to their different solubilities and mechanisms of 
action against HIV-1. TFV is a hydrophilic drug that has been evaluated in vaginal 
gels; DAP is a hydrophobic agent that has been incorporated in IVRs and 
evaluated in Phase III clinical trials and has been evaluated against both HIV-1 
and HSV-2 infections, and RAL is a small hydrophilic molecule that is used late in 
pregnancy to reduce the risk of transferring HIV from mother to child281. We 
demonstrated that the co-administration of free or encapsulated active agents with 
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different mechanisms of action may increase the prophylactic effect and decrease 
the dose needed to attain efficacy against HIV-1 infection. Moreover, given the 
potential of NP-based platforms to modulate active agent release, we sought to 
preliminarily assess the release of different active agent agents from NPs, and 
selected the most synergistic NP formulations for incorporation in multilayered NP-
fiber composites.  
Materials and Methods 
Poly(lactic-co-glycolic) acid used for synthesizing NPs (50:50, 0.55-0.75 
dL/g, 31-57k MW) was purchased from Lactel Absorbable Polymers (Cupertino, 
CA). Polycaprolactone (PCL, MW=80,000 Da), polyethylene oxide (PEO, 
MW=600,000 Da), TFV and DAP were purchased from Sigma Aldrich (St Louis, 
MO), while RAL was provided from Selleckchem (Houston, TX). Q-GRFT was 
kindly provided by Dr. Fuqua (University of Louisville, KY). Dichloromethane 
(DCM) and keratinocyte serum-free medium (KSFM) were purchased from Thermo 
Fisher (Waltham, MA). Other chemicals, including dimethyl sulfoxide (DMSO), 
acetonitrile HPLC grade (ACN), trifluoroacetic acid (TFA), and thiazolyl blue 
tetrazolium bromide (MTT), were obtained from Sigma Aldrich.  
Nanoparticle Fabrication  
Blank NPs and NPs loaded with Q-GRFT, TFV, RAL or DAP were fabricated 
using either single or double emulsion technique. For each formulation, 100 mg 
PLGA was dissolved in 2 mL of DCM and incubated overnight. For Q-GRFT, TFV, 
and RAL NPs, 10 mg of the active agent was dissolved in 200 μL Tris-EDTA (TE) 
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buffer. For DAP NPs, 10 mg of DAP was dissolved in 200 μL DCM. The active 
agent solution was added dropwise to the polymer solution while the solution was 
vortexed. Then, the active agent-polymer solution was sonicated and added to 5% 
PVA in Milli-Q water (2 mL), vortexed and sonicated again. The emulsified solution 
was then added to a larger volume of aqueous solution (50 mL of 0.3% PVA) and 
incubated for 3 hr while stirring to evaporate DCM. Then, NPs were centrifuged 
(25,364 x g for 10 min at 4°C), washed twice using 30 mL Milli-Q water, suspended 
in 5 mL Milli-Q water and stored at -80°C for 2 hr. Finally, NPs were lyophilized to 
obtain solid particles and were subsequently stored at -20°C. 
NP-Fiber Composite Fabrication  
To prepare the electrospinning solution, PEO and PCL were dissolved in DI 
water (5% w/w) and TFE (11% w/w), respectively, and incubated at 37°C 
overnight. Prior to electrospinning, 10% w/w of PLGA NPs were added to the PEO 
solution and the solution was electrospun with a flow rate of 0.3 mL/hr and voltage 
of 25 kV. Pre-cut NP-PEO fibers (3-5 mg) were placed on the freshly electrospun 
PCL layer followed by electrospinning another layer of PCL fiber on top to make a 
sandwich-shaped structure. The electrospinning conditions for PCL layers were 
set to 15 cm needle to collector distance, flow rate of 2.2 mL/hr, and voltage of 20 
kV. The NP-fiber composite was desiccated overnight and stored at 4°C. 
NP Characterization: Size, Loading, and Release  
Size. The size and morphology of unhydrated NPs were determined using 
scanning electron microscopy (SEM). First, samples were sputter-coated with a 
 65 
palladium/gold alloy layer with a thickness of 15 to 18 nm, and imaged using a 
Supra 35 SEM (Zeiss, Oberkochen, Germany). The average size of unhydrated 
NPs was evaluated with ImageJ software (NIH, Bethesda, Maryland) by measuring 
the diameter of 50 NPs per image and 3 images for each formulation.  
Loading. To assess the loading of NPs, 1-2 mg of NPs were dissolved in 
100 μL DMSO and diluted with TE buffer to the final volume of 1 mL. Serial 1:2 
sample dilutions were then made in TE buffer. To quantify the amount of TFV, 
RAL, and DAP, spectrophotometric absorbance was measured at 260, 300 and 
290 nm, respectively, on a Synergy HT reader (BioTek, Winooski, VT, USA). To 
quantify the amount of Q-GRFT, an enzyme-linked immunosorbent assay (ELISA) 
was used. Briefly, 96-well Nunc Maxisorp plates were incubated with 100 µL of 
250 ng/mL gp120 in 1x phosphate-buffered saline (PBS) as a coating buffer and 
stored at 4ºC overnight. Then, plates were blocked with 300 μL of 3% w/v bovine 
serum albumin (BSA) in PBS containing 0.05% Tween-20 (1x PBST) and 
incubated at room temperature for 2 hr. Plates were then washed using a Gardner 
Denver Multiwash III plate washer (Milwaukee, WI) followed by adding 100 μL of 
the samples. Afterwards, 100 μL of rabbit anti-GRFT (1:10,000) and goat anti-
rabbit IgG-HRP (1:20,000) were subsequently added after 1 hr incubation at 37°C 
to detect gp120-bound Q-GRFT. Finally, 100 µL of SureBlue TMB microwell 
peroxidase substrate (Sera Care, Milford, MA, USA) was added to each well and 
the reaction was quenched by adding 100 µL of 1 N H2SO4 (Thermo Fisher) 
followed by reading the absorbance at 450 nm.  
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In Vitro Release. The release of Q-GRFT, TFV, RAL, and DAP loaded 
PLGA NPs was determined over 30 days in simulated vaginal fluid (SVF, pH 4.5). 
Three to five mg of NPs were dispersed in 1 mL of SVF in 1.5 mL centrifuge tubes 
and incubated at 37°C with continuous shaking (150 rpm). At each time point, 
samples were centrifuged at 18,500 x g at 4°C for 10 min, the eluates were 
collected, and NPs were resuspended in 1mL of fresh SVF.  Similarly, the release 
of the active agent from NP-fiber constructs was evaluated by placing a 5 mg fiber 
composite piece in a 5 mL microcentrifuge tube filled with 1 mL SVF. The samples 
were incubated on a shaker at 150 rpm at 37°C, under sink conditions. At each 
time point, the solution was replaced with fresh SVF and release from NP-fiber 
composites was assessed for up to 90 days. The release of Q-GRFT, from NPs 
and NP-fiber composites, was quantified via ELISA as mentioned before. For 
quantifying DAP released from NP-fiber composites, reverse phase high 
performance liquid chromatography with UV detection (HPLC-UV) was used 
(Agilent, CA, USA). First, the composite eluates in SVF were diluted with ACN to 
obtain a 1:1 SVF:ACN v:v ratio. Then, 50 µL of sample was injected into a Jupiter 
C18 300 A-C18 column (250 × 4.6 mm; Agilent Technologies, CA, USA). The 
mixture of 65% of 0.01 v/v% TFA and 35% ACN was used as mobile phase with 
the flow rate of 1 mL/min and the running time for DAP was 22 min. Finally, DAP 
was detected via absorbance at 290 nm and the concentration of DAP in unknown 
samples was determined by plotting the area under the curve versus 
concentration. The standard curve over the range of 0.08 to 10 µg/mL was 
determined to be linear.   
 67 
Cell Lines, Virus and Cell Culture 
TZM-bl cells were obtained from the NIH AIDS Research and Reference 
Reagent Program (ARRRP) and were used for HIV infection. These cells are 
engineered HeLa cells that express CD4, CCR5, and CXCR4 receptors and have 
Tat-responsive reporter genes for firefly luciferase (Luc) that allows accurate 
measuring of HIV-1 infection234. TZM-bl cells were maintained in Dulbecco's 
Modified Eagle medium (DMEM, from VWR) supplemented with 10% fetal bovine 
serum (FBS), 25 mM HEPES buffer, and 50 μg/mL gentamicin (Thermo Fisher). 
Vaginal epithelial (VK2/E6E7), End1/E6E7 (End1), and ectocervical, Ect1/E6E7 
(Ect1) cell lines were provided courtesy of Dr. Kenneth Palmer from the University 
of Louisville, and were originally from ATCC (Rockville, MD). VK2, End 1, and Ect 
1 cells were cultured in Keratinocyte Serum-Free (KSFM) media containing 
recombinant human epidermal growth factor (0.1 ng/mL), bovine pituitary extract 
(50 μg/mL), calcium chloride (0.4 mM) (Thermo Fisher), and 1% penicillin and 
streptomycin. HEK-293T/17 cells (ATCC, Rockville, MD) were used for HIV 
production and were cultured in minimum essential medium (MEM) supplemented 
with 10% FBS, and 1% penicillin (100 µg/mL) and streptomycin (100 µg/mL) (VWR 
Radnor, PA). The HIV-1 pseudovirus was made in house by transfecting 
HEK293T/17 cells with envelope (env)-expressing plasmid (CCR5-tropic clade A 
strain, Q769.h5), env-deficient HIV-1 backbone vector (HIV-1pNL4-3.Luc.R-E-, 
NIH AIDS Reagent Program,11884 and 3418) and Mirus reagent (Mirus, Madison, 
WI ). After incubating cells with transfection complex for 72 hr at 37°C, the cells 
were centrifuged (200 x g, 5 min) and the supernatant containing viral particles 
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was collected, filtered using a 0.45 μm membrane filter (VWR), and stored at -
80°C.  
In Vitro HIV Inhibition 
To evaluate the anti-HIV-1 activity of anti(retro)viral NPs, an in vitro HIV 
inhibition assay was conducted by infecting TZM-bl cells with HIV-1 
pseudovirus  (CCR5-using clade A strain Q769.h5) and quantifying the luciferase 
activity of cell lysates. Briefly, the desired amount of free or encapsulated active 
agent was dissolved in 1 mL of DMEM, followed by 1:2 serial dilutions to a final 
volume of 50 μL. Then, 100 μL of cell solution (106 cells per plate) was added to 
each well. After incubating the cells and treatment for 1 hr at 37°C, 50 μL of virus 
solution was added to each well. Untreated cells only and virus-infected cells were 
used as negative and positive controls of infection, respectively. After 48 hr 
incubation at 37°C, 100 µL culture medium was replaced with 100 µL Bright-Glo 
reagent solution (Promega Corporation, Madison, WI) and luminescence was 
measured after 3 min. HIV-1 infection was determined based on the luminescence 
deviations from the virus-infected cell control. 
 In Vitro Cytotoxicity 
An MTT assay was used to determine the cytotoxicity of blank and 
anti(retro)viral NPs (0.1 and 1 mg/mL) administered to VK2, End1, and Ect1/E6E7 
cell lines. First, cells were plated at a density of 150,000 cells/well in 24-well plates 
and incubated for 24 hr at 37°C, followed by adding treatments in triplicate. Media 
only (no treatment) and 10% DMSO were used as viable and non-viable cell 
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controls. After 24, 48, and 72 hr incubation at 37°C, 55 µL of MTT reagent was 
added to each well and incubated at 37°C for 4 hr, followed by adding 100 µL of 
lysis buffer containing 10% sodium dodecyl sulfate (Fisher Scientific) and 0.01 M 
hydrochloric acid. After overnight incubation, the absorbance was read at 570 nm 
and normalized to cell-only absorbance to attain the relative percent of cell viability. 
Combination Effect 
The activity of the active agents in combination was determined using the 
combination index (CI). First, the half-maximal inhibitory concentration (IC50) value 
of each drug in free and encapsulated form was measured with the HIV inhibition 
assay. Then, each drug was mixed with either Q-GRFT or Q-GRFT NPs in an 
equipotent IC50 ratio (1:1 ratio of IC50). For NPs, the amount of each active agent 
was determined based on the actual loading. After measuring the IC50 values of 
each active agent in combination, the Chou-Talalay method was used to measure 
CI282-284. 









    
When Q-GRFT and the drug are in free form, Ds1 and Ds2 represent the 
IC50 of free Q-GRFT and the free drug applied separately, while DC1 and DC2 are 
the IC50 values of free Q-GRFT and free drug applied in combination, respectively. 
When Q-GRFT NPs are co-administered with free drug, Ds1 and Ds2 represent the 
IC50 of Q-GRFT NPs and the free drug when applied separately, while DC1 and DC2 
are the IC50 values of Q-GRFT NPs and free drug when they are co-administered. 
Finally, in the case of Q-GRFT NPs and encapsulated drug co-administration, Ds1 
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and Ds2 represent the IC50 of Q-GRFT NPs and drug NPs, while DC1 and DC2 are 
the IC50 values of Q-GRFT NPs and drug NPs in combination, respectively. Values 
of CI > 1, CI = 1, and CI < 1 determine additive, antagonistic, and synergistic 
interactions, respectively.  
Statistical Analysis  
All experiments were done in triplicate and GraphPad Prism (GraphPad 
Software, La Jolla, CA) was used for data analysis. Unless otherwise noted, three 
independent replicates were assessed for each sample and statistical significance 
was evaluated using a one-way ANOVA test (Bonferroni), and p-values ≤ 0.05 
were considered statistically significant. 
Results 
NP Characterization 
PLGA NPs formulated with 100 µg of ARVs (TFV, RAL, or DAP) or Q-GRFT 
per mg of NP were successfully synthesized with high yield (> 70%) and spherical 
morphology. SEM images of ARV and Q-GRFT NPs are shown in Figure 2.1, 
demonstrating NP sizes ranging from 98.9 to 107.2 nm. Furthermore, nanoparticle 
loading efficiency varied with the active agent (Table 2.1); Q-GRFT, TFV, RAL, 
and DAP NPs were loaded with 48.9 ± 12.7, 15.4 ± 3.3, 103.5 ± 11.9, and 60.2 ± 
2.7 µg active agent/mg NP, respectively, directly corresponding to the 











Figure 2.1. Scanning electron microscopy images of PLGA nanoparticles loaded 
with 10% w/w (A) Q-GRFT, (B) TFV, (C) RAL, and (D) DAP. Scale bars represent 
200 nm. 
Table 2.1. Size, loading, and encapsulation efficacy of PLGA nanoparticles. 
Nanoparticles had theoretical loading values of 100 µg Q-GRFT, TFV, RAL, or 




Active Agent Size (d. nm ± STD) Loading (µg/mg) Encapsulation Efficacy (%)
Q-GRFT 98.5 ± 37.2 48.9 ± 12.7 48.9 ± 12.7
TFV 89.9 ± 25.3 15.4 ± 3.3 15.4 ± 3.3
RAL 106.3 ± 29.7 103.5 ± 11.9 103.5 ± 11.9
DAP 107.2 ± 27.1 60.2 ± 2.7 60.2 ± 2.7
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In Vitro Release from NPs   
The cumulative release of each active agent as a function of mass and 
percent total loading, from PLGA NPs over 4 wk in SVF is shown in Figure 2.2. 
For all formulations, a burst release was observed within the first eight hours, 
followed by a more gradual release over 2 wk. Specifically, 2.51, 1.72, 8.96, and 
8.99 µg Q-GRFT, TFV, RAL, and DAP per mg of NPs (representing 5%, 11%, 9%, 
and 15% of actual loading) were released after 8 hr. Over 2 wk, the total cumulative 
release of Q-GRFT, TFV, RAL, and DAP from their respective NP formulations 
was 4.64, 2.64, 11.84, and 13.41 µg/mg, resulting in less than 20% release of each 
active agent. 
 
Figure 2.2. The cumulative release of Q-GRFT, TFV, RAL, and DAP from PLGA 
nanoparticles as a function of (A) total active agent release or (B) the percent of 
total loading, after exposure to SVF for up to 14 d. Release values are shown as 
the mean ± standard deviation of three independent NP batches. Please note 
panel B y-axis is scaled to 20% to more easily visualize differences in release. 
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In Vitro HIV-1 Inhibition Studies  
Individual administration of Q-GRFT or ARVs in free or encapsulated 
form. The ability of individual active agents to protect against infection in free and 
encapsulated forms was evaluated by the administration of free active agent to 
TZM-bl cells for 1 hr, followed by virus administration. The IC50 values of free Q-
GRFT, TFV, RAL, and DAP were 57.2 ± 13.8, 382.3 ± 39.6, 3.3 ± 0.2, and 0.034 
± 0.008 ng/mL, respectively, while the encapsulation of individual in agents in NPs 
generally decreased the IC50 values to 14.0 ± 4.1, 273.7 ± 78.8, 3.0 ± 0.5, and 
0.043 ± 0.0007 ng/mL (Figure 2.3). For all ARVs, the IC50 values of free and 
encapsulated agents based on release were similar (p > 0.05), while the IC50 
values of Q-GRFT NPs were ~4-fold lower than observed for free Q-GRFT (p ≤ 
0.05) (Table 2.2).   
 74 
 
Figure 2.3. The IC50 curves of (A) free and (B) NP-encapsulated active agents 
after administration to TZM-bl cells 1 hr prior to HIV-1 pseudovirus infection. 
Infectivity values are normalized to uninfected cells and are shown as the mean ± 
standard deviation of three NP batches. 
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Table 2.2.  IC50 values of free and encapsulated agents after administration to 
TZM-bl cells 1 hr before HIV-1 pseudovirus infection. Data are shown in units of 
ng/mL and nM. 
 
Combinations of Q-GRFT with each ARV. Q-GRFT was subsequently co-
administered with each ARV at an equipotent IC50 value ratio to compare the 
combined efficacy with each active agent. As shown in Figure 2.4, when free Q-
GRFT was co-administered with free ARVs, all IC50 curves were shifted to the left, 
demonstrating that a lower dose of each agent is able to achieve similar efficacy. 
When free Q-GRFT was co-administered with free TFV, RAL, or DAP, the IC50 of 
Q-GRFT decreased by 6.3, 4.4, and 3.7-fold respectively, relative to the 
administration of Q-GRFT alone (p ≤ 0.05).  Similarly, the IC50 values of free TFV, 
RAL, or DAP co-administered with free Q-GRFT decreased by 2.8, 5.6, and 4.6-




 IC50 Free Active Agent 
(ng/mL)
 IC50 Free Active Agent 
(nM)
IC50 Encapsulated 
Active Agent (ng/mL) 
IC50 Encapsulated 
Active Agent (nM) 
Q-GRFT 57.2 ± 13.8 4.5 ± 1.1 14.0 ± 4.1 1.1 ± 0.3
TFV 382.3 ± 39.6 1329.6 ± 137.8 273.7 ± 78.8 962.6 ± 274.3
RAL 3.3 ± 0.3 7.4 ± 0.7 3.0 ± 0.5 6.7 ± 1.1
DAP 0.034 ± 0.008 0.1 ± 0.024 0.043 ± 0.0007 0.1 ± 0.002
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Figure 2.4. The IC50 curves for free ARVs and free Q-GRFT co-administration 
demonstrate synergistic interactions. (A) Free TFV + free Q-GRFT, (B) free RAL + 
free Q-GRFT and (C) free DAP + free Q-GRFT. (D) Fold decrease in the IC50 
values of Q-GRFT and ARVs after co-administration to TZM-bl cells 1 hr prior to 
HIV-1 pseudovirus infection. The normalized infectivity values are shown as the 
mean ± standard deviation of three independent samples. Please note differences 
in log scale on the x-axis.  
Combinations of Q-GRFT NPs with each ARV. The activity Q-GRFT NPs 
with each free ARV was assessed using the equipotency ratio of Q-GRFT NPs to 
each ARV, with the IC50 of Q-GRFT NPs calculated based on the loading value. 
As shown in Figure 2.5, the IC50 values of Q-GRFT NPs decreased by 6.6, 4.3, 
and 2.2-fold when co-administered with free TFV, RAL, or DAP, respectively, 
relative to the administration of Q-GRFT NPs alone. The IC50 values of free TFV 
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and RAL co-administered with free Q-GRFT NPs decreased by 1.6 and 1.4-fold, 
relative to free TFV and RAL; however, minimal reduction (~0.5-fold) was observed 
in the IC50 value of DAP.  
Figure 2.5. The IC50 curves for free drugs and Q-GRFT NP co-administration 
demonstrate synergistic interactions. (A) Free TFV + Q-GRFT NPs, (B) free RAL 
+ Q-GRFT NPs and (C) free DAP + Q-GRFT NPs. (D) Fold decrease in the IC50 
values of Q-GRFT NPs and ARVs after co-administration to TZM-bl cells 1 hr prior 
to HIV-1 pseudovirus infection. The normalized infectivity values are shown as the 
mean ± standard deviation of three independent samples. Please note differences 
in log scale on the x-axis. 
Combinations of Q-GRFT NPs with ARV NPs. Lastly, the efficacy of Q-
GRFT NPs and individual ARV NP groups was determined using the equipotency 
ratio of Q-GRFT NPs to each ARV NP based on loading values. A significant shift 
was observed in the IC50 curves after Q-GRFT NP and ARV NP co-administration 
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(Figure 2.6). Specifically, a 2.5, 2.7, and 6.0-fold reduction in Q-GRFT NP IC50 
values was observed when they were co-administered with TFV NPs, RAL NPs, 
or DAP NPs. In addition, co-administration of TFV NPs, RAL NPs, or DAP NPs 
with Q-GRFT NPs resulted in 3.3, 2.3, and 8.6-fold reduction in the IC50 of each 
encapsulated drug in combination, relative to each encapsulated drug alone. In 
general, although all NPs showed synergistic interactions when administered at an 
equipotency ratio, the most synergistic interactions were observed for DAP NPs 
and Q-GRFT NPs, resulting in 8.6 and 6.1-fold decreases in IC50 respectively, 
relative to individual DAP NPs and Q-GRFT NPs. The summary of IC50 values of 
different active agents administered individually, relative to the IC50 values after 





Figure 2.6. The IC50 curves for ARV NP and Q-GRFT NP co-administration. (A) 
TFV NPs + Q-GRFT NPs, (B) RAL NPs + Q-GRFT NPs and (C) DAP NPs + Q-
GRFT NPs. (D) Fold decrease in the IC50 values of Q-GRFT NPs and ARV NPs 
after co-administration to TZM-bl cells 1 hr prior to HIV-1 pseudovirus infection. 
The normalized infectivity values are shown as the mean ± standard deviation of 
three independent samples. Please note differences in log scale on the x-axis. 
 
 80 
Table 2.3. Summary of the IC50 values of each individual active agent after co-
administration in different forms. Active agents were administered to TZM-bl cells 
1 hr before HIV-1 pseudovirus infection.  
 
Evaluation of Synergistic Interactions based on CI Calculations 
The CI value was calculated using the Chou-Talalay method based on the 
ratio of IC50 values for each active agent when administered separately and in 
combination (Figure 2.7).  
ARV Q-GRFT ARV Q-GRFT ARV Q-GRFT
Q-GRFT+TFV 135.4 ±  7.0 9.1 ± 2.2 244.4 ± 21.3 2.1 ± 0.1 83.3 ± 10.3 5.5 ± 0.7
Q-GRFT+RAL 0.6 ± 0.1 12.9 ± 2.0 2.4 ± 0.1 3.3 ± 1.2 1.3 ± 0.1 5.2 ± 0.2
Q-GRFT+DAP 0.00737 ± 0.006 15.4 ± 0.1 0.06 ± 0.02 6.5 ± 2.0 0.005 ± 0.001 2.3 ± 0.1
 IC50 of Active Agents after Co-administration (ng/mL)
Active Agents
Free ARV + Free Q-GRFT                           Free ARV + Q-GRFT NP                      ARV NP + Q-GRFT NP                     
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Figure 2.7. Combination indices of free Q-GRFT and free ARVs, Q-GRFT NPs 
and free ARVs, and Q-GRFT NPs and ARV NPs co-administered to TZM-bl cells.  
Combinations of Q-GRFT with each ARV. When Q-GRFT was co-
administered with free TFV, RAL, or DAP, the corresponding CI values were 0.53, 
0.45, and 0.54, indicating similarly strong synergistic interactions between all 
protein-drug combinations.  
Combinations of Q-GRFT NPs with each ARV. When Q-GRFT NPs were 
administered in combination with free TFV, RAL, or DAP, the calculated CI values 
were 0.9, 1.12, and 1.47 showing synergistic interactions between Q-GRFT NPs 
and TFV.  
Combinations of Q-GRFT NPs with ARV NPs. Co-administration of Q-
GRFT NPs with ARV NPs demonstrated strong synergistic interactions with DAP 
NPs (CI = 0.21) and more modest synergistic interactions with TFV NPs and RAL 
NPs (CI = 0.82 and 0.96, respectively). Among the different combined treatment 
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groups, the strongest synergistic interaction was observed for Q-GRFT NPs when 
administered with DAP NPs (CI = 0.21).  
Assessment of NP-Fiber Composites  
Based on the most synergistic formulation evaluated above, nanoparticles 
containing 10% of either Q-GRFT or DAP were successfully incorporated into the 
PEO portion of multilayered fibers to demonstrate the release of active agents over 
a longer duration. Q-GRFT and DAP were added in a ratio of 1:10 w:w NP:PEO 
fiber (1 mg NP:10 mg fiber) to obtain a final concentration of 10 µg active agent/mg 
NP-fiber composite (based on 100 µg active agent/mg NP and 100 µg NP/mg PEO 
fiber loading). The actual loading of Q-GRFT and DAP in the NP-fiber composite 
was 6.9 ± 1.9 and 7.1 ± 0.46 µg/mg, respectively. As shown in Figure 2.8, DAP 
was fully released within the first few days, with negligible release over 3 months. 
For Q-GRFT NP-fiber composites, a burst release of 0.68 µg Q-GRFT/mg PEO 
was observed in the first day, followed by minimal release over 42 days. A second 
phase of release was observed between days 42 to 63, followed by a gradual 
release for up to 90 days. The release values from most of the time points, for a 5 
mg fiber-composite piece was within the in vitro IC50 range of free Q-GRFT and 
DAP (57 and 0.03 ng/mL, in TZM-bl cells), with the exception of the 8 and 72 hr 
time points for Q-GRFT (30 and 16 ng/mL) and 14 d, 63 to 84 d, in which the 




Figure 2.8. (A) Schematic of NP-fiber composites in which spheres may depict Q-
GRFT NPs or DAP NPs. (B) The cumulative release of Q-GRFT and DAP from 
NP-fiber composites with an initial theoretical loading of 10 µg active agent per mg 
PEO fiber. Release values are shown as the mean ± standard deviation of three 
independent NP-fiber batches. 
In Vitro Cytotoxicity Studies  
Blank NPs, as well as Q-GRFT and ARV NPs were evaluated for 
cytotoxicity at the highest concentrations used for cell inhibition assays (1 mg/mL). 
No significant decreases in viability were observed in the viability of VK2, Ect1, 
and End1/E6E7 cell lines, after treatment with Q-GRFT, TFV, or RAL NPs, relative 
to untreated cells. These groups showed greater than 92% viability after 24, 48, 
and 72 hr NP administration; however, a significant decrease in cell viability was 
observed in VK2 cells treated with 1 mg/mL DAP NPs after 48 and 72 hr (p ≤ 0.01). 
In contrast, the negative control for viability (10% DMSO) resulted in dramatically 
decreased cell viability spanning 7 to 18% across different cell lines (Figure 2.9, p 
≤ 0.05).  
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Figure 2.9. In vitro cytotoxicity of NPs encapsulating different agents administered 
to (A) VK2/E6E7 (B) End1/E6E7, and (C) Ect1/E6E7 cell lines using MTT assay. 
Viabilities are shown as the mean ± standard deviation from administration of three 
independent samples. Statistical significance between experimental groups, as 
calculated by one-way ANOVA, is represented by **p ≤ 0.01. 
Discussion 
The co-administration of multiple active agents offers the potential to 
address some of the challenges surrounding PrEP, including low user adherence, 
high toxicity, and modest efficaciousness, by enabling virus targeting via different 
mechanisms of action and a corresponding decrease in the required dose and 
adaptation to drug resistance. Due to these benefits, synergistic interactions 
between a variety of ARVs have been studied to evaluate the effectiveness of a 
multi-agent approach to treat STIs such as HIV-1222,262,285-287. While the efficacy of 
TFV, RAL, or DAP in combination with other active agents including lamivudine, 
emtricitabine, and maraviroc has been investigated in clinical trials288-290, the 
combination of these ARVs with biologics, such as Q-GRFT, has been lesser 
explored286.  To date, there are only two studies that have evaluated the potential 
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synergy between GRFT, a potent antiviral biologic, and ARVs for HIV-1 
prevention222,286. Furthermore, a new oxidation-resistant variant of GRFT (Q-
GRFT) was developed which has not been investigated in combination with other 
active agents. Lastly, only one study has evaluated the impact of wild-type GRFT 
(relative to Q-GRFT) and ARV NP co-administration. Therefore, the goal of this 
study was to evaluate the synergy between the free and encapsulated forms of Q-
GRFT and a few key “model” ARVs, which are used in oral PrEP and span different 
hydrophilicities and mechanisms of action.   
While most ARVs inhibit virus post-cell entry, Q-GRFT is a biologic entry 
inhibitor with the potential to inhibit virus at the source of infection, prior to mucus 
penetration and cell entry. Due to the different mechanisms of action and the 
potential for early intervention with Q-GRFT, co-administration of Q-GRFT with 
established ARVs may enhance prophylactic and therapeutic outcomes.  
Yet despite the promise of Q-GRFT and other antiviral agents, challenges such as 
the lack of consistent user adherence – often requiring frequent administrations 
and high dosing – and inadequate transport to target tissue, limit the utility of these 
agents in free form in clinical translation. To address these challenges, different 
dosage forms have been used to provide combinational delivery of these agents 
for HIV treatment. As two examples, polymeric films and IVRs have been used to 
deliver combinations of different active agents including TFV, DAP, and 
maraviroc288,291 for rapid versus sustained-delivery applications. For applications 
requiring delivery to physiologically complex environments, such as the FRT, 
polymeric NPs have been shown to dramatically enhance the transport of biologics 
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and other active agents, and to enhance agent instability and cellular 
internalization268,270,292. A recent study in our lab showed that PLGA NPs can 
encapsulate GRFT with high loading and showed promising efficacy against HIV-
1 in vitro and HSV-2 in vivo273. A recent study external to our group286, evaluated 
the synergy between GRFT and DAP in free, encapsulated, and co-encapsulated 
forms, demonstrating strong synergy between GRFT and DAP co-encapsulated in 
PLGA NPs at an equipotent IC50 value ratio, against HIV-1286. To expand our 
knowledge to a variety of ARVs and to obtain a better understanding of synergistic 
interactions between active agent in free and encapsulated forms, we sought to 
evaluate the synergistic interactions between an oxidation-resistant variant of 
GRFT (Q-GRFT) and three different ARVs co-administered in free form, free and 
NP form, or NP form.  
In this study, individual active agent encapsulation efficacy in NPs varied 
between 15 to 100%, based on the properties of the encapsulated agent. Overall, 
NPs that encapsulated Q-GRFT, RAL, or DAP obtained encapsulation efficiencies 
higher than 49%, while NPs provided lower loading (15%) of the hydrophilic ARV, 
TFV (Table 2.1). Similar observations have been reported in previous studies, 
demonstrating only 16% TFV loading in PLGA NPs266. In contrast with TFV, Q-
GRFT NPs had relatively high loading (49%), which was similar to other studies 
that reported 41 and 42% loading of wild-type GRFT in PLGA NPs273,286, indicating 
similar loading potential for GRFT and Q-GRFT. This high level of loading may be 
attributed to the hydrophilicity of Q-GRFT and potential interactions of the 
mannose-binding sites which may interact via polar, electrostatic, or hydrogen 
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bonding with hydrophobic residues of the PLGA matrix. In addition, protein surface 
absorption on polymeric NPs may also contribute to the higher loading observed 
with Q-GRFT, which may be further enhanced in future work by optimizing the 
concentration of protein and the use of stabilizers293. Interestingly, and despite the 
hydrophilicity and smaller size of RAL (e.g., relative to Q-GRFT), in our 
formulations, RAL obtained the highest loading, which was significantly higher than 
previously reported (55%)287. Similarly, hydrophobic DAP achieved high NP 
encapsulation, which was in agreement with other studies that reported 70% 
loading of DAP in PLGA NPs. The high loading levels observed with DAP may be 
attributed to the efficiency with which the double emulsion technique encapsulates 
hydrophobic molecules286.  
In addition to evaluating active agent loading, the release of each active 
agent from PLGA NPs was evaluated over 2 wk. Release results showed that all 
NP formulations provided modest and similar trends in sustained-release over the 
course of two weeks in SVF (< 20%, Figure 2.2). For Q-GRFT specifically, 11% of 
the total loading was released after 7 d, which is similar to that reported for similarly 
loaded wild-type GRFT from PLGA NPs (11%286 and 20%273). For TFV NPs, ~17% 
release was achieved over 14 d, similar in amount released, to that observed under 
acidic pH conditions in another study266. Due to the relatively low loading and 
similarly low release of TFV observed from blended PLGA NPs in other work, 
formulations have moved to incorporate a more hydrophobic prodrug of TFV, 
tenofovir disoproxil fumarate, to obtain more desirable loading (~57%), and 
increased release (~80% release after 48 hr)294. For RAL NPs, similar release 
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(~11%) to Q-GRFT was achieved, based on total loading; however, the release 
was lower than a previous report which showed ~60% release after 7 d from PLGA 
NPs (in PBS) with similar 100 µg/mg theoretical loading234. Similarly, in our study, 
DAP release (16%) was lower than previously reported results (69% and 
65%286,295); however, the theoretical loading was not reported, which is known to 
have a significant impact on release. Overall, similar ranges of release, as a 
function of overall loading, were observed for the active agents, which may be 
attributed to active agent entrapment in the NP, due to non-covalent binding 
between the agent and polymer. However, RAL and DAP NPs surprisingly 
exhibited higher levels of release as a function of mass active agent, which was 
unexpected due to their hydrophobicity. Previous studies have illustrated that 
encapsulant-polymer interactions and compatibilities have a significant impact on 
the particle structure, loading, and release characteristics296. In future work, these 
interactions may be modulated by integrating different materials and processing 
parameters such as polymer and drug concentration, polymer molecular weight, 
aqueous and organic phase volume, and drug content297. In addition, assessing 
the release of agents from NPs under more basic pH conditions is also 
recommended due to the increase in vaginal pH in the presence of semen. A 
previous study showed that GRFT release from PLGA NPs increased in PBS (pH= 
7.4), relative to SVF (pH=4.5), while less DAP released from PLGA NPs in more 
basic pH conditions286. 
Prior to conducting synergy studies, the IC50 of each individual free agent 
against HIV-1 in vitro, was determined relative to each corresponding NP-
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encapsulated agent (Figure 2.3). The IC50 of free Q-GRFT (57.2 ng/mL, 4.5 nM) 
was slightly higher than the values for GRFT reported in previous studies (24 and 
0.51 ng/mL), when virus was added either 1 hr post-incubation256 or simultaneous 
to treatment of TZM-bl cells286. In comparison, the IC50s of free TFV and RAL in 
this study were 1.3 µM (382 ng/mL) and 7.42 nM (3.3 ng/mL) which were similar 
to previous studies (517 nM262 and 1.5 nM234 for TFV and RAL, respectively) using 
the same cell line and administration time. For DAP, an IC50 of 0.1 nM (0.034 
ng/mL) was observed here, which was lower than previous reports of 4.7 nM. 
However, the higher IC50 value may be attributed to differences in treatment 
regimen. In our study, cells were infected with the virus 1 hr post-administration, 
while in previous work, TZM-bl cells were infected with the virus immediately after 
drug administration. In addition, it has been shown that the virus subtype impacts 
the IC50 of DAP (and other active agents), and based on this, these values can 
vary between 0.8 to 3.5 nM298. When these active agents were encapsulated in 
NPs, similar IC50 values to those with free agent administration were observed, 
with the exception of Q-GRFT NPs in which the IC50 was 4.1-fold lower than 
observed with free Q-GRFT. For Q-GRFT NPs, the lower IC50 values are in 
agreement with another study that showed the IC50 of wild-type GRFT in PLGA 
NPs decreases, relative to free GRFT273, possibly by enhancing protein stability 
and activity.  
 To evaluate the potential of Q-GRFT and ARV combinations to 
synergistically prevent HIV-1 infection, free Q-GRFT was co-administered with free 
ARVs, Q-GRFT NPs with free ARVs, and Q-GRFT NPs with ARV NPs, and the 
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IC50 values of the individual agents were compared to their combinations in each 
form (Table 2.3). When free Q-GRFT was co-administered with each free ARV, 
synergistic interactions were observed for all co-administration groups with a 3.7 
to 6.3-fold decrease in the IC50 of free Q-GRFT and a 2.8 to 5.6-fold reduction in 
the IC50 values of free ARVs (Figure 2.4). These results are in agreement with 
previous studies that assessed the impact of co-administering equipotent ratios 
(1:1 IC50 ratios) of free GRFT and TFV (CI = 0.6) in CD4+ MT-4 cells222. Another 
study demonstrated very strong synergy (CI < 0.1) between free GRFT and free 
DAP co-administered to TZM-bl cells in equipotent ratios286.  
More interestingly, when Q-GRFT and ARVs were each encapsulated in 
NPs, the synergistic interactions observed between Q-GRFT and DAP 
incorporated in NPs significantly improved relative to free Q-GRFT and free DAP 
co-administration (Figure 2.6). In fact, among all of the co-administration groups, 
the most synergistic interaction was observed between Q-GRFT NPs and DAP 
NPs with 6.0 and 8.6-fold improvements in activity for Q-GRFT and DAP, 
respectively. This observation is in agreement with a previous study that showed 
strong synergy between GRFT NPs and DAP NPs (CI = 0.08) using TZM-bl cells 
and equipotent active agent ratios286. The lower synergy observed in our study, 
between Q-GRFT NPs and TFV NPs or Q-GRFT NPs and RAL NPs may be due 
to the higher IC50 value for each ARV, which requires higher drug concentrations 
to be released from NPs to exert efficacy. Co-administration of active agents with 
different mechanisms of action in NPs may increase prophylactic effect, decrease 
the dose needed to attain efficacy against HIV-1 infection, and reduce the chance 
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of developing drug resistance. Furthermore, previous work has shown that 
encapsulating active agents in NPs may improve synergistic interactions by 
enhancing drug uptake and cell internalization262. Moreover, NPs may overcome 
chemical incompatibilities between co-administered agents262. While synergy was 
observed in all NP formulations, in future studies, different molar ratios of Q-GRFT 
NPs:ARV NPs can be explored to seek the most synergistic ratios. Moreover, the 
administered ratios may be adjusted based on the toxicity of each agent to balance 
toxicity with efficacy. In addition, the time frame of agent administration prior to 
virus exposure may be of interest to investigate. Since each active agent has 
different mechanism of action and inhibits the virus at different stages of infection, 
administration time can play a role in obtaining efficacy and synergistic interactions 
between agents.  
In addition to free Q-GRFT/free ARV and Q-GRFT NP/ARV NP co-
administration, the efficacy of co-administration of Q-GRFT NPs with free ARVs 
was evaluated. Overall, no reduction in the IC50 values of free DAP was observed; 
however, there was a modest decrease of 1.6 and 1.4-fold in the IC50 values of 
free TFV and free RAL (Figure 2.5). Antagonistic interactions between Q-GRFT 
NPs and free RAL as well as Q-GRFT NPs and free DAP (CI > 1) may be attributed 
to the unfavorable electrostatic interactions between PLGA NPs and the free drug 
due to the negative charge of PLGA NPs. Moreover, the high protein binding 
affinity of PLGA NPs with proteins in the cell media may affect the efficacy of active 
agents. In addition, the lower release of Q-GRFT, relative to available free TFV, 
RAL, and DAP, may not provide the most synergistic ratio.  
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In addition to efficacy, the safety of NPs encapsulating each of the active 
agents was evaluated in vitro, and showed that encapsulated Q-GRFT, TFV, RAL, 
and DAP at the maximum dose used in efficacy studies (1 mg/mL), are non-toxic 
to vaginal cells. Previous studies have also demonstrated the safety of PLGA NPs 
loaded with GRFT273, TFV267, RAL287, and DAP286,295 in vitro and in vivo273,286 
further validating that co-administration can enhance the efficacy of these active 
agents while maintaining their safety. It should be mentioned that the relatively 
higher toxicity of DAP NPs in VK2/E6E7 cells may be mitigated with the 
administration of lower doses via synergistic and targeted NP delivery. Moreover, 
due to the high synergy between Q-GRFT NPs and DAP NPs, a lower dose of 
active agent may be considered to obtain strong efficacy against HIV-1.  
In line with promising efficacy and safety, another important criterion is to 
provide a practical long-term prevention strategy in an effective delivery platform. 
The NP co-administration strategy evaluated here inhibited HIV-1 infection in vitro, 
and with one exception (i.e., TFV), released efficacious concentrations within the 
IC50 range of each active agent in TZM-bl cells, for up to 7 days. However, this 
release may be improved, by either improving the NP formulation, or creating a 
hybrid delivery platform similar to previous work299. In this study, we preliminarily 
evaluated NP-fiber composites to prolong the release of our most synergistic NP 
formulations, by incorporating Q-GRFT NPs and DAP NPs. In our NP-fiber 
composite platform, DAP, a small hydrophobic molecule, showed a burst release 
followed by a minimal release that was still in the IC50 range of DAP observed in 
TZM-bl cells. On the other hand, the Q-GRFT release curve followed an “S” shape, 
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indicating two distinct release phases on day 1 and days 42 through 60, each of 
which was followed by more gradual release. We attribute DAP release within the 
first few hours to the small size of DAP, while Q-GRFT, due to its larger size, may 
have been entrapped within fiber layers, providing slightly more gradual release 
through day 42. The second phase of release is attributed to NP-fiber polymer 
degradation, resulting in another burst release. These release profiles are in 
agreement with our previous work with that incorporated wild-type GRFT in a NP-
fiber composite273. Furthermore, the release profile may be optimized by changing 
the NP content and altering the outer layer thickness273.  
In addition to modulating the release, NP-fiber composites like NPs alone, 
may also enable virus inhibition at different stages by providing a burst release 
(here of DAP and NNRTI), which can provide an on-demand rapid protection 
against HIV-1, followed by more prolonged release of Q-GRFT, an entry inhibitor, 
for long-term prevention and treatment. In addition to virus inhibition via the use of 
active agents, previous studies in our group have shown that the electrospun fibers 
can also physically trap the virus, which may lend increased protection through 
physical interactions128. Moreover, lower doses of active agents are released from 
these platforms which may result in less toxicity. In the future, NP-fiber composites 
may serve as a multipurpose delivery platform to target multiple infection types by 
encapsulating different agents and may enhance NP retention relative to free NP 




In this work, NPs encapsulating Q-GRFT, TFV, RAL, and DAP were 
successfully developed with high loading and efficacy against HIV-1 pseudovirus 
infection in vitro. In addition, the synergistic interactions between free Q-GRFT and 
free ARVs, Q-GRFT NPs and free ARVs, and Q-GRFT NPs and ARV NPs were 
assessed. Significant enhancements in efficacy were observed when free Q-GRFT 
and free ARVs were co-administered, relative to the administration of individual 
active agents. Moreover, synergy was observed between free Q-GRFT and all 
ARVs when they were individually encapsulated in PLGA NPs. For Q-GRFT and 
DAP in particular, synergistic interactions improved upon co-administration of Q-
GRFT NPs with DAP NPs. Overall, this work shows that the potent HIV-1 inhibitor, 
Q-GRFT, can be co-administered with different ARVs, including NRTIs and 
integrase inhibitors, to improve antiviral efficacy against HIV-1, and that modest, 
therapeutically-relevant sustained-release can be achieved over 14 days. 
Furthermore, the co-administration of Q-GRFT with ARVs may be further 
considered in future studies to impart long-term protection by modulating multi-





A COMPUTATIONAL STUDY OF INTERACTIONS BETWEEN 
ANTIRETROVIRALS AND PLGA NANOPARTICLES 
Introduction 
The human immunodeficiency virus (HIV) is one of the most serious viral 
infections worldwide, impacting more than 37 million people300. Antiretrovirals 
(ARVs) have been used to treat HIV-1 by inhibiting virus replication at different 
stages of the viral life cycle213. These active agents are classified into five different 
groups based upon their mechanism of action: 1. Nucleoside reverse transcriptase 
inhibitors (NRTIs); 2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs); 3. 
Protease inhibitors (PIs); 4. Integrase inhibitors (INI); and 5. Co-receptor inhibitors 
(CRI). TFV, RAL, and DAP are a few examples of thirty approved ARVs that have 
been widely used for HIV-1 treatment. Tenofovir is a NRTI that is phosphorylated 
in situ to obtain its virologically active form, tenofovir diphosphate. Tenofovir 
diphosphate prevents both HIV-1 and HIV-2 DNA polymerases from integrating 
into viral DNA by competing against the nucleotide deoxyadenosine 5′- 
triphosphate. After integration, tenofovir diphosphate terminates DNA synthesis 
due to the absence of a ribose ring, a moiety responsible for elongating a proviral 
DNA strand301. RAL is an INI that inhibits the integration of HIV-1 DNA into the host 
genome by preventing the formation of covalent bonds between integrase, an 
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enzyme responsible for the transfer of viral DNA into the host chromosome and 
the host DNA218,302. Moreover, the fluorine atom in RAL is strongly electronegative 
and can interact with H-atom donors in the enzyme as well as contributing to an 
enhancement of the inhibitor lipophilicity that improves cell permeability303. 
Dapivirine (DAP), an NNRTI, is a substituted diarylpyrimidine derivative that tightly 
binds to HIV reverse transcriptase and prevents virus replication304.  
Antiretrovirals can be delivered via different modalities that include oral and 
topical pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). 
Oral delivery of ARVs is challenged with serious adverse effects such as bone 
marrow suppression and toxic hematologic side effects220 and has been shown to 
cause virus mutations221. These harmful effects are often exacerbated by the poor 
oral bioavailability and frequent dosing required by many of these drugs. As an 
alternative, topical, intravaginal, or intrarectal administration of ARVs using 
different delivery platforms has been used to address these challenges and have 
shown promise in HIV-1 treatment. In particular, polymeric NPs have been widely 
used to encapsulate different agents since they can maintain agent stability, 
improve cell penetration, and provide sustained release of the active 
agents295,305,306. PLGA is one of the most widely used polymers for ARV delivery 
due to its biocompatibility and biodegradation properties. Previous studies have 
shown that using PLGA NPs can increase the permeability and bioavailability of 
the agents307. 
Despite the potential importance of drug and polymer interactions in 
developing effective delivery vehicles, there are only a few studies that have used 
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computational chemistry or molecular dynamics (MD) to investigate interactions 
between drugs and their delivery platforms308-313. One study has used MD 
simulations to predict the compatibility of two hydrophobic drugs in poly(ethylene 
oxide)-b-poly(ε-caprolactone) (PEO-b-PCL) block copolymer micelles with 
different molecular weights308. Flory–Huggins interaction parameters calculated for 
different drug–polymer systems in this study have shown that this parameter is not 
sensitive to the hydrophilic PEO chain length but strongly depends on the 
hydrophobic chain length of PCL308. In a similar study, the drug loading capacity 
of PEO-b-PCL copolymer for two anticancer hydrophobic drugs was assessed 
utilizing the Flory–Huggins interaction parameter and radial distribution function 
(RDF). Findings were compared to in vitro drug release from PEO-b-PCL 
micelles309. This study demonstrated that an increase in the PCL/PEO (w/w) ratio 
increases the solubility of hydrophobic drugs due to the multiple hydrogen bonding 
sites on the PCL block that may interact with hydrogen bonding sites on the drug 
molecule309. Another study regarding drug and polymer interactions focused on 
the analysis of intermolecular interactions between hydrophobic drugs and PEO-
b-PCL block copolymers to evaluate the encapsulation capability of multi-
hydrophobic block structures310.  The results showed that using three PCL blocks 
can significantly enhance the drug–polymer interactions by increasing the number 
of hydrogen bond donors and acceptors310. An additional study on this subject 
utilized MD simulations to characterize interactions between an insoluble drug and 
PEG−poly(hexyl-substituted poly(lactide) micelles311. Solubility parameters 
resulting from MD simulations in that study were in agreement with experimental 
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results, indicating that simulation methods can provide an insight into the 
encapsulation capabilities of delivery platforms311. Another study used MD 
simulations and docking calculations to develop a model to predict the loading of 
different agents in polymeric nanospheres313. This model was established using 
the binding energies of different agents including curcumin, paclitaxel, and vitamin 
D3 in an ABA-triblock nanosphere comprised of poly(ethylene glycol) (A blocks) 
and tyrosine-derived polyacrylate (B block)313.  
While there is no study on simulating the intermolecular interactions 
between polymeric delivery platform and anti-HIV agents, there is one study that 
used MD simulation to investigate the interactions between water-soluble anionic 
carbosilane dendrimers and primary proteins of HIV-1 such as gp120312. That 
study showed that gp120 and the dendrimer make a complex with high binding 
affinity which inhibits the virus binding to the cell receptor and results in viral 
inactivation. 
Some of the challenges in developing nanoparticle formulations involve the 
successful encapsulation of different active agents with diverse properties 
including molecular weight, hydrophobicity, size, and drug–polymer compatibility. 
These challenges may limit the choice of polymers and drugs for encapsulation 
purposes. Simulation methods, however, can help to reduce the time required to 
identify the best candidate among countless number of polymer formulations for a 
specific active agent ranging from small drug molecules to peptides and large 
proteins. Given the importance of simulations in optimizing experiments and 
predicting experimental results, several studies have reported different 
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encapsulation efficiencies for PLGA NPs encapsulation of different ARVs that can 
depend on drug hydrophobicity, size, and other physical and structural 
factors266,287,295. A better understanding of the polymer and active agents can help 
to explain and predict experimental results and improve the drug–delivery systems. 
To provide insight into the ARV encapsulation of PLGA NPs, molecular mechanics 
and MD simulations are applied in the current study to investigate the interactions 
between different ARVs and their polymeric delivery platforms. The objective of 
this study is to investigate the importance of hydrogen bonding between the 
polymer and different drug molecules on the loading capacity of PLGA NPs.  
Experimental Design  
Materials 
Materials. Poly(vinyl alcohol) (PVA, 87–90% hydrolyzed, 30000–70000 
MW) and PLGA used to synthesize NPs (lactic acid:glycolic acid 50:50, viscosity: 
0.55-0.75 dL/g, 31000-57000 MW) were purchased from Sigma Aldrich (St. Louis, 
MO) and Lactel Absorbable Polymers (Cupertino, CA), respectively. Tenofovir 
(TFV) and Dapivirine (DAP) were obtained from Sigma Aldrich (St. Louis, MO) 
while Raltegravir (RAL) was provided by Selleckchem (Houston, TX). 
Dichloromethane (DCM) was purchased from Thermo Fisher (Waltham, MA). 
Other chemicals including dimethyl sulfoxide (DMSO) were acquired from Sigma 
Aldrich. 
NP Synthesis. Blank NPs and NPs loaded with TFV, RAL, or DAP were 
fabricated using either single or double emulsion techniques. These drugs were 
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selected as model molecules because of their different hydrophilicity. For each 
formulation, 100 mg of PLGA was dissolved in 2 mL of DCM and incubated 
overnight. For TFV and RAL NPs, 10 mg of the active agent was dissolved in 200 
μL of Tris-EDTA (TE) buffer. For DAP NPs, 10 mg of DAP was dissolved in 200 
μL of DCM. The active agent solution was added dropwise to the polymer solution 
while the solution was vortexed. Then, the active agent–polymer solution was 
sonicated and added to 5% PVA in Milli-Q water (2 mL), vortexed, and sonicated 
again. The emulsified solution was then added to a larger volume of aqueous 
solution (50 mL of 0.3% PVA) and incubated for 3 hr with stirring in order to 
evaporate DCM. Next, NPs were centrifuged and pelleted (25,364 x g for 10 min 
at 4°C), washed three times using 30 mL Milli-Q water, resuspended in 5 mL Milli-
Q water, and incubated at -80°C for 2 hr. Finally, NPs were lyophilized to obtain 
solid particles and stored at −20°C. 
Size. The size and morphology of unhydrated NPs were determined using 
scanning electron microscopy (SEM). First, samples were sputter-coated with a 
palladium/gold alloy layer of a thickness of 15–18 nm, and imaged using a Supra 
35 SEM (Zeiss, Oberkochen, Germany). The average size of NPs was analyzed 
with ImageJ software (NIH, Bethesda, Maryland) by measuring the diameter of 50 
elements per image and 3 images for each formulation.  
Loading. To assess the loading of NPs, 1–2 mg of NPs was dissolved in 
100 μL of DMSO and diluted with TE buffer to the final volume of 1 mL. Serial 1:2 
sample dilutions were then made in TE buffer. To quantify the amount of TFV, 
RAL, and DAP, plate absorbance was measured at 260, 300, and 290 nm on a 
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Synergy HT reader (BioTek, Winooski, VT, USA). After assessing the loading, the 
encapsulation efficiency of each drug was calculated by dividing the weight of drug 
encapsulated in the NPs by the mass of drug added to the polymer solution during 
the synthesis. 
Simulation Method  
The Condensed-phase Optimized Molecular Potentials for Atomistic 
Simulations Studies (COMPASS) forcefield314,315 was used for all atomistic 
simulations. This forcefield was developed using ab initio and empirical 
parametrization techniques and is especially parameterized for the simulation of 
polymers and small molecules. Gaussian 09 Software316 was used for all 
computational chemistry calculations. 
Cohesive Energy Density. First, water, a polymer chain (40 repeat units), 
and each drug molecule were built individually and the geometry was optimized 
using COMPASS forcefield. Next, an amorphous cell with periodic boundary 
conditions containing 100 drug molecules, or 5 polymer chains, was constructed 
to achieve a cell size of 30-40 Å on aside. The amorphous cell was then geometry 
optimized followed by 200-ps NVT molecular dynamics using the Nosé 
thermostat317 at a constant temperature of 310 K to mimic biological temperature. 
The final configuration was used for NPT calculations that were performed at 310 
K and 1 bar using Nosé thermostat. The simulation time of 2 ns for NPT 
calculations was long enough for the system to equilibrate as measured by the unit 
cell size stabilization. The cohesive energy density (CED) was obtained by 
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calculating the summation of bounded and non-bounded energies. The Hildebrand 
solubility parameter (δ) was calculated from the square root of the CED. For 
comparison, the CED of each drug was obtained from experimental results found 
in literature318,319 or calculated using a group–contribution method320. In this 
approach, each molecular structure is split into parameterized groups. The CED 
was obtained by summing all the group contributions. For water318 and PLGA319, 
solubility parameters were directly obtained from experimental values found in 
literature. The drug–polymer miscibility was then evaluated by comparing the 
solubility parameters of each drug and PLGA.  
Radial Distribution Function (RDF).  The radial distribution function 
provides the probability density (g) for a specific atom to have another atom as a 
neighbor at a given distance and therefore is a useful tool to investigate atomistic 
interactions. If the value of gOH between different pairs of interacting hydrogen and 
oxygen atoms, gOH, is larger than unity, strong interactions between the two atoms 
are indicated. The positions of peaks in the RDF plot show the preferred 
interatomic distances between oxygen and hydrogen atoms. Thus, if the RDF for 
an oxygen and hydrogen of two separate molecules is smaller than their covalent 
radii (1.5–2.5 Å), an interaction between atoms is evident. In our simulations, the 
amorphous cell containing either 15 drug molecules and 2000 water molecules or 
1 polymer chain and 2000 water molecules was created to achieve the cell with 
desired size of ~30–40 Å. This was followed by geometry optimization. The last 
200 frames of the trajectory file from NPT calculations (1.8-2.0 ns) were used to 
obtain the RDF values. Hydrogen and oxygen atoms of each molecule were 
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selected as a group and the intermolecular interactions between each forcefield 
type (OH and HN groups) were determined.  
Computational Chemistry Calculations. Each drug molecule and PLGA 
were created in Gaussian and geometry optimized using density–functional theory 
(DFT) calculations (B3LYP/6-311G(d,p)) to determine atomic ESP charges. Then, 
the calculated charges were compared to the electrostatic point charges used in 
the MD force fields. 
Results and Discussion 
Nanoparticle Characterization.  PLGA NPs encapsulating 100 µg of each 
ARV per mg of NP, were synthesized with high yield (>70%) and spherical 
morphology, are shown by SEM images provided in the Figure 3.1. Information on 
NPs size, loading, and encapsulation efficacy is given in Table 3.1. The size of the 
NPs ranged from 89.9 to 107.2 nm. Loadings of 15.4 ± 3.3, 103.5 ± 11.9, and 60.2 
± 2.7 µg/mg NP were obtained for TFV, RAL, and DAP NPs, respectively. These 
results show differences in encapsulation capabilities of PLGA NPs for different 
active agents. To obtain a better understanding of those experimental results, 
molecular dynamics simulations were used in this work to study the potential 
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Figure 3.1. Scanning electron microscopy images of PLGA nanoparticles loaded 
with 10% w/w (A) Q-GRFT, (B) TFV, (C) RAL, and (D) DAP. Scale bars represent 
200 nm. 
Table 3.1. Size, loading, and encapsulation efficiency (%) of PLGA NPs 
encapsulating different ARVs. 
 
 
Drug Size (dia. nm ± STD) Loading (µg/mg) Encapsulation Efficacy (%)
TFV 89.9 ± 25.3 15.4 ± 3.3 15.4 ± 3.3
RAL 106.3 ± 29.7 103.5 ± 11.9 103.5 ± 11.9
DAP 107.2 ± 27.1 60.2 ± 2.7 60.2 ± 2.7
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 Atomic Charge Distribution. The geometry-optimized structures for the 
ARVs and PLGA are shown in Figure 3.2. ESP Charges for each atom are shown 
in Table 3.2. Results indicated that although there are slight differences between 
charges obtained from molecular dynamics using the COMPASS forcefield and 
B3LYP/6-31(d, p) calculated from Gaussian, similar trends in charge distribution 
were observed. In the case of TFV, phosphorus (COMPASS forcefield type P4=) 
and nitrogen (n3h2) atoms connected to hydrogen atoms had the highest positive 
and negative partial atomic charges, respectively. The highest positive and 
negative atoms in RAL were hydrogen connected to the oxygen (h1o) and nitrogen 
(n3mh and n3h1) atoms connecting to hydrogen. In the case of DAP, hydrogen 
atoms connected to the nitrogen and nitrogen (n1t and n2a) atoms connected to 
carbon atoms possessed highly positive and negative partial atomic charges. 
These atoms were specifically chosen to investigate electrostatic interactions 
between drug molecules and water or the drug molecules and the polymer.  
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Figure 3.2. Geometry-optimized structure of A) PLGA, B) TFV, C) RAL, and D) 
DAP. Phosphorus, Fluoride, oxygen, nitrogen, carbon, and hydrogen atoms are 
shown in magenta, cyan, red, blue, gray, and white.  
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P P4= 0.82 1.14 1
o2e -0.32 -0.42 1
o1= -0.49 -0.40 1
o2e -0.55 -0.61/-0.69 2
h1o 0.41 0.40 2
h1 0.05 0.01-0.10 12
h1 (ring) 0.13 0.07-0.10 2
h1n 0.35 0.34 2
n2a -0.48 -0.51/-0.79 3
n3a 0.00 -0.46 1
n3h2 -0.72 -0.70 1
F f1 -0.13 -0.25 1
o1= -0.45 -0.30-(-0.58) 3
o2h -0.44 -0.57 1
o2a -0.06 -0.44 1
n2a -0.24 -0.3/-0.47 2
n3h1 -0.64 -0.44 1
n3mh -0.57 -0.85 1
n2= -0.3 -0.59 1
c3' 0.45 -0.3-(-0.58) 3
c4 -0.16 -0.45 7
c3a 0.27 -0.01-(-0.41) 7
c3= 0.03 0.23/0.30 2
c3o 0.48 0.38 1
h1 0.127 0.09-0.15 17
h1o 0.41 0.39 1
h1n 0.35 0.23/0.30 3
n1t -0.43 -0.71 1
n3h1 -0.37 -0.45/-0.54 2
n2a -0.48 -0.53 2
c3a 0 0.01-0.53 15
c2t 0.22 0.75 1
c3az 0.21 0.4 1
c4 -0.16 0.97 3
h1 0.05 0.09-0.12 17















Cohesive Energy Densities. In order to validate the COMPASS forcefield 
for water, PLGA, and drugs, the cohesive energy density (CED) for each 
compound was obtained using MD (COMPASS forcefield) calculations and 
compared to experimental values for water318 and PLGA319 in the literature or using 
a group–contribution method320. As shown in Table 3.3, the solubility parameters 
calculated for water, PLGA, TFV, RAL, and DAP were 44.87, 25.26, 26.25, 24.51, 
and 22.67 MPa1/2, respectively. The computed values were in reasonable 
agreement with those calculated using functional–group contributions and 
experimental values with 7% to 20% difference between two values. This is in 
agreement with previous studies that have shown that molecular simulations using 
COMPASS forcefield can satisfactorily predict the structural, conformational, and 
cohesive properties of polymers and drug molecules308,309. In addition, previous 
studies have demonstrated that if the difference in solubility parameters between 
two molecules is less than 7 MPa1/2, they are likely to be miscible321. Given this, 
similar solubility parameters for TFV, RAL, DAP, and PLGA indicate that all of 
these ARVs and the polymer are thermodynamically miscible, suggesting that 
PLGA–drug blend is a physically stable dispersion, while experimental results 
showed low compatibility between TFV and PLGA. In addition, the large difference 
between solubility parameters of water and PLGA as well as water and drugs, 
indicates that PLGA and ARVs are not miscible with water that contradicts 
hydrophilic properties of TFV. Based on this, the Hildebrand solubility parameter 
is not an accurate measurement of drug–carrier compatibility for our system. This 
might be attributed to the fact that the Hildebrand solubility parameter is often used 
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to predict nonpolar and slightly polar systems and does not include hydrogen 
bonding322. Thus, RDF plots were created to predict the hydrogen bonding 
interactions between each drug and PLGA.  
Table 3.3. Cohesive energy densities obtained from MD simulations and 
calculated values. a. CED calculated using MD simulations and b. CED calculated 
using experimental values in literature or calculated based on group contributions. 
 
Radial Distribution Function. The first peak in RDF plot with gab(r)>1 
indicates interactions between the a and b atoms. Figure 3.3 identified forcefield 
types for atoms in each drug, water, and PLGA that showed distinguishable peaks 
in the RDF plot. As shown in Figure 3.4, no peak was evident in the RDF plots 
between oxygen atoms in ether (o2s) or carbonyl (o1=) groups of PLGA and 
hydrogen atoms of water (h1o). In addition, no peak was observed in the RDF plot 
between the hydrogen atom in PLGA (h1) and the oxygen atom in water (o2*). This 
indicates no apparent interactions between hydrogen bonding moieties probably 
because hydrogen connected to carbon in PLGA is not electropositive enough to 
form a hydrogen bond with oxygen in water and this observation is consistent with 
the hydrophobicity of the polymer.  
Compound
MD simulated Cohesive 
Energy Density (MPa)
MD Simulated Solubility 
Parameter  (MPa)
1/2
Solubility Parameter in 
Literature (MPa)
1/2 % difference
water 2013 44.866 47.9 -7%
PLGA 638 25.259 23.1 9%
TFV 689 26.249 23.35 11%
RAL 601 24.515 22.76 7%
















Figure 3.3. Identification of atoms participating in intermolecular interactions 
between drugs and water/polymer. A) oxygen atom (o2*) in water; B) oxygen atom 
(o1=) in PLGA; C) hydrogen atom (h1o) in TFV; D) hydrogen atom (h1o) in RAL; 
 111 
and E) hydrogen atom (h1n) in DAP. Forcefield types are showed for all atoms and 
interacting atoms are identified by boxes. 
 
Figure 3.4. RDF for intermolecular interactions between A) oxygen atom (o2s) in 
the ether group of PLGA and hydrogen atom (h1o) in water; B) oxygen (o1=) in the 
carbonyl group of PLGA and oxygen (o2*) in water; and C) hydrogen (h1) in PLGA 
and oxygen in water. 
The RDF plots for functional atoms in combinations of TFV and either water, 
PLGA, or a mixture of water and PLGA are shown in Figure 3.5. Only the RDF 
plots having distinct peaks for hydrogen and oxygen pairs are shown in this figure. 
The sharp peak at 1.8 Å between the hydrogen atom connected to the oxygen 
atom in TFV (h1o) and the oxygen atom in water suggests that there is hydrogen 
bonding between both molecules. Similar interactions were observed between 
hydrogen connected to oxygen in TFV (h1o) and oxygen in the carbonyl group of 
PLGA (o1=). Interestingly, hydrogen bonding was not observed between TFV and 
PLGA in the presence of water, but it was still present between TFV and water in 
the presence of the polymer. This suggests that hydrogen bonding between water 
and drug is stronger than between polymer and drug. 
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Figure 3.5. RDF for intermolecular interactions between hydrogen atom (h1o) in 
TFV and oxygen atoms (o1= or o2*) in A) PLGA in the absence of water; B) water 
in the absence of PLGA; C) PLGA in the presence of water and D) water in the 
presence of PLGA.  
For RAL, hydrogen bonding between the hydrogen atom connected to the 
oxygen atom in RAL (h1o) and oxygen atoms of water (o2*) was observed at the 
distance of 1.8 Å but the peak in RDF was less sharp than observed for TFV, which 
is in agreement with the lower solubility of RAL in water (Figure 3.6). However, 
there was evidence of strong hydrogen bonding between the hydrogen atoms 
connected to the oxygen atom in RAL (h1o) and the oxygen atom of the carbonyl 
group in PLGA (o1=). The interactions between RAL and PLGA are as strong as 




Figure 3.6. RDF for intermolecular interactions between hydrogen atom (h1o) in 
RAL and A) oxygen atom (o1=) in PLGA in the absence of water; B) oxygen atom 
(o2*) in water in the absence of PLGA; C) oxygen atom (o1=) in PLGA in the 
presence of water; and D) oxygen atom (o2*) in water in the presence of PLGA.  
No interactions between DAP and water molecules were detected due to 
the hydrophobicity of this drug. Hydrogen bonds formed between the hydrogen 
atom connected to the nitrogen atom in DAP (h1n) and the oxygen atom of the 
carbonyl group in PLGA (o1=) and hydrogen bonding was still detected in the 
presence of water, even though it was much weaker (Figure 3.7). No difference in 
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interactions between DAP and water was observed in the absence or presence of 
PLGA.  
Figure 3.7. RDF for intermolecular interactions between hydrogen atom (h1n) in 
DAP and oxygen atom (o1=) in A) PLGA in the absence of water; B) water in the 
absence of PLGA; C) PLGA in the presence of water; and D) water in the presence 
of PLGA.  
Hydrogen Bonding. To further evaluate the hydrogen bonding strength for 
different drugs and the polymer, we compared the charges on individual hydrogen 
and oxygen atoms. In TFV, the charge of the hydrogen atom connected to oxygen 
(h1o) and the hydrogen atom connected to nitrogen atoms (h1n) were 0.41 and 
0.35, respectively, showing that the hydrogen atom connected to the oxygen atom 
is more electropositive. Moreover, the oxygen in the carbonyl group (C=O) and the 
oxygen in the ether group (C-O-C) of PLGA were -0.45 and -0.27, respectively.  
Therefore, the double-bonded oxygen atom (C=O) has a higher tendency to form 
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hydrogen bonding compare with single-bonded oxygen atom (C-O-C). However, 
the electrostatic interactions between opposite charges include both columbic 
interactions and hydrogen bonds formed between the drug and water or the drug 
and polymer. To study the hydrogen bonding contribution, the distance between 
the hydrogen atom and the acceptor atom was measured (Figure 3.8). Among all 
different atoms in each drug, the distance between the hydrogen atom connected 
to oxygen in TFV (h1o), the hydrogen atom connected to oxygen in RAL (h1o), 
and the hydrogen atom in DAP (h1) and the oxygen atom in the carbonyl group of 
PLGA (o1=) was ≤ 2.8 nm, indicating moderately strong hydrogen bonding.  
Based on the experimental values for loading of different ARVs, RAL NPs 
possessed the highest loading and TFV NPs had the lowest loading. In addition, 
the predictions from MD simulations verified the fact that encapsulation capability 
of PLGA NPs is higher for RAL, relative to TFV due to stronger hydrogen bonding 
between RAL and carboxyl group of PLGA. One possible reason for weaker 
hydrogen bonding between TFV and PLGA might be the attributed to the steric 




Figure 3.8. Visualization of hydrogen bond formation between the oxygen atom 
(o1=) of PLGA and A) hydrogen atom (h1o) of TFV, B) hydrogen atom (h1o) of 





One of the challenges in delivering small hydrophilic therapeutics 
encapsulated in polymeric NP is low encapsulation efficacy. In this study, we 
studied the interactions between three different ARVs and PLGA and their effect 
on the encapsulation efficacy of PLGA NPs. Our experimental data has shown that 
the encapsulation efficacy of TFV was as low as 15%; however, the loading for 
RAL and DAP NPs was much higher (> 70%). First, the solubility parameter of 
each model compound was computed and compared to literature values to 
validate and verify the simulation model. MD simulations indicated that hydrogen 
bonding between TFV and PLGA in the presence of water is weaker than between 
TFV and water in the same system, causing the drug to leach into the aqueous 
phase in the process of NP fabrication and causing low encapsulation efficacy. On 
the other hand, hydrogen bonding between the oxygen atom in the carbonyl group 
of PLGA and the hydrogen atom connected to the oxygen atom in RAL was 
stronger than RAL and the oxygen atom in water, resulted in high encapsulation 
efficacy for RAL NPs.  
This study demonstrated the potential of MD simulations to accurately 
predict the encapsulation capability of polymeric NPs by evaluating the 
intermolecular interactions between the drug and polymer. This approach has the 
potential to be used to optimize formulation of polymeric NPs as well as tailor-make 
the polymer nanoparticles to achieve higher encapsulation efficacy, especially for 
hydrophilic small drugs. Moreover, this computational method can be applied to 
other polymeric delivery systems to evaluate the compatibility of drug and dosage 
 118 
form and predict encapsulation efficacy of polymeric drug carriers. In the future, 
the effect of adding different functional groups on polymer chain can be evaluated 
















PROBIOTIC FIBERS AS AN ALTERNATIVE DOSAGE FORM FOR BACTERIAL 
VAGINOSIS TREATMENT 
Introduction 
Bacterial vaginosis (BV) is the most common vaginal infection in women 
between the ages of 15 to 44, impacting ~30% of women in the U.S. and globally. 
Within the healthy female reproductive tract (FRT), microorganisms belonging to 
the genus Lactobacillus are the most abundant, and aid in maintaining host 
homeostasis and providing innate defense against incoming pathogens5. 
However, for women afflicted with BV, the microbial ecology of the reproductive 
tract is altered, and resident lactobacilli are replaced by an overgrowth of 
pathogenic vaginal anaerobes such as Gardnerella vaginalis (G. vaginalis), as well 
as Atopobium vaginae, Prevotella, Peptostreptococcus, and Bacteroides spp. This 
increased diversity and dysbiosis of the vaginal microbiota is associated with an 
elevated risk of adverse pregnancy outcomes, post-surgical infections, acquisition 
of sexually transmitted infections (STIs), and other deleterious health outcomes5. 
Several antibiotics have been used to manage BV, including metronidazole, 
clindamycin, and tinidazole, which are administered orally or topically in the form 
of tablets, creams, and gels323. Currently recommended BV treatments consist of 
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oral metronidazole tablets, taken twice daily for one week; metronidazole 
gel applied once daily for 5 days; or clindamycin cream applied once a day for one 
week5. While ~80% of infections are initially effective with these approaches, 
chronic antibiotic usage has been shown to contribute to antibiotic-resistance, 
while also promoting adverse gastrointestinal effects and opportunistic yeast 
infections323. More importantly, there is no cure for BV, and nearly 50% of women 
experience recurrence of infection within 12 months post-treatment323.  
Relative to antibiotic-based strategies, the administration of probiotics, or 
beneficial bacterial species, has been shown to provide anti-inflammatory effects 
and help in modulating host immunity. The administration of probiotics via orally- 
or topically-administered dosage forms may help to disrupt abnormal microflora 
and restore balance to the vaginal microbiota324.  Thus, new approaches have 
begun to focus on the delivery of probiotics to stabilize the vaginal microbiome and 
prevent the growth of BV-associated bacteria. Of the probiotic candidates, 
lactobacilli are the most abundant, and help to promote vaginal health by producing 
a variety of molecules including: lactic acid to decrease the vaginal pH; 
biosurfactant-containing collagen-binding proteins to compete against pathogenic 
species for vaginal epithelial adherence; and hydrogen peroxide and bacteriocins, 
which act as antimicrobials and enhance host immune responses325. In fact, 
mechanisms such as auto-aggregation of Lactobacillus, Lactobacillus adherence 
to epithelial cells, or the co-aggregation of Lactobacillus and pathogenic 
microorganisms have been shown to modulate the composition of the healthy 
vaginal microbiota  and to improve endogenous microflora326-328.  
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Given their role in mediating pathogenesis, several studies have 
investigated the efficaciousness of different Lactobacillus species in inhibiting BV 
infection326. Previous studies have shown that Lactobacillus acidophilus (L. 
acidophilus) is one of the few taxa with promising evidence of microbiological and 
clinical cure329,330, and are believed to impact BV infection by producing hydrogen 
peroxide and bacteriocins that have a wide range of antibacterial activities323. One 
study showed that L. acidophilus GLa-14 significantly reduces G. vaginalis 
adherence to HeLa cells in vitro by regulating immune responses such as 
macrophage activation, thereby indicating or promoting anti-BV effect331. In 
another study, two Lactobacillus species, L. fermentum MG901 and L. plantarum 
MG989, were individually co-cultured with G. vaginalis and both strains 
significantly decreased G. vaginalis viability 332. Furthermore, studies in a murine 
model have shown that combining the oral delivery of capsules containing either 
L. acidophilus GLa-14, L. rhamnosus HN001, or both probiotics with lactoferrin 
RCXTM reduced G. vaginalis vaginal colonization and inhibited G. vaginalis-
induced expression of cytokines involved in adaptive immunity, and that of these 
formulations, L. acidophilus GLa-14 was the most effective 331.  
Lasty, clinical trials have demonstrated promising outcomes with the 
administration of lactobacilli to treat BV. A clinical study with women infected with 
BV, candida vaginitis, or both showed that daily ingestion of yogurt containing 108 
colony forming units (CFU) L. acidophilus/mL significantly increased the number 
of L. acidophilus-positive vaginal cultures (86%), relative to those who ingested 
pasteurized yogurt with no probiotic (36%), indicating the potential of L. acidophilus 
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in treating BV329. Another clinical study evaluated the oral co-administration of two 
Lactobacillus species, L. rhamnosus GR-1 and L. reuteri RC-14 (109 CFU each per 
capsule), for thirty days after a conventional twice-daily oral metronidazole tablet 
regimen spanning one week, and demonstrated a 48% decrease in BV infection 
after 28 d, relative to antibiotic-only treatment 333. Similarly, a clinical trial with 
women suffering from BV recurrence demonstrated that the oral administration of 
one capsule per day for 7 days, that contained 8 × 109 CFU of L. acidophilus, L. 
rhamnosus and Streptococcus thermophilus in total per capsule, resulted in 
recurrence rates as low as 15%, relative to the placebo group (45%)334. 
Despite these advances, some of the challenges confronting oral probiotic 
delivery include transport and degradation associated with exposure to the acidic 
environment of the gastrointestinal tract , often necessitating increased dosing and 
administration frequency to achieve colonization and subsequent effect335. 
Localized intravaginal probiotic administration may circumvent these challenges 
and offer a promising alternative to oral administration strategies. Vaginal dosage 
forms, including gel, cream, and capsule formulations have been used to locally 
deliver probiotics to the FRT, and to induce local acidification and epithelial 
colonization, thereby preventing the adherence of pathogenic bacteria334,336,337. In 
clinical trials, 95 patients who were administered vaginal capsules containing a 
mixture of L. gasseri, L. casei., L. rhamnosus, L. fermentum, and P. acidilactici  for 
5 days experienced reduced vaginal discharge and a higher clinical cure rate 
relative to placebo capsules after two menstrual cycles338. In another clinical trial, 
vaginal tablets containing ≥ 107 CFU L. acidophilus per tablet reduced BV infection 
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by up to 76%, after a two week, 1-2 tablet(s) per day regimen339. Yet, similar to 
oral dosage forms, most vaginal dosage forms require frequent daily or twice-daily 
administration over a one to two-week duration. These regimens can be 
inconvenient and may also induce discomfort, due to product leakage. The most 
effective dosage form to date, which reduced BV infection by up to 88%, required 
the administration of 1 to 2 vaginal tablet(s) containing ≥ 107 CFU L. 
acidophilus/tablet and 0.03 mg estriol for 6 days339.  
To avoid the challenges and inconvenience of daily treatment regimens, a 
delivery vehicle that offers prolonged delivery (> 1 wk) may be desirable; however, 
few dosage forms are currently available to achieve sustained-release of 
probiotics. To date, only one dosage form, in the form of a pod-based intravaginal 
ring, has shown the potential to provide sustained-release of probiotics for 
intravaginal application340. However, rings may be susceptible to biofilm formation 
and yeast adhesion, posing an additional challenge to BV treatment 5. Recently, 
electrospun fibers have emerged as a viable platform to deliver prophylactic and 
therapeutic agents341 and probiotics342,343 for viral and bacterial female 
reproductive health applications. Hydrophilic polymers such as polyethylene oxide 
(PEO), polyvinyl alcohol (PVA) and polyvinyl pyrrolidone (PVP) have been used to 
fabricate fibers that incorporate different bacteria including Pseudomonas, 
Zymomonas, Escherichia, and Lactobacillus for a variety of applications ranging 
from synthetic biofilm-based membrane bioreactors to the development of stable 
solid probiotic dosage forms such as electrospun nanofibrous matrices342,344,345. 
Polymeric fibers made from PEO and PVA offer rapid dissolution and a variety of 
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attributes including bioadhesivity, which may increase retention for intravaginal 
applications, and as a result may extend probiotic (or other active agent) residence 
time, thereby decreasing the risk of recurrence323,341. In addition to these attributes, 
encapsulant release by electrospun fibers can be tuned by changing the material, 
electrospinning parameters346, and architecture341 which may enable the 
prolonged delivery of lower active agent doses within the FRT. Lastly, fibers have 
been shown to enhance encapsulant stability and half-life347, which is particularly 
important for the incorporation of live cells.  
Previous work in our group has focused on the development of electrospun 
fibers that deliver proteins, and anti(retro)virals against viral125,128,273,348-350 and 
bacterial infections in the FRT and oral cavity 351, respectively. In particular, our 
recent studies in an HSV-2 murine model demonstrated the efficacy and 
preliminary safety of intravaginally administered, single and multilayered PEO 
fibers273,349. Here we sought to extend this work to develop rapid-dissolve fibers 
that incorporate L. acidophilus, as a first step in developing a sustained-release 
probiotic fiber platform. We first assessed the ability of PEO fibers to function as 
an inert and safe delivery platform in vivo, using a traditional antibiotic treatment 
as early proof-of-concept in a murine model of G. vaginalis infection. Based on 
these promising results with a traditional treatment strategy, we subsequently 
formulated fiber scaffolds made of two different water-soluble polymers, PEO and 
PVA, to provide high loading, viability, stability, and release of L. acidophilus in 
vitro. The optimal PEO and PVA formulations were then evaluated for their ability 
to inhibit G. vaginalis viability in broth co-culture and epithelial-G. vaginalis co-
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colonization assays. These studies suggest that PEO fibers are preliminarily safe 
and capable of intravaginally delivering effective therapeutics in a murine model of 
G. vaginalis infection, and further highlight the versatility of electrospun fibers to 
functionally incorporate probiotics against in vitro infection.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
Materials and Methods 
Fabrication and characterization of metronidazole (met)-containing PEO 
fibers 
Blank and metronidazole (met)-containing polyethylene oxide (PEO, 600 
kDa) fibers were electrospun to evaluate the preliminary safety and efficacy of 
fibers in a murine model of G. vaginalis infection. To prepare the polymer solution 
for electrospinning, a 5% w/w PEO solution was formulated in a final 
electrospinning volume of 3 mL dimethylformamide and was incubated for 30 min 
at room temperature. The mentioned polymer percentage (5% PEO) was based 
on a previously optimized formulation that resulted in bead-free and well-defined 
fiber structure 273,349. Then, 100 µg met per mg polymer, was added to the polymer 
solution, vortexed thoroughly, and incubated for 30 min. The resulting met-
containing or blank PEO solution was electrospun using a flow rate of 0.3 mL/hr, 
with an applied voltage of 20 kV. The resulting fiber mats were collected on a 
rotating, 8 mm outer diameter stainless steel mandrel, positioned 15 cm from the 
blunt needle tip of the syringe. The sample flow rate was regulated by an infusion 
pump (Fisher Scientific, Pittsburgh, PA) and the voltage was applied using a high 
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voltage power supply (Spellman CZE 1000R). After electrospinning, the fiber was 
removed from the mandrel and desiccated overnight at room temperature. 
To measure the loading of met-containing fibers, 3 mg of fiber were 
dissolved in 1 mL 1X phosphate buffered saline (PBS). This solution was diluted 
by adding 100 µL of sample to 900 µL PBS (1:10) and the amount of met was 
quantitated via reverse phase high performance liquid chromatography with UV 
detection (HPLC-UV), as previously described352.  Briefly, diluted samples were 
separated on a Sunfire 4.6 x 250 mm C18 column (Waters) using a mobile phase 
of 80:20 (v/v) mixture of 5 mM potassium phosphate:acetonitrile, pH 4.0, at a flow 
rate of 1 mL/minute. Eluates were monitored at 324 nm (Waters 2487 detector) 
and quantified relative to an external standard of purified met. 
Preliminary preclinical assessment of PEO fibers to safely deliver vaginal 
therapies 
As a first test of the feasibility of the in vivo fiber approach, the safety of 
fibers and the fiber placement approach was evaluated in a murine model of G. 
vaginalis infection. Ten female 6-8-week-old C57Bl/6J mice were purchased from 
Jackson Laboratories in June 2018 and allowed to convalesce in the Washington 
University facility for 1 week prior to experimentation. All mice were first given an 
intraperitoneal injection of -estradiol-17-valerate (0.5 mg in 100 L sterile sesame 
oil) to synchronize the estrus cycle; this is standard practice in vaginal bacterial 
infection models. Three days later, mice were given a second -estradiol injection 
and vaginal washes were collected by inserting a sterile P20 pipette with 60 L 
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PBS and pipetting up and down. Then microdissection forceps were used to 
carefully insert 6 mm PEO discs into the vaginas of 5 mice, while 5 mice were 
untreated (negative controls). Immediately following fiber insertion, all 10 of these 
mice were then intravaginally infected with ~108 CFU of a streptomycin-resistant 
clinical isolate of G. vaginalis (JCP8151B, GenBank JX860320) in 20 L PBS using 
a P20 pipette. The next day, vaginal washes were collected and plated for CFU 
and vaginas were collected and fixed in 4% paraformaldehyde for histological 
analysis.  
To begin to assess the potential therapeutic benefit of fiber delivery with a 
known standard therapy, twenty female C57Bl/6J mice were estrogenized as 
above. The mice were divided into two (10 mice each) experimental arms: 
“prevention” and “treatment.” For the “prevention” experiment, microdissection 
forceps were used to carefully insert 6 mm met-PEO discs into the vagina of 5 
mice, while 5 mice received blank fibers (negative control). Immediately following 
fiber insertion, all 10 of these mice were then intravaginally infected with ~108 CFU 
G. vaginalis in 20 L PBS using a P20 pipette. The next day, after ~24 hr, vaginal 
washes were collected and then the mice were sacrificed to collect vaginal and 
uterine horn tissue, which were homogenized and plated for CFUs by serial dilution 
and plating on selective media (NYCIII + strep). Vaginal washes were likewise 
plated for CFU counts. 
For the “treatment” arm of the experiment, 10 mice were inoculated with G. 
vaginalis as described above. The next day, ~24 hr later, vaginal washes were 
collected from all mice to determine the level of G. vaginalis infection prior to 
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treatment by CFU plating. Immediately after vaginal wash collection, 5 mice were 
given met-PEO fibers and the remaining 5 were given blank fibers. The following 
day (thus 48 hr after G. vaginalis inoculation, 24 hr after fiber administration), 
vaginal washes and vaginal and uterine tissue were collected, serially diluted, and 
plated as above. G. vaginalis CFUs were counted from the vaginal wash and 
vaginal/uterine tissue homogenate dilutions and H&E-stained sections were 
examined. 
Histological analysis 
Following fixation, vaginas were processed for histological analysis by 
embedding in paraffin, sectioning, and staining with hematoxylin and eosin by the 
Department of Developmental Biology Histological Core at Washington University 
School of Medicine. Stained sections were visualized on an Olympus BX61 
microscope. 
Bacterial cultures 
L. acidophilus was purchased from American Type Culture Collection 
(ATCC 4356) and a streptomycin-resistant clinical isolate of G. vaginalis 
(JCP8151B, GenBank JX860320) was generously provided by Dr. Amanda Lewis 
(Washington University, St. Louis, MO). L. acidophilus was grown using de Man, 
Rogosa, and Sharpe (MRS, Sigma 69966) broth and agar plates, both 
supplemented with 0.1% Tween 80.  G. vaginalis was grown using New York City 
III (NYC III) broth and agar plates, both supplemented with 10% heat-inactivated 
horse serum (Gibco 26050088). The NYC III agar plates contained 1 mg/mL 
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streptomycin sulfate salt (Sigma S9137) to select for the antibiotic-resistant G. 
vaginalis strain.  
Bacterial cultures were initially prepared from frozen stocks using an 
inoculation loop to streak frozen culture on the appropriate agar plates. Both L. 
acidophilus and G. vaginalis were initially cultured on agar plates under anaerobic 
conditions and maintained at 37°C in 5% hydrogen, 5% carbon dioxide, and 
balanced with nitrogen using a Bactronez Anaerobic Workstation (Shel Lab). The 
incubation time to observe the growth of L. acidophilus on MRS plates was 48 hr, 
while G. vaginalis cultures were incubated for 72 hr on NYC III agar plates due to 
slower colony formation. For all bacterial sub-cultures, a single bacteria colony was 
selected from the agar plate and cultured in 1 mL of MRS or NYC III broth in a 
closed microcentrifuge tube for 48 or 72 hr at 37°C, to minimize exposure to air. 
The bacteria were subsequently sub-cultured in broth by diluting 200 µL of L. 
acidophilus with 9.8 mL of MRS broth (1:50 dilution) and 20 µL of G. vaginalis with 
980 µL NYC III broth (1:50 dilution). Growth curves were evaluated prior to 
conducting experiments, to determine the exponential phase of bacterial growth, 
and to compare the OD600 absorbance values with respect to time. To generate 
the growth curves, each bacterium was sub-cultured by adding 0.1 mL of the first 
L. acidophilus or G. vaginalis sub-culture solution to 10 mL media and grown until 
the stationary phase was achieved. The correlation between the OD600 and 
respective CFU counts was determined by plating serial dilutions of each culture 
on MRS and NYC III agar plates for L. acidophilus and G. vaginalis, respectively. 
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One OD600 of L. acidophilus and G. vaginalis was found to be equivalent to 5.8 x 
107 and 1.3 x 109 CFU/mL, respectively.  
During the late exponential phase (OD600 between 2 and 7), L. acidophilus 
was harvested for fiber fabrication. L. acidophilus cultures in MRS growth media 
were centrifuged at 3000 x g for 10 min at room temperature (25°C). The bacterial 
pellet was then either resuspended in MilliQ water, MRS broth, or MRS broth with 
5% v/v glycerol in preparation for electrospinning. To maximize the loading of L. 
acidophilus into fibers and to assess the proper media for co-culture assays, L. 
acidophilus and G. vaginalis growth rates were evaluated in both MRS and NYC 
III broths and the concentration of each bacterial species was determined by 
measuring the OD600 at various time points over 48 hr or 72 hr, respectively. 
Bacterial lyophilization 
For the lyophilized L. acidophilus electrospun group, MRS media containing 
6% (w/v) skim milk and 4% (w/v) trehalose was added to a fresh L. acidophilus 
pellet from a first sub-culture. The suspension was then aliquoted to 5 mL solutions 
in cryovials and frozen at -80°C for a minimum of 2 hr. The frozen L. acidophilus 
suspensions were then lyophilized for 48 hr, resulting in a dry powder that was 
then stored at -80°C. The viability of post-lyophilized L. acidophilus was 
determined by CFU count. 
Fabrication of L. acidophilus-containing PEO and PVA fibers 
Polyethylene oxide (PEO, 600 kDa) and PVA (146-186 kDa, 87% 
hydrolyzed) were prepared to fabricate fibers using a uniaxial electrospinning 
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approach. Different formulations of 5% w/w PEO and 10% w/w PVA fibers were 
electrospun in either water, MRS broth, or MRS broth with 5% glycerol, with or 
without the addition of fresh or lyophilized L. acidophilus, to determine the most 
favorable electrospinning conditions to maximize L. acidophilus viability. The 
mentioned polymer percentages (5% PEO, 10% PVA) were previously optimized 
concentrations that resulted in bead-free and well-defined fiber structures273,349. 
Formulations, incorporating lyophilized L. acidophilus, were evaluated to assess 
the impact of lyophilization on bacterial cell viability. Different concentrations of L. 
acidophilus in various solutions (detailed below) were added to the PEO or PVA 
solutions to determine the maximum concentration of viable probiotics that could 
be incorporated into fibers. 
Each probiotic fiber formulation was optimized by adjusting the 
electrospinning flow rate, applied voltage, and the distance between the syringe 
needle and mandrel. To fabricate the fibers, PEO and PVA solutions were 
prepared at 5% and 10% w/v respectively, in a final electrospinning solution 
volume of 3 mL. The day before electrospinning, PEO or PVA was added to either 
2 mL of Milli-Q water, MRS broth, or MRS with glycerol, and incubated overnight 
at 37°C. The next day, fresh L. acidophilus was centrifuged (3000 x g) in a 50 mL 
centrifuge tube and an aliquot of the pellet, containing 5 x 106, 5 x 107, or 5 x 108 
CFU L. acidophilus/mg polymer, was resuspended in 1 mL MRS broth and 
vortexed thoroughly. For lyophilized L. acidophilus, 1 mg of dry bacteria was 
weighed and suspended in 1 mL MRS broth, plated to assess CFU count per mg, 
and the desired amount of bacteria was added to the polymer solution. After 
 132 
incubating bacteria with the polymer solution for 30 min at 37°C, PEO or PVA 
solution was electrospun using a flow rate of 0.3 mL/hr (for water) or 0.25 mL/hr 
(for MRS and MRS with glycerol). 
The required voltage was either 20 kV (for water) or 25 kV (for MRS or MRS 
with glycerol). The resulting fiber mats were collected on a rotating, 8 mm outer 
diameter stainless steel mandrel, positioned 15 cm from the blunt needle tip of the 
syringe. After electrospinning, the fiber was removed from the mandrel and 
desiccated overnight at room temperature. Each fiber formulation was tested for 
bacterial viability as a function of time in -20°C, 4°C, and 25°C storage conditions 
for up to 3 months. 
Probiotic viability in PEO and PVA fibers 
The CFU counts of L. acidophilus in the initial electrospinning solution were 
compared to the CFU counts in fibers immediately after electrospinning to 
determine changes in L. acidophilus viability as a result of the electrospinning 
process. To determine CFU counts, a series of 10-fold dilutions were made of the 
initial electrospinning solution and of fibers dissolved in MRS broth. Each dilution 
was plated on an MRS agar plate, incubated in anaerobic conditions at 37°C, and 
evaluated for CFU counts after 48 hr. 
Probiotic fiber morphology 
The morphology of PEO and PVA electrospun fibers (with or without L. 
acidophilus) was characterized using scanning electron microscopy (SEM). Fibers 
were placed on carbon tape, sputter-coated with a layer of palladium/gold alloy, 
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and imaged using Supra 35 SEM (Zeiss, Oberkochen, Germany). Images were 
analyzed using ImageJ software and the average fiber diameter of each 
formulation was determined by drawing a line across a minimum of 50 fibers per 
image (n = 3 images per fiber formulation). 
Probiotic stability in PEO and PVA fibers 
In addition to the assessment of post-spin viability and morphology, the 
temperature stability of L. acidophilus formulated in different PEO or PVA fibers 
(electrospun in water, MRS broth, MRS broth with 5% glycerol, or with lyophilized 
L. acidophilus in MRS broth with/without 5% glycerol) was tested by CFU counting 
on MRS agar plates, as described above. Fibers containing L. acidophilus were 
stored in sealed Petri dishes at either -20°C, 4˚C, or 25°C, and probiotic viability 
was evaluated up to 90 days post-electrospinning. After 1, 3, 7, 30, and 90 days, 
a fiber piece (~2 to 5 mg) was cut, weighed, dissolved, and incubated in 1 mL MRS 
broth for 30 min on a shaker at 37°C and 150 rpm. The dissolved fiber solution 
was then diluted using 10-fold serial dilutions, 2 µL was plated on MRS agar plates, 
and CFUs were counted after 48 hr of anaerobic incubation at 37°C. 
Inhibitory potential of L. acidophilus fibers in soluble G. vaginalis co-
cultures 
To initially determine the ability of L. acidophilus fibers to inhibit G. vaginalis 
growth, free L. acidophilus and L. acidophilus fibers were first co-cultured in media 
with G. vaginalis As described above, the selectivity of co-culture medium for L. 
acidophilus and G. vaginalis growth was determined prior to experiments by 
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measuring the growth of free L. acidophilus and G. vaginalis over 48 and 72 hr, 
respectively in either MRS or NYC III broth 353,354. From these experiments, it was 
observed that G. vaginalis was unable to grow in MRS broth, while L. acidophilus 
grew in both MRS and more slowly in NYC III. Furthermore, to assess the viability 
of G. vaginalis and L. acidophilus in each media at the specific concentrations and 
time points required for co-culture assays, free G. vaginalis (108 CFU/mL) or free 
L. acidophilus (107 and 108 CFU/mL) were added to 10 mL MRS and 10 mL NYC 
III separately, and incubated for 24 hr. At 4 and 24 hr, each sample was diluted 
using 10-fold serial dilutions, 2 µL was plated on appropriate agar plates, and 
CFUs were counted after 48 hr of anaerobic incubation at 37°C. 
Inhibitory potential of L. acidophilus fibers in HeLa monolayer G. vaginalis 
co-cultures 
Human cervical cancer cells (HeLa, originally from ATCC, kindly provided 
by Dr. Kenneth Palmer, University of Louisville) were cultured at 37˚C in a 5% CO2 
incubator using Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
10% heat-inactivated (30 min, 56°C) fetal bovine serum. The culture medium was 
changed every 48 hr to maintain the cells. HeLa cells were plated in 24-well plates 
(150,000 cells/well) and incubated overnight at 37°C in a 5% CO2 incubator to 
create a confluent cell monolayer. The next day, 1 x 107 or 1 x 108 CFU/mL of L. 
acidophilus or L. acidophilus fiber containing equivalent dose, and 1 x 108 CFU/mL 
of G. vaginalis were co-cultured simultaneously with HeLa cell monolayers. Control 
groups, including no treatment, blank fibers, free L. acidophilus only, and free G. 
vaginalis only, were added in parallel to HeLa monolayers. Treatment and control 
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plates were then incubated for either 4 or 16 hr at 37°C in 5% CO2 incubator. HeLa 
cells were checked under the microscope before and after incubation to ensure 
their viability. After incubation, the media was removed, and non-adherent bacteria 
were removed by washing each well with 500 µL sterile 1X PBS twice. HeLa cells 
were lysed by adding 1 mL of sterile water and incubating for 30 min at 37˚C in a 
5% CO2 incubator. The resulting cell suspensions were then collected, serial 
diluted, and plated on the appropriate agar plates to determine CFU counts. 
Inhibition of G. vaginalis viability was determined as the log-decrease in 
expression, relative to the CFU count obtained for free G. vaginalis-HeLa sample 
groups, at each corresponding time point. 
Statistical analysis 
All of the in vitro experiments were performed in triplicate, with 3 replicates 
per sample and the results were shown in average ± standard deviation. Statistical 
analyses of samples for fiber morphology, loading, and in vitro assays were 
performed using one-way ANOVA with the Tukey post hoc test (P ≤ 0.05). 
Statistical analyses of G. vaginalis titers were performed using the Mann-Whitney 
test using Graph Pad Prism version 8.4.3. 
Results 
Preliminary preclinical assessment of PEO fibers to deliver vaginal therapies 
To first test the feasibility of utilizing PEO fibers in a mouse model of 
infection, we assessed the vaginal administration of fibers in C57Bl/6J mice 
vaginally infected with G. vaginalis or PBS vehicle control (Figure 4.1A). Data 
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comparing H&E stained fixed tissue sections from control mice (No fibers (EFs); 
n=10) and those receiving fibers (fibers (EFs); n=10) suggested that fibers alone 
did not markedly alter the vaginal mucosa (Figure 4.1B and Figure 4.S1). The 
vaginal epithelium remained protected by a layer of keratinized epithelial cells 
(typical of estrogenized mice) and the squamous epithelium appeared intact. 
Further, robust polymorphonuclear (PMN) cell infiltration into the epithelium or the 
stroma were not observed. In line with previous observations, no PMN recruitment 
into the epithelium was observed in G. vaginalis-infected animals +/- fibers (n=5 
per group; Figure 4.1B). Administration of fibers did not promote G. vaginalis 
infection; mice administered blank PEO fibers had nearly identical G. vaginalis 
titers as mice that were administered no treatment (Figure 4.1C). While further 
studies in other model systems are necessary, these data preliminarily suggest 
that PEO fibers are inert to the vaginal mucosa in uninfected and G. vaginalis-




Figure 4.1. PEO fibers (EFs) are safely delivered in the vagina. (A) Blank PEO 
fiber discs were inserted vaginally into estrogenized C57Bl/6J mice infected with 
PBS (top row, panel B) or G. vaginalis (G.v., bottom row, panel B) at the same time 
point (0). Twenty-four hr later, vaginal washes were collected, and mice were 
sacrificed to collect vaginas for histology. (B) Vaginas were fixed, processed and 
sections stained with hematoxylin and eosin (H&E). Scale bars = 200 m. Images 
are representative of 10 No EFs, 10 EFs, 5 No EFs + G.v. and 5 EFs + G.v. mice. 
See Figure S1 for additional images. (C) G.v. titers in vaginal washes. Each dot 















Figure 4.S1. Histological analysis of mouse vaginal tissue. Vaginas were fixed, 
processed and sections stained with hematoxylin and eosin (H&E). Scale bar = 
200 m. 
To begin to assess the potential therapeutic benefit of fiber delivery with a 
current standard therapy, we fabricated PEO fibers loaded with the first-line BV 
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therapeutic metronidazole (met). Met-containing PEO fibers, successfully loaded 
with 828 ± 72 µg met/mg fiber, were evaluated for their ability to prevent and to 
treat G. vaginalis vaginal infection in mice. In the “prevention” experimental group, 
met-containing PEO or blank PEO control fibers, were administered immediately 
prior to G. vaginalis inoculation (Figure 4.2A), while in the “treatment” group, met-
containing or blank PEO fibers were administered 24 hr after G. vaginalis 
inoculation (Figure 4.2B). 
The administration of met-containing PEO significantly reduced G. vaginalis 
infection in both experimental arms. In the prevention arm, the administration of 
met-containing fibers resulted in a significant decrease of nearly 3-logs in 
CFUs/mL, relative to the administration of blank PEO fibers (Figure 4.2C). 
Similarly, in the treatment arm, mice that received met-containing PEO fibers had 
> 500-fold lower G. vaginalis titers after 24 hr treatment (48 hpi) than mice that 
received blank fibers (Figure 4.2D, right panel). This difference was not due to 
differences in initial colonization levels between the two groups of mice; G. 
vaginalis levels were indistinguishable at 24 hpi immediately prior to fiber 
administration (Figure 4.2D, left panel). Finally, whereas 8 of 10 mice that received 
blank PEO fibers had uterine G. vaginalis above the limit of detection (dotted line), 
only 4 of 10 mice that received met-containing PEO fibers had uterine G. vaginalis 
above the limit of detection (Figure 4.2E). Together, these results suggest that 
fibers can effectively deliver therapy to reduce vaginal G. vaginalis infection in the 
context of prevention and treatment. Overall these preliminary studies suggest that 
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PEO fibers are able to safely deliver active agents shown to be capable of reducing 
G. vaginalis infection. 
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Figure 4.2. Evaluation of the ability of metronidazole-containing PEO fibers (EFs) 
to exert a therapeutic effect in a mouse model of BV using vaginal inoculation of 
G. vaginalis. (A) For the prevention arm of the experiment, at time point zero, mice 
were administered 6 mm PEO discs, with and without metronidazole, and were 
immediately intravaginally infected with G.v. Vaginal washes and tissues were 
collected 24 hr later. (B) In the treatment arm, mice were inoculated with G.v. at 
time zero, and 24 hr later were administered fibers with or without metronidazole. 
Vaginal washes were collected immediately prior to fiber insertion, and 24 hr after 
fiber administration (48 hpi). Vaginal wash titers are shown for both (C) prevention 
and (D) treatment experiments. (E) G. vaginalis titers in uterine horn tissue from 
both experimental arms. In panels C-D, each data point represents one mouse. 
For samples from which G. vaginalis was not detectable, the detection limit was 
plotted (dotted lines). * P < 0.05, ** P < 0.01, ns = not significant by Mann-Whitney 
test. 
Probiotic viability in PEO and PVA fibers 
To develop these fibers for probiotic administration, the viability of L. 
acidophilus in electrospun PEO and PVA fibers was first compared with the loading 
measured prior to electrospinning (5 x 107 CFU/mg), as a function of probiotic 
freshness, polymer choice, and electrospinning solution (Figure 4.3). Overall, high 
probiotic viability on the order of 1.70 x 107 and 2.26 x 107 CFU/mg fiber was 
achieved with the incorporation of fresh L. acidophilus in PEO and PVA fibers, 
respectively. In comparison, the incorporation of lyophilized bacteria decreased 
the overall viability to 4.40 to 7.20 x 102 CFU/mg and 1.30 to 2.60 x 104 CFU/mg, 
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for PEO and PVA fibers, respectively. For the majority of formulations, fibers 
electrospun with fresh L. acidophilus had significantly higher L. acidophilus viability 
relative to fibers electrospun with lyophilized L. acidophilus (P ≤ 0.05), 
demonstrating as much as a 4 to 5-log increase in L. acidophilus viability in fibers 
that contained fresh L. acidophilus. The only exceptions were for PEO and PVA 
fibers electrospun in MRS and MRS with glycerol, respectively. In comparison, no 
statistical significance in L. acidophilus viability was observed between otherwise 
similar PEO and PVA fiber formulations, as a function of polymer choice (PEO or 









Figure 4.3. L. acidophilus (L.a.) viability in different (A) PEO and (B) PVA 
formulations after electrospinning. The concentration of L.a. aliquoted to the 
polymer solution prior to electrospinning (5 × 107 CFU/mg polymer), was 
determined via CFU counts, and was considered as 100% viability. Viability values 
are shown as the mean ± standard deviation from three independent fiber batches. 
Statistical significance between groups, as calculated by one-way ANOVA, is 
represented by *P ≤ 0.05. 
Probiotic fiber morphology and diameter 
The morphology of PEO and PVA fibers, electrospun with an intermediate 
concentration of fresh or lyophilized L. acidophilus (5 x 107 CFU/mg) was evaluated 
to assess the impact of polymer type, probiotic lyophilization, and electrospinning 
solution on fiber morphology (Figure 4.S2). As a function of polymer type, PEO 
fibers possessed well-defined morphologies (Figure 4.S2A-F), while PVA fibers 
resulted in thicker, more melded morphologies (Figure 4.S2G-L). An uneven 
distribution of L. acidophilus and more pronounced fiber beading were observed in 
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some PVA fibers (Figure 4.S2H and I), which was attributed in part to difficulty in 
electrospinning PVA in aqueous, relative to organic solutions, obscuring the 
visualization of fresh and lyophilized probiotics in these images. Additionally, the 
incorporation of fresh bacteria in both PEO and PVA fibers (Figure 4.S2A-C and 
G-I), regardless of electrospinning solution, seemed to result in more uniform fiber 
morphology, while fibers electrospun with lyophilized L. acidophilus exhibited 
increased beading, less consistent morphology, and fewer bacteria per area 
(Figure 4.S2D-F and J-L). Lastly, as a function of solute type, both water and MRS 
broth provided feasible solutions for electrospinning PEO and PVA fibers, resulting 
in well delineated and reproducible fiber morphologies. However, when glycerol 
was incorporated into the electrospinning solution, fibers seemed to meld together, 




Figure 4.S2. SEM images of 5% w/v PEO and 10% w/v PVA electrospun fibers 
containing 5 x 107 CFU L.a./mg polymer: (A through F) 5% PEO fiber formulations; 
(G through L) 10% PVA fiber formulations. Formulations electrospun with (A) – (C) 
and (G) – (I) fresh L.a. and (D) – (F) and (J) – (L) lyophilized L.a. Fibers electrospun 
in (A), (D), (G), (J) water; (B), (E), (H), (K) MRS broth; and (C), (F), (I), (F) MRS 
with 5% glycerol. Arrows point to incorporated probiotics and scale bars represent 
2 µm. 
The diameters of PEO and PVA fibers electrospun with an intermediate 
concentration of L. acidophilus (5 x 107 CFU/mg) were measured to assess the 
impact of different electrospinning parameters and conditions on fiber diameter 
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(Figures 4.S2 and 4.S3). Overall, PEO fibers had smaller diameters, with a tighter 
range of distribution between 270 ± 90 and 693 ± 460 nm compared to PVA fibers 
with diameters ranging from 400 ± 210 to 2136 ± 71 nm that were electrospun with 
similar conditions (Figure 4.S3). Furthermore, no statistical significance in fiber 
diameter was observed between PEO and PVA fibers electrospun in similar 
solutes that were loaded with fresh L. acidophilus (P > 0.05). However, PVA fibers 
loaded with lyophilized L. acidophilus in MRS with and without glycerol had 
significantly larger diameters than similarly spun PEO fibers (P ≤ 0.05). 
Additionally, no differences in fiber diameter were observed among PEO fibers 
electrospun, with either fresh or lyophilized L. acidophilus (P > 0.05); however, 
some PVA fibers containing lyophilized L. acidophilus demonstrated larger fiber 
diameters relative to similar formulations that contained fresh L. acidophilus (P ≤ 
0.05). Last, electrospinning solution had minimal impact on fiber diameter, with the 
exception of fresh L. acidophilus PEO fibers, which had a significantly larger 
diameter when electrospun in MRS and glycerol (versus water, P ≤ 0.05). Overall, 
PEO fibers incorporating fresh L. acidophilus that were electrospun in water or 
MRS broth had the smallest mean diameter (270 ± 90 nm), while PVA fibers that 
were electrospun in MRS and glycerol with lyophilized probiotic had the largest 




Figure 4.S3. The diameters of PEO and PVA fibers electrospun with 5 x 107 
CFU/mg fresh or lyophilized L.a. electrospun in water, MRS broth or MRS broth 
and glycerol. Statistical significance between groups, as calculated by one-way 
ANOVA, is represented by *P ≤ 0.05. 
To evaluate the impact of probiotic loading on fiber morphology, PEO and 
PVA fibers were electrospun in water with different concentrations of fresh L. 
acidophilus (5 x 106 to 5 x 108 CFU /mg polymer, Figure 4.4). Overall, increased 
probiotic loading resulted in more rod-shaped regions throughout both PEO and 
PVA fibers and both PEO and PVA fibers formulations demonstrated well-defined 
fiber morphology, independent of probiotic loading concentration. However, PVA 
fibers that were electrospun with the maximum theoretical probiotic loading (5 x 
108 CFU L. acidophilus/mg), exhibited increased beading, consistent with 
challenges experienced in electrospinning viscous PVA solutions. However, no 
significant changes in fiber diameter were observed with an increase in probiotic 
concentration for PEO and PVA fibers electrospun with water and fresh L. 














Figure 4.4. SEM images of 5% w/v PEO and 10% w/v PVA fibers that were 
electrospun in water and contain different concentrations of fresh L.a. (A) Blank 
PEO fiber and PEO fibers theoretically loaded with (B) 5x106, (C) 5x107, and (D) 
5x108 CFU L.a./mg fiber; (E) Blank PVA fiber and PVA fibers loaded with (F) 5x106, 
(G) 5x107, and (H) 5x108 CFU L.a./mg fiber. Scale bars represent 2 µm. 
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Probiotic stability in PEO and PVA fibers 
To determine the storage stability of PEO and PVA fibers, the long-term viability of 
L. acidophilus was evaluated at room temperature (25˚C), 4˚C, and -20˚C storage 
conditions. Multiple formulations were tested using fresh L. acidophilus at a 
concentration of 5 x 107 CFU/mg, in PEO and PVA fibers that were electrospun in 
water, MRS broth, or MRS broth with 5% glycerol (Figure 4.S4). The highest post-
spun viability during long-term storage (90 days) was observed when fibers were 
stored at either 4˚C or -20˚C, regardless of the polymer and solute type. In contrast, 
when fibers were stored at room temperature, the viability of L. acidophilus was 
dependent on both the polymer type and electrospinning solution. Within room 
temperature conditions, L. acidophilus viability in the water-based PEO and PVA 
formulations rapidly decreased, with no viability seen by day 7. In contrast, PEO 
and PVA fibers that were electrospun in MRS broth maintained L. acidophilus 
viability at room temperature for up to 30 and 7 days, respectively. The addition of 
glycerol to the MRS broth, decreased the duration of viability to levels seen with 
water. These data indicate that -20 and 4˚C are the optimal storage conditions to 
maintain L. acidophilus viability (in the current formulations), independent of 
polymer type and electrospinning solution.
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Figure 4.S4. The viability of L.a. in (A) PEO and (B) PVA fibers electrospun with 5 
x 107 CFU L.a./mg in water, MRS broth, or MRS broth with 5% glycerol, was 
evaluated after storage in -20˚C, 4˚C, and 25˚C for up to 90 days after 
electrospinning. Viability values are shown as the mean ± standard deviation from 
three independent fiber batches. Statistical significance between groups after 90 
days, as calculated by one-way ANOVA, is represented by *P ≤ 0.05, **P ≤ 0.01, 
and ****P ≤ 0.0001. 
Inhibitory potential of L. acidophilus fibers in soluble G. vaginalis co-
cultures 
Soluble co-culture experiments were conducted to evaluate the impact of L. 
acidophilus fibers on G. vaginalis viability (Figure 4.5). To ensure appropriate 
culture conditions, the selectivity of L. acidophilus and G. vaginalis growth was first 
evaluated on various agar plates (Table 4.1). Overall, MRS agar was selective for 
L. acidophilus growth, while NYC III media supplemented with streptomycin was 
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selective for G. vaginalis growth. In addition, L. acidophilus and G. vaginalis growth 
was evaluated in MRS and NYC III broth (without antibiotic) for 48 and 72 hr, 
respectively. In MRS broth, both L. acidophilus and G. vaginalis growth 
approached the stationary phase ~32 hr post-inoculation, with high L. acidophilus 
growth (OD600 = 4.36) and significantly diminished G. vaginalis growth (OD600 = 
0.62, Figure 4.S5, P ≤ 0.05). When NYC III media was used, L. acidophilus growth 
in the stationary phase was slightly lower than G. vaginalis growth in the same 
conditions (OD600 = 0.54 and 1.71, respectively). Overall, the resulting growth 
curves demonstrate the ability of L. acidophilus to grow in both MRS and NYC III 
broths, albeit with lesser growth in NYC III, while G. vaginalis showed somewhat, 
but significantly higher growth in NYC III media (P ≤ 0.05). Lastly, to evaluate the 
effect of broth on bacteria viability for the specific concentrations and time frames 
used in co-culture experiments, the viability of free G. vaginalis (108 CFU/mL) or 
free L. acidophilus (107 and 108 CFU/mL) in either MRS or NYC III broth was 
evaluated for up to 24 hr. Even at these higher starting concentrations, similar 
decreases in G. vaginalis growth were observed in MRS, relative to NYC III broth, 
after 4 and 24 hr (P ≤ 0.05), while no inhibitory effects were observed for L. 
acidophilus in either broth (Figure 4.S6). These results are similar to those 
observed in previous work355 and validated appropriately conservative cell culture 
conditions of using NYC III broth for co-culture assays. 
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Figure 4.5. L.a. incorporated in PEO and PVA fibers inhibits G.v. viability in soluble 
co-culture assays. (A) L.a. PEO fibers, (B) L.a. PVA fibers, or (C) free L.a. were 
co-cultured at one log less (left) or equal (right) concentration relative to G.v. The 
viability of L.a. or G.v. alone, or as a result of co-culture is noted in the legend. G.v. 
viability significantly decreased after administration of both tested concentrations 
of L.a. fibers or free L.a. Columns with zero viability (or viability below the limit of 
plate-based detection) are represented with a star, and viability values are shown 
as the mean ± standard deviation from three independent batches. Statistical 
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significance between the viability of free G.v. and G.v. in competition, as calculated 
by one-way ANOVA, is represented by *P ≤ 0.05 and ****P ≤ 0.0001. 
Table 4.1. G. vaginalis and L. acidophilus growth on different selective agar.  
 
 
Figure 4.S5. L.a. and G.v. growth in NYC or MRS broth. All bacterial cultures were 
inoculated from a starting seed culture, which were each sub-cultured to an OD600 
of 0.05. The OD600 was read every 4 hr. Three replicate cultures were grown in 10 
mL of either MRS or NYC III broth in conical tubes. Each time-point sample was 
taken and analyzed by taking the average of triplicate samples. 
 
Organisms Selective Agar  Growth 
L. acidophilus (ATCC 4356) MRS agar (Sigma-Aldrich)  Yes 
L. acidophilus (ATCC 4356) NYC III agar with streptomycin (Recipe, Dr. 
Lewis, WUSTL)  
None 
G. vaginalis (clinical isolate JCP8151B) MRS agar (Sigma-Aldrich) None 









Figure 4.S6. G.v. and L.a. viability after culture in either MRS or NYC III broth. (A) 
108 CFU/mL of G.v., (B) 107 CFU/mL of L.a., and (C) 108 CFU/mL of L.a. were 
inoculated in MRS and NYC III broth and the viability at inoculation, 4 hr, and 24 
hr post-inoculation were evaluated. MRS slightly inhibited G.v. growth, while no 
inhibitory effects were observed for L.a. when either broth was used. Statistical 
significance between groups, as calculated by one-way ANOVA, is represented by 
*P ≤ 0.05. 
In the soluble co-culture assay, the effect of L. acidophilus dosage form 
(fiber-incorporated vs. free) and concentration (107 vs. 108 CFU/mL) was evaluated 
on G. vaginalis inhibition.  L. acidophilus PEO fibers at 107 and 108 CFU/mL, 
demonstrated a partial inhibitory effect on G. vaginalis viability (2.8 and 1.5-logs, 
respectively) 4 hr post-inoculation (although L. acidophilus PEO fibers at 107 
CFU/mL were not statistically significant), followed by complete inhibition of G. 
vaginalis (9.9 and 11.1-logs) 24 hr post-inoculation (Figure 4.5A). Similarly, L. 
acidophilus PVA fibers at 107 and 108 CFU/mL, demonstrated a modest inhibitory 
effect after 4 hr (0.6 and 4.9-logs) and nearly complete or complete inhibition after 
24 hr as a function of increased dosing (7 and 8.7-logs, Figure 5B). Free L. 
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acidophilus at 107 and 108 CFU/mL, demonstrated strong inhibition of G. vaginalis 
(6.7 and 9.0-logs) after 4 hr, and complete inhibition (9.0 and 9.6-logs) after 24 hr 
(Figure 4.5C). Blank PEO and PVA fibers were used as negative controls for 
inhibition and demonstrated no inhibitory effects when co-cultured with G. vaginalis  
Inhibitory potential of L. acidophilus fibers in HeLa monolayer G. vaginalis 
co-cultures 
Similar experiments were conducted to evaluate the impact of L. acidophilus 
fibers on G. vaginalis co-cultured with confluent HeLa cell monolayers (Figure 
4.6). L. acidophilus fibers or free L. acidophilus were incubated with G. vaginalis 
and HeLa cells at 37°C in a 5% CO2 incubator for up to 16 hr to ensure HeLa cell 
viability in the presence of bacteria. Administration of low and high doses 
(equivalent to 107 and 108 CFU/mL L. acidophilus) of PEO L. acidophilus fibers 
resulted in negligible changes to G. vaginalis viability after 4 hr (0.83-log increase 
and 1.1-log increase, P > 0.05), with complete inhibition observed (6.9 and 5.8-
logs, respectively) after 16 hr (Figure 4. 6A). Similarly, 107 and 108 CFU/mL of L. 
acidophilus PVA fibersdecreased G. vaginalis viability by 1.7 and 1.5-logs, 
respectively after 4 hr, followed by complete inhibition after 16 hr (both 8-logs, 
Figure 4.6B). In comparison, administration of free L. acidophilus (107 CFU/mL) 
for 4 hr resulted in partial inhibition of G. vaginalis (1.7-log), while after 16 hr, G. 
vaginalis viability was completely inhibited. However, at the higher dose of free L. 
acidophilus (108 CFU/mL), G. vaginalis viability was completely inhibited as early 
as 4 hr post-co-culture (Figure 4.6C). 
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Figure 4.6. L.a. incorporated in PEO and PVA fibers inhibit G.v. growth in epithelial 
cell co-culture competition assays. (A) L.a. PEO fibers, (B) L.a. PVA fibers, or (C) 
free L.a. were co-administered with G.v. to HeLa cell monolayers. Columns with 
zero viability (or viability below the limit of plate-based detection) are represented 
with a star, and viability values are shown as the mean ± standard deviation from 
three independent batches of fibers or free bacteria. Statistical significance 
between the viability of free G.v. and G.v. in competition, as calculated by one-way 




Lactobacilli play an important role in modulating the vaginal environment, 
and contribute to overall female reproductive health by fostering an environment 
that is less amenable to pathogenic bacteria adhesion and growth. Numerous in 
vitro and in vivo studies have shown that the administration of different 
Lactobacillus species/strains can improve vaginal health as a primary or adjunct 
treatment to BV, and can outcompete the growth of facultative pathogens including 
G. vaginalis, Prevotella anaerobius, and Prevotella bivia356,357. In addition, studies 
have shown that species such as L. crispatus CTV-05 can inhibit G. vaginalis 
association with cervicovaginal epithelial cells358 and may be more broadly 
applicable to decreasing the adhesion of uropathogenic organisms to vaginal 
epithelial cells. Among different lactobacillus species, L. acidophilus has shown 
strong adhesion to epithelial cells359 and has demonstrated success in treating BV 
both in vivo and in clinical studies329,330. Due to these characteristics, L. acidophilus 
was selected for incorporation in electrospun fibers as a novel alternative delivery 
platform to inhibit BV infection. 
In parallel with the consideration and application of probiotic species for 
vaginal applications, a variety of vehicles have been developed for probiotic 
delivery. Currently, orally- or intravaginally-administered probiotic dosage forms 
exist, but often result in transient effects, requiring frequent administration 
regimens to be efficacious in the time frame surrounding infection. In particular, 
several platforms, including gels, films, and capsules, have been developed to 
locally deliver agents against female reproductive bacterial infections 334,336,337,360. 
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However, some challenges exist with traditional “drug” delivery formulations in that 
they may be less amenable to the incorporation of live cells, such as probiotics. 
Furthermore, even with once or twice daily application, BV recurrence persists, 
emphasizing the need for new dosage forms that can provide on-demand delivery 
and a foundation upon which to develop sustained-release capabilities to more 
significantly impact the course of BV infections. 
Electrospun fibers have demonstrated versatility and efficacy in preventing 
and treating intravaginal virus infections341,361,362, stimulating interest in their 
application as a new intravaginal dosage form against bacterial infections. In 
addition to their versatility in incorporating a variety of active agents with different 
properties, electrospun fibers incorporate key features including ease-of-
manufacturing, mechanical flexibility, enhanced encapsulant stability, and tunable 
release of active agents. Recent work has demonstrated the incorporation of 
probiotics in electrospun fibers for a variety of applications343,347,363-365, and has the 
potential to impact female reproductive health in a multitude of ways by providing 
localized delivery, maintaining normal vaginal pH, and enabling prolonged release 
of probiotics or active agents to prevent recurrence. While previous studies have 
shown success in incorporating live bacteria relevant to biomedical347, 
food347,363,364, and female reproductive health applications342,343, to our knowledge, 
there are no studies to date that have evaluated the efficacy of probiotic fibers 
against BV or other female reproductive bacterial infections.  
To first assess the feasibility of our approach for the envisioned application, 
we wanted to examine the preliminary safety and functional impact of fiber 
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administration. There are several important factors to consider. First, it is important 
that the fibers themselves do not disrupt the vaginal mucosa or trigger tissue 
inflammation and recruitment of immune cells. Our results suggest that the fibers 
were relatively inert in the mouse vagina and did not adversely affect the tissue. 
This finding is promising and provides preliminary evidence regarding the safety 
of these fibers. However, it is important to acknowledge that these tests were 
performed in mice injected with -estradiol, which is known to have effects on 
inflammatory processes. Therefore, further safety testing outside of the context of 
estrogenization, and also at later time points, is still needed. A second factor to 
consider is whether the fibers themselves promote infection by known pathogens. 
Importantly, we found that blank fibers did not enhance vaginal infection by G. 
vaginalis Finally, for the fiber approach to be useful, it must be capable of delivering 
effective therapies. We showed that fibers were capable of delivering 
metronidazole (current standard-of-care antibiotic for BV) at sufficient levels to 
both prevent and treat G. v. infection in a mouse model. Together these data 
provide a proof-of-concept foundation that supports the feasibility of utilizing fibers 
for intravaginal therapeutics.   
Based on these promising results, both PEO and PVA were selected for 
probiotic fiber fabrication due to their known biocompatibility, mucoadhesivity, and 
hydrophilicity for on-demand applications. From an engineering design and 
feasibility perspective, we first evaluated the effect of different parameters 
including electrospinning solution, polymer type, and the incorporation of fresh or 
lyophilized probiotics on post-spin viability. First, we showed that electrospinning 
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solution and polymer type have minimal impact on probiotic viability, whereas the 
choice of fresh or lyophilized bacteria exerted a significant impact on probiotic 
viability. Overall, the viability of L. acidophilus in fibers electrospun with fresh 
bacteria was ~4-logs higher (~107 CFU/mg) than fibers that incorporated 
lyophilized bacteria (~103 CFU/mg), regardless of polymer type. This striking 
difference may be attributed in part to the lyophilization process, which is known 
to exert stress on bacteria. Previous studies have shown that removing water from 
cells can cause changes in protein conformation and cell membrane structure366 
leading to low viability, while conversely, water remaining post-lyophilization plays 
an important role in bacteria survival. One study showed that residual water 
content between 3 to 6% can enhance the survival of Lactobacillus salivarius 
during storage. Additionally, it has been shown that the choice of cryoprotectant 
can have a significant impact on bacteria viability. In this study, we used skim milk 
and trehalose which, based on previous studies, demonstrated high viability and 
functionality relative to other protectants367. Lastly, rehydration solution and 
conditions are also important factors in cell recovery after the dehydration process. 
While previous studies have shown that a slow rehydration procedure (over the 
course of 7 to16 days) and at moderate temperatures (15-25°C) can improve cell 
recovery368,  more rapid rehydration may weaken bacteria and increase 
susceptibility to the applied electric field and shear stress, resulting in lower cell 
recovery. While our initial viability results provide functional activity within a 
therapeutic range, in future work lyophilization and rehydration conditions may be 
optimized to increase probiotic health and recovery.  
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Among the different formulations tested in this work, the highest probiotic 
viability was achieved by incorporating 5 x 107 CFU fresh L. acidophilus per mg 
PEO/PVA fibers. The resulting viability values (~107 CFU/mg) were within the 
anticipated ranges shown in previous work focused on other applications including 
food engineering347 and vaginal drug delivery systems342,343; however, viability is 
known to vary significantly based on factors including loading concentration, 
polymer composition, and Lactobacillus type. The highest probiotic viability 
reported in previous studies demonstrated post-spun viability as high as 90% for 
10% w/w PVA fibers that incorporated fresh L.g. at 2 x 106 CFU/mL water347. 
Similarly, a viability as high as 68% was reported in a study that incorporated fresh 
L. acidophilus in PVA fibers with the post-spun viability of 1.9 x106 CFU/mg342. In 
contrast, a study that incorporated L. plantarum in PEO fibers for mucosal delivery 
purposes, obtained only 2% post-spun viability (4.7 x108 CFU/mL) with a 
theoretical loading of  2.3 x 1010 CFU/mL369, indicating that higher initial loading 
may decrease probiotic viability. Another study in which 10% PVA, 20% PVP, or 
45% w/w PVP solutions were electrospun in water with 3 x 106 CFU/mg fresh L. 
acidophilus, obtained 68%, 34%, and 40% L. acidophilus viability in the respective 
fiber formulations, suggesting the impact of polymer composition on probiotic 
viability342. A study which evaluated the feasibility of encapsulating bacteriocins 
and lactic acid producing bacteria in PEO fibers, demonstrated cell viability as low 
as 0.1% for Escherichia coli and as high as 75% for Micrococcus luteus cells 
incorporated, suggesting that smaller gram-positive bacteria such as Micrococcus 
luteus may be more resistant to high voltages and the electrospinning process369. 
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Lastly, a recent study that incorporated 10 different fresh Lactobacilli species in 
4% w/w PEO (900 kDa) fibers, achieved viabilities as high as 109 CFU/mg polymer, 
but varied based on species (e.g., L.g. (79%) and L. acidophilus (20%))343. In our 
study, this high level (109 CFU/mg) of probiotic incorporation in fibers was 
challenging to achieve, possibly due to the differences in formulation of lyophilized 
vs. fresh bacteria used comparatively and the resulting electrospinning solution 
viscosity. However, these studies confirm that probiotic viability may be impacted 
by a multitude of factors including loading concentration, polymer type, 
electrospinning conditions, and bacterial species.  
In addition to probiotic viability, we assessed the effect of different 
processing conditions including electrospinning solution, lyophilization, and 
polymer composition on fiber morphology and diameter. In general, 
electrospinning in water or MRS broth led to well-defined fiber morphologies, 
relative to fibers spun with MRS and glycerol, which resulted in fiber beading and 
increased fiber diameters. These observations are in agreement with previous 
work that showed the addition of 10% glycerol to 40% w/v zein in 90% ethanol, 
doubled the diameter of zein fibers relative to fibers spun without glycerol, and 
decreased the conductivity of polymer solution while negligibly impacting solution 
viscosity 370. We anticipate that the addition of glycerol may have had a similar 
effect on fiber morphology here, and with no overarching benefit to probiotic 
viability, may be excluded in future formulations. Another parameter in our study 
that seemed to result in less uniform morphology and larger fiber diameters was 
the incorporation of lyophilized, relative to fresh probiotic, which may be attributed 
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in part to the use of cryoprotectants during lyophilization, known to alter the 
viscosity of electrospinning solution. Lastly, while PEO and PVA both resulted in 
well-defined fibers at low probiotic concentrations, alterations to fiber morphology 
became more pronounced in PVA fibers as probiotic loading increased. Notably, 
fiber beading was observed, which may be attributed to changes in the viscosity 
and conductivity of the polymer solution. Furthermore, at all loading concentrations 
tested, PEO fibers had smaller diameters and more uniform properties, making 
PEO formulations more conducive to reproducible spinning. Similar observations 
have been reported for PEO, relative to PVA fibers that incorporated an 
antimicrobial agent, showing overall smaller diameters for PEO fibers, and 
suggesting that even the incorporation of low molecular weight agents (relative to 
cells) can impact fiber diameter371. 
In addition to evaluating L. acidophilus viability immediately after 
electrospinning, the stability of L. acidophilus viability in fibers was examined at 
different storage temperatures for up to 90 days. As anticipated, storage 
temperature was a primary factor that impacted probiotic viability over prolonged 
durations. When fibers were stored at room temperature, L. acidophilus viability 
decreased dramatically over the first few days and resulted in negligible viability 
after one month, regardless of polymer composition or electrospinning solution (P 
≤ 0.0001). However, minimal decreases (0.5 and 0.1-log) in L. acidophilus viability 
were observed in PEO fibers that were electrospun in MRS and MRS with glycerol, 
respectively after 3 months storage at -20°C (P > 0.05). Furthermore, minimal 
differences in L. acidophilus viability were observed over prolonged durations 
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when PVA fibers were stored in 4°C (P > 0.05). This increased viability is likely 
attributed to a lower probiotic metabolism at reduced temperatures, requiring less 
nutrients for prolonged survival. Based on a comparison of electrospinning 
solutions, when MRS broth (with or without glycerol) was used for electrospinning, 
a slight, but statistically non-significant increase in L. acidophilus viability was 
observed (P > 0.05), relative to probiotics electrospun in water, regardless of 
storage temperature. This may be partially attributed to providing a probiotic 
nutrient source that remains within the fibers after solute evaporation, and may be 
investigated more thoroughly in future work via the incorporation of other and more 
concentrated nutrient sources. Lastly, L. acidophilus maintained slightly, but not 
statistically significant, higher viability in PEO fibers spun in MRS (with or without 
glycerol, 0.04- and 0.30-logs reduction in viability), relative to PVA fibers spun with 
the same conditions (0.72- and 0.38-logs reduction in viability) over 3 months at -
20°C, indicating that the well-defined morphology of PEO fibers may better protect 
probiotics from environmental stresses such as temperature and dehydration. 
Together these results indicate that PEO fibers electrospun in water, MRS, or MRS 
with glycerol provide similar L. acidophilus stability at 4 or -20°C.  
While previous studies have incorporated probiotics for food processing and 
biomedical applications, to our knowledge, probiotic fibers have not yet been 
investigated as a dosage form, demonstrating efficacy against vaginal bacterial 
infections in vitro (or in vivo). In these studies, soluble co-culture experiments 
showed that PEO fibers containing L. acidophilus at 107 and 108 CFU/mL 
decreased G. vaginalis viability after 4 hr by ~3- and 1.5-log, while corresponding 
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concentrations of PVA fibers decreased G. vaginalis viability by 0.6-log and 4.9-
log, respectively. After 24 hr, PEO fibers completely inhibited G. vaginalis, 
regardless of concentration, while PVA fibers necessitated a higher dose (108) to 
completely inhibit G. vaginalis Overall these results suggest a time- and dose-
dependent effect of fibers on G. vaginalis viability, that was somewhat more 
pronounced at the early time point (4 hr) for PVA fibers. These observations are in 
agreement with a previous study that showed that G. vaginalis viability decreased 
significantly (by 1.3 to 2.4-logs) after 4 hr co-culture with 7 different strains of lactic 
acid producing bacteria372.  
Parallel to soluble co-culture experiments, we evaluated the ability of L. 
acidophilus fibers to prevent G. vaginalis viability (and adhesion to) HeLa cells. In 
competition assays, PEO and PVA fibers demonstrated therapeutic levels of 
inhibition of G. vaginalis after 16 hr delivery at both 107 and 108 CFU/mL. Overall, 
within the set of conditions tested here, it seems that fibers may take slightly longer 
(on the order of hours) to exert an effect on G. vaginalis viability and adhesion. 
However, these results from L. acidophilus fibers are in agreement with previous 
studies showing that the adhesion of free lactobacilli to epithelial cells limits the 
adherence and growth of other pathogenic bacteria such as G. vaginalis373. Some 
studies have shown that the bactericidal activity of lactobacilli against vaginal 
pathogens occurs within the first hours of application, while other studies indicate 
that a longer administration time may be required373. In this study, the incorporation 
of probiotics within fibers may initially provide some level of probiotic localization 
due to entrapment in the fibers, perhaps preventing or delaying probiotic diffusion 
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and corresponding epithelial surface coverage, relative to free L. acidophilus 
Furthermore, some of the mucoadhesive attributes, which we anticipate will be 
beneficial in in vivo studies, may be less (or more) evident in the context of in vitro 
assays. Finally, the adhesion and colonization of probiotics may vary across 
vaginal cell types, hence we plan to examine these features in vaginal epithelial 
cells EpiVaginalTM tissue, and in the more complex in vivo model in near-future 
studies. 
For the first time, this work demonstrates the promising potential that new 
probiotic fibers may have against bacterial vaginosis. Previous ex vivo and clinical 
studies have shown the potential of free probiotics against BV 353,374; however, new 
dosage forms are needed to improve current treatment regimens and outcomes. 
Our in vivo studies suggest that fibers are safe in vivo and can effectively deliver 
therapeutics in a murine model of G. vaginalis infection, In parallel, our in vitro 
studies show that probiotics are highly and viably incorporated in electrospun 
fibers, and that prolonged stability of probiotics in electrospun fibers is achieved 
for up to 3 months, in -20 or 4°C storage conditions. Furthermore, PEO and PVA 
fibers inhibit G. vaginalis viability and adhesion to cells suggesting their ability to 
exert health-promoting effects to treat BV. In parallel work, we are building upon 
this formulation to create a delivery platform that can sustain probiotic release to 
offer a potentially new dosage form that may be developed with other attributes. 
Furthermore, we anticipate that probiotic fibers have the potential to further the 
existing understanding of the effects of probiotics and delivery vehicles on the 
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MESH AND LAYERED FIBER ARCHITECTURES AS NOVEL PLATFORMS TO 
SUSTAIN PROBIOTIC RELEASE AGAINST BACTERIAL VAGINOSIS 
INFECTION 
Introduction 
Nearly 33% of women worldwide are afflicted with bacterial vaginosis 
(BV)375,376, a dysbiosis in which Lactobacillus-dominance in the female 
reproductive tract (FRT) is partially or completely displaced with vaginal 
pathogens, most prominently Gardnerella vaginalis (G. vaginalis)323,326,377,378. 
Bacterial vaginosis infections are challenging to treat and highly recurrent379. 
Furthermore, BV infection is also associated with significant adverse effects, 
including increased risk of adverse pregnancy outcomes, preterm labor, 
postsurgical infections, and the increased acquisition of sexually transmitted 
infections (STIs)375,376,380-383.  
The current treatment of BV consists of orally- or intravaginally-
administered antibiotic regimens, comprised of the antibiotics metronidazole, 
clindamycin, and tinidazole, that have an initially high efficacy ranging from 50-
80%384. Despite this initially high efficacy, patients suffer from frequent recurrences 
and the development of antibiotic-resistant bacteria, as well as other negative 
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symptoms including painful sexual intercourse, rectal pain, inflammation, Crohn’s 
disease385, and opportunistic yeast infections386. To address these challenges, 
recent research has begun to focus on alternatives, specifically probiotic delivery, 
to stabilize the vaginal microbiota by providing a Lactobacillus-dominant 
environment in which to inhibit the growth and adherence of pathogenic bacteria 
involved in BV. Probiotic approaches have been shown to help treat BV by 
modulating the endogenous composition of the vaginal microbiota and local pH 
through the production of hydrogen peroxide and lactic acid, modulation of host 
immune responses, and preventing pathogenic bacteria adhesion to epithelial 
cells326-328.  
Lactic acid-producing Lactobacillus species such as L. crispatus and L. 
acidophilus (have shown non-inflammatory properties and are two of the few 
species that have shown promise to cure BV384,387. Lactic acid, a metabolic by-
product produced by Lactobacillus, promotes Lactobacillus-dominance in the 
reproductive tract388, exerts immunomodulatory and antimicrobial effects against 
many pathogenic bacteria378,389, and acts as a barrier to pathogen colonization (by 
inducing weak acid stress). L. crispatus is considered to be one of the most 
predominant, stable, and protective species that promotes vaginal health, by 
producing a variety of compounds including lactic acid, which in large amounts has 
been shown to have microbicidal and virucidal properties390. Previous clinical 
studies have shown that both capsules containing low concentrations of L. 
crispatus (106 to 108 colony-forming units (CFU)/capsule) and tampons containing 
higher concentrations of L. crispatus (2 × 109 CFU/dose) are safe, and result in 
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successful colonization391,392. Lactobacillus acidophilus is another extensively 
explored species that has been associated with a reduced risk of BV. Previous in 
vitro studies have shown that L. acidophilus isolated from the healthy FRT can 
inhibit a variety of pathogenic bacteria including Bacteroides spp., Prevotella bivia 
and G. vaginalis, isolated from vaginal swabs of BV-infected women. These 
impacts are attributed to the high production of hydrogen peroxide, lactic acid, and 
bacteriocins, and lactic acid which enhance host immune response and inhibit 
pathogen growth393. In addition, a variety of studies have suggested that oral or 
intravaginal administration of L. acidophilus increases lactobacilli colonization in 
the reproductive tract and restores vaginal flora, relative to administration of a  
placebo394-396. 
A very recent approach that has shown potential to treat initial and recurring 
BV infections, is the use of vaginal microbiome transplantation (VMT) to re-
establish the vaginal microbiota397,398. A clinical study investigated the impact of 
VMT on five BV patients and reported that after 1 to 3 VMT sessions, four patients 
achieved full remission during a 5 to 21 month follow-up period, with no adverse 
effects399. Furthermore, due to the preliminary success of VMT in clinical trials, a 
universal donor screening protocol was developed to consider donor matching, 
ethical considerations, and the potential for STI transmission400. Based on these 
early results seen after multiple transient administrations, it may be envisioned that 
prolonged delivery of diverse patient-specific microbiota populations to the FRT, 
may be advantageous to provide robust colonization and stabilization of the 
vaginal microbiota. The promise of VMT highlights the potential that a diverse set 
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of patient-derived beneficial species may have on female reproductive health 
outcomes. However, questions still remain regarding how best to deliver individual 
or multiple species to meet the long-term delivery needs of women. 
Several methods, including gels, capsules, tampons, and liposomes, have 
been developed to deliver probiotics and other BV treatments to the 
FRT334,336,337,401,402. Vivagel®, a product containing sulfated anionic polymers, has 
been used to deliver SPL7013, a polylysine dendrimer with anionic sulfate surface 
functional groups; however, Vivagel® was found to elicit pro-inflammatory cytokine 
production and polymer-induced toxicity to both epithelial cells and endogenous 
lactobacilli155. Similarly, for the delivery of lactic acid, gels in combination with 
antibiotics have shown increased lactobacilli colonization and decreased BV 
recurrence, relative to the administration of traditional antibiotics alone323,403; 
however, transient delivery and antibiotic resistance remain concerns. In addition, 
tampons and pessaries have demonstrated low BV cure rates, attributed to 
decreased quantities of delivered bacteria404. Lastly, these dosage forms are 
generally plagued with low intravaginal residence time; transient protection; 
messiness via leakage; and unfavorable discharge that can adversely impact user 
adherence and efficacy155,246,378,405,406.  
To avoid BV recurrence and address the challenges and inconvenience of 
daily treatment regimens, a delivery vehicle that provides for sustained probiotic 
release may be impactful, particularly for infections that require frequent 
administration regimens. However, to-date, only one dosage form, a pod-based 
intravaginal ring (IVR), has shown the potential to provide sustained-release of 
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probiotics for intravaginal application, with modest daily release of L. gasseri as 
high as ~107 CFU/day for 21 days340,378. However, IVRs may be susceptible to 
pathogenic biofilm formation and yeast adhesion, posing an additional challenge 
to BV treatment5,407,408.  
Relative to the currently available dosage forms, electrospun fibers may 
offer an effective new strategy to deliver probiotics to the FRT127,129,130,249-
254,256,260,261,264,409-413. These delivery platforms may extend treatment and 
prevention applications to BV, as fibers have been shown to enhance encapsulant 
stability and half-life, lower the doses necessary to achieve efficacy, prolong active 
agent delivery in the FRT, and provide a scaffold for bacterial residence. 
Additionally, electrospun fibers provide high surface-area-to-volume ratio411,414 and 
porous morphology, which may be therapeutically envisioned to foster an 
environment for prolonged probiotic growth and retention415. Previous studies have 
shown that electrospun fibers can incorporate different probiotics with high viability 
and may be used as a patient-friendly solid-dosage form for intravaginal 
delivery342,344,345. A recent study by our group showed that polyethylene oxide 
(PEO) fibers formulated alone or with a traditional antibiotic are preliminarily safe 
and capable of delivering effective therapeutics in an established murine model of 
BV infection. In addition, this study showed that hydrophilic rapid-dissolve PEO 
and polyvinyl alcohol (PVA) electrospun fibers incorporating L. acidophilus 
provided high in vitro viability, stability, and release of L. acidophilus Additionally, 
probiotic fibers completely inhibited G. vaginalis viability and cell adhesion in vitro 
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in both co-culture and epithelial-G. vaginalis infection, suggesting their feasibility 
to exert health-promoting effects against BV-associated pathogens416.  
In this work, we developed novel probiotic fibers with two different fiber 
architectures, mesh and layered, to locally deliver lactobacilli for prolonged 
durations (~ 2 wk) (Figure 1). We hypothesized that the incorporation of two model 
organisms, L. crispatus and L. acidophilus, in fibers may be used as a proof-of-
concept that can be generalized to other Lactobacillus species. First, the changes 
in the macro- and microstructure of each fiber architecture were evaluated to 
obtain a better understanding of probiotic integration and fiber degradation. Then, 
the sustained-release of probiotics from these fibers was evaluated by assessing 
the cumulative release and proliferation of L. crispatus and L. acidophilus, D- and 
L-lactic acid production, and changes in pH over a period of 2 wk. Lastly, within 
each architecture (e.g., mesh and layered), the formulation with the highest 
probiotic release was selected to evaluate its efficacy against G. vaginalis growth 
in a soluble co-culture assay. Our results showed that after 48 hr and 6 days, all 
formulations produced as much as 108 and 109 CFU probiotic/mg fiber in total, 
respectively, with corresponding daily release on the order of 108 CFU/(mg·day). 
In addition to high levels of probiotic release, probiotic fibers produced 
therapeutically-relevant levels of lactic acid, causing a significant reduction in pH. 
Finally, mesh and layered probiotic fiber dosage forms demonstrated strong 
inhibition of G. vaginalis, resulting in an 8- and 6.5-log decrease in G. vaginalis 
viability after 24 hr .These promising results suggest that electrospun fibers have 
the potential to serve as an alternative dosage form by sustaining probiotic and 
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lactic acid release and inducing changes relevant to achieving prolonged 
prevention and treatment of BV. 
Materials and Methods 
Bacterial cultures 
Probiotics (L. crispatus MV-1A-US and L. acidophilus 4356) were 
purchased from American Type Culture Collection (ATCC) and a streptomycin-
resistant clinical isolate of G. vaginalis (JCP8151B, GenBank JX860320) was 
generously provided by Dr. Amanda Lewis (Washington University, St. Louis, MO). 
L. acidophilus and L. crispatus were grown using deMan, Rogosa, and Sharpe 
(MRS, Sigma 69966) broth and agar plates, both supplemented with 0.1% Tween 
80. G. vaginalis was grown using New York City III (NYC III) broth and agar plates, 
both supplemented with 10% heat-inactivated horse serum (Gibco 26050088). The 
NYC III agar plates contained 1 mg/mL streptomycin sulfate salt (Sigma S9137) to 
select for the antibiotic-resistant G. vaginalis strain.  
Bacterial cultures were initially prepared from frozen stocks using an 
inoculation loop to streak frozen culture on the appropriate agar plates. Each 
bacterium was initially cultured on agar plates under anaerobic conditions and 
maintained at 37°C in 5% hydrogen, 5% carbon dioxide, and balanced with 
nitrogen using a Bactronez Anaerobic Workstation (Shel Lab). The incubation time 
to observe the growth of Lactobacillus species on MRS plates was 48 hr, while G. 
vaginalis cultures were incubated for 72 hr on NYC III agar plates due to slower 
colony formation. For all bacterial sub-cultures, a single bacteria colony was 
 175 
selected from the agar plate and cultured in 1 mL of MRS or NYC III broth in a 
closed microcentrifuge tube for 48 or 72 hr at 37°C, to minimize exposure to air. 
The bacteria were subsequently sub-cultured in broth by diluting 200 µL of L. 
crispatus or L. acidophilus with 9.8 mL of MRS broth (1:50 dilution) and 20 µL of 
G. vaginalis with 980 µL NYC III broth (1:50 dilution). The method of determining 
the correlation between the OD600 and respective CFU counts was reported 
previously416. One OD600 of L. crispatus, L. acidophilus, and G. vaginalis was found 
to be equivalent to 5.8 × 107, 9.2 × 107, and 1.3 × 109 CFU/mL, respectively. 
Fiber synthesis 
PLGA (50:50, 0.55–0.75 dL/g, 31-57 kDa MW) and PEO (600,000 MW) 
were purchased from Lactel Absorbable Polymers (Cupertino, CA) and Sigma 
Aldrich (St. Louis, MO), respectively. To fabricate blank fibers, PLGA (15% w/w) 
and PEO (5% w/w) were dissolved in 3 mL of hexafluoro-2-propanol (HFIP, Fisher 
Scientific, Waltham, MA, USA) and MRS broth, respectively and were incubated 
at 37°C overnight. For probiotic-containing formulations, 150 mg of PEO w/w was 
added to 2.5 mL MRS broth and immediately before electrospinning, 0.5 mL of 
MRS incorporating 5 × 107 CFU L. crispatus or L. acidophilus/ mg PEO was added 
to PEO solution. To minimize the risk of fiber contamination, polymer solutions 
were passed through a 0.45 µm syringe filter (VWR, PA, USA) before probiotic 
incorporation. In addition, the electrospinning box and all materials that were in 
contact with fibers were sterilized prior to electrospinning.  
During electrospinning, a positive voltage of 18 and 25 kV was applied at 
the tip of a needle connected to two syringes containing PLGA and PEO, 
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respectively. The electrospun fibers were collected on a rotating, 8 mm outer 
diameter stainless steel mandrel, positioned 18 cm from the blunt needle tip of the 
PLGA syringe and 15 cm from the needle tip of PEO syringe. The syringe flow 
rates were maintained at 0.3 mL/hr for both PLGA and PEO to fabricate 
PLGA:PEO (1:1) fibers, while flow rates of 0.1 and 0.3 mL/hr were used to fabricate 
PLGA:PEO (1:3) fibers. For the mesh architecture, the collector was placed in 
between the PLGA and PEO syringes at a distance of 18 and 15 cm, and fibers 
were collected simultaneously on the collector. For the layered architecture, a layer 
of PLGA fibers was electrospun (1 mL) and a PEO layer (1 mL) was subsequently 
electrospun on top of PLGA fibers. The schematic design of mesh and layered 
fibers, as well as the anticipated probiotic delivery mechanism from these platforms 
to the FRT are shown in Figure 5.1. 
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Figure 5.1. Schematic design of (A) mesh and (B) layered fiber architectures. 
Orange and green fibers represent PEO and PLGA fibers and purple rod-shape 
structures represent Lactobacillus. (C) Envisioned delivery of probiotic-containing 
fibers to the vaginal mucosa. 
Characterization of fiber morphology and degradation 
The morphology of PEO and PLGA fibers in mesh and layered architectures 
(with or without probiotic) was characterized using scanning electron microscopy 
(SEM). Fibers were placed on carbon tape, sputter-coated with a layer of 
palladium/gold alloy, and imaged using Supra 35 SEM (Zeiss, Oberkochen, 
Germany). Images were analyzed using ImageJ software and the average fiber 
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diameter of each formulation was determined by drawing a line across a minimum 
of 50 fibers per image (n = 3 images per fiber formulation).   
The mass loss of blank mesh and layered PLGA:PEO fibers (1:1 and 1:3) 
was determined over 3 wk by comparing the dry weight remaining at a specific 
time point with the initial weight. For each fiber formulation, 8 pieces of fibers with 
predetermined weight (8 to 10 mg) were placed in a 5 mL centrifuge tube filled with 
5 mL simulated vaginal fluid (SVF, pH 4.5) and incubated at 37°C. At each time 
point (e.g. 1, 8, 24, 48, 72 hr, 1, 2, and 3 wk), the fiber was removed and desiccated 
for 1 wk and weighed to calculate the mass loss.  
Quantification of probiotic release and proliferation from fibers 
The release of L. crispatus and L. acidophilus from, and proliferation of 
these probiotics in mesh and layered fibers were assessed in MRS broth for 2 wk. 
Pre-weighed fibers were placed in 5 mL centrifuge tubes and incubated in 5 mL 
MRS broth at 37°C with constant shaking at 150 rpm. At each time point (e.g., 1, 
4, 8, 24, 48, 72 hr, 1, 2, and 3 wk), the full volume (5 mL) of MRS broth was 
collected and serially diluted (10-fold dilutions), plated on MRS agar plate, 
incubated in anaerobic conditions at 37°C for 48 hr, and then evaluated for CFU 
counts. After collection, the centrifuge tube was filled with 5 mL fresh MRS broth.  
Quantification of lactic acid production and pH changes in probiotic fiber 
eluates 
Fiber release eluates, collected at the corresponding probiotic release time 
points were used to assess lactic acid production and pH change resulting from 
fiber administration. One mL of each eluate was first centrifuged at 2500 x g for 5 
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min to separate the bacteria from the solution and then the solution was serially 
diluted (10-fold dilutions). The amount of D- and L-lactic acid was assessed using 
a lactic acid detection kit (R-biopharma; Darmstadt, Germany) with a sensitivity 
limit of 1.5 µg/mL. The corresponding pH of eluates at these time points was 
determined using Fisherbrand™ plastic pH strips 5-9 (Fisher Scientific) with an 
accuracy of 0.5 pH units.  
Inhibitory potential of mesh and layered fibers in soluble G. vaginalis co-
cultures 
To evaluate the potential of mesh and layered fibers to inhibit G. vaginalis 
growth, free probiotics and probiotic-containing fibers were co-cultured with G. 
vaginalis in NYC III. For this experiment, the optimal formulation for each 
architecture was selected based on the highest probiotic release and proliferation 
observed over 2 wk. Based on results, L. crispatus PEO: PLGA (1:1) was chosen 
as a model for efficacy studies for both mesh and layered designs due to the high 
release and structural flexibility.  
Briefly, 1 × 106 CFU/mL of probiotic or equivalently dosed L. crispatus 
PEO:PLGA (1:1) mesh and layered fibers (1.2 mg/mL) were added to 5 mL 
microcentrifuge tubes. For free L. crispatus, the bacterial solution was centrifuged 
(3000 x g) and the broth was removed, while for L. crispatus fibers, the fiber itself 
was placed in the tube. Then, 1 x 106 CFU/mL of G. vaginalis in NYC III, 
corresponding to the range of G. vaginalis observed during BV infection (104 to 108 
CFU/mL)417, were added to the tube, followed by the addition of 5 mL NYC III broth. 
Fifty µL of the co-culture media was removed after 4, 24, and 48 hr anaerobic 
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incubation at 37°C and was serially-diluted in 96-well plates by adding 4 µL of 
bacteria solution to 196 µL of NYC III broth (1:50 dilutions). The plates were placed 
on a shaker to ensure complete mixing and 5 µL of each sample were plated in 
triplicate on the appropriate media agar plates to determine the resulting 
concentration of L. acidophilus and G. vaginalis After 24 and 48 hr incubation of 
MRS and NYC III plates in anaerobic condition (37 °C), the number of colonies for 
each dilution was counted and converted to CFU/mL. Control groups included free 
G. vaginalis, free L. crispatus, and blank fibers (without L. crispatus) cultured in 
NYC III media. Inhibition of G. vaginalis viability was determined as the log-
decrease in expression, relative to the free G. vaginalis CFU count for that sample 
group, at each corresponding time point. 
Statistical Analyses 
All in vitro experiments were performed 3 independent times with 3 
replicates for each sample, and the results are shown as the average ± standard 
deviation. Statistical analyses of samples for probiotic release and proliferation, 
lactic acid release, pH changes, and in vitro co-culture assays were performed 
using one-way ANOVA with the Tukey post hoc test (P ≤ 0.05) using Graph Pad 
Prism version 8.4.3.  
Results 
Physical Characterization of Mesh and Layered Electrospun Fibers 
First, fluorescently-labeled PLGA:PEO fibers (1:1 and 1:3) were 
electrospun to visually distinguish and evaluate the ratio of PLGA to PEO fibers 
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resulting from the dual-electrospinning process. The resulting mesh PLGA:PEO 
(1:1 and 1:3) fibers were imaged using fluorescence microscopy (Figure 5.S1), 
and PLGA fibers (shown in green) were discernible by the larger fiber diameters, 
relative to PEO fibers (shown in red). Mesh fibers with the same flow rate (1:1), 
resulted in a 2.5-fold increase (from 0.2 to 0.5) in the green-to-red ratio of 
PLGA:PEO fibers, relative to fibers dual-spun with a 1:3 PLGA:PEO flow rate.   
 
Figure 5.S1. Fluorescence microscopy images of different mesh fiber 
compositions as a result of dual-electrospinning with different PLGA (green) to 
PEO (red) flow rate ratios: (A) PLGA 0.3 mL/hr, (B) PLGA 0.1 mL/hr, (C) PEO 0.3 
mL/hr, (D) mesh PLGA:PEO (0.3:0.3 mL/hr), and (E) PLGA:PEO (0.1:0.3 mL/hr). 
Fibers were collected on glass slides after 30 seconds of electrospinning. Image 
magnification was 40X and scale bars represent 40 µm.  
The SEM images of blank and probiotic mesh and layered PLGA:PEO (1:1 
and 1:3) fiber architectures are shown in Figure 5.2 and Figure 5.S2, respectively. 
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Mesh and layered fibers comprised of 15 w/w% PLGA in HFIP and 5 w/w% PEO 
in MRS broth resulted in well-defined, uniform, and bead-free fibers. The average 
diameters of blank mesh architecture PLGA and PEO fibers were 2.16 ± 0.31 µm 
and 339 ± 132 nm, respectively. For blank layered architecture fibers, images were 
taken from the PEO side, showing uniform and bead-free PEO fibers with a mean 
diameter of 425 ± 177 nm. The PLGA side of the layered fibers (data not shown) 
had an average diameter of 1.33 ± 0.41 µm. Furthermore, the uniform morphology 
of mesh and layered fibers was retained when either L. crispatus or L. acidophilus 
was incorporated, and rod-shaped structures, highlighted in yellow, were 
distributed throughout the fibers, forming wider regions in PEO fibers (with an 
average diameter of 1.10 ± 0.14 µm). However, no differences were observed in 
fiber morphology and diameter as a function of probiotic type (i.e., L. crispatus or 
L. acidophilus) or flow rate, within each fiber architecture. No alterations to PLGA 




Figure 5.2. Probiotics are successfully incorporated within mesh PLGA:PEO (1:1) 
and PLGA:PEO (1:3)  fiber architectures. SEM images of probiotic electrospun 
fibers composed of different ratios of PLGA and PEO.  (A, B) blank fibers, (C, D) 
L. crispatus (L.c.)-containing fibers, and (E, F) L. acidophilus (L.a.)-containing 





Figure 5.S2. Probiotics are successfully incorporated within layered PLGA:PEO 
(1:1) and PLGA:PEO (1:3) fiber architectures. SEM images of probiotic 
electrospun fibers composed of different ratios of PLGA and PEO. (A, B) blank 
fibers, (C, D) L. crispatus (L.c.)-containing fibers, and (E, F) L. acidophilus (L.a.)-





In addition to assessing the morphology of fibers in mesh and layered 
architectures, probiotic proliferation on the fiber surface was assessed by exposing 
the probiotic fibers to MRS broth for up to 2 wk. In both mesh and layered fibers, 
probiotic biofilms began to form on the fiber surfaces after 48 hr and persisted 
through the 2 wk study (Figure 5.3 and Figure 5.S3). Both L. crispatus and L. 
acidophilus PLGA:PEO (1:1 and 1:3) fibers were able to localize probiotic growth 
on their surfaces, developing probiotic biofilms with similar morphologies.  
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Figure 5.3. Probiotic biofilms are formed on mesh fiber surfaces after 48 hr and 
persist through 2 wk. SEM images of mesh fibers composed of either PLGA:PEO 
(1:1) or (1:3) that incorporate L. crispatus or L. acidophilus after 1, 24, 48, and 72 
hr, and 1, and 2 wk in MRS broth. Scale bars represent 5 µm. 
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Figure 5S.3. Probiotic biofilms are formed on layered fiber surfaces after 48 hr and 
persist through 2 wk. SEM images of layered fibers composed of either PLGA:PEO 
(1:1) or (1:3) that incorporate L. crispatus or L. acidophilus after 1, 24, 48, and 72 




Micro and macroscale alterations to blank mesh and layered PLGA:PEO 
(1:1 and 1:3) fibers were evaluated for up to 2 wk (Figures 5.4 and 5.5A). In the 
mesh architecture, intact PEO fibers were observed for up to 48 hr, which was 
attributed to the simultaneous integration of soluble PEO with insoluble PLGA 
fibers during the dual-electrospinning process (Figure 5.4). Similarly, PEO fibers 
were still observed in layered PLGA:PEO (1:3) for up to 48 hr, while layered fibers 
with a smaller volume fraction of PEO (1:1) exhibited more rapid dissolution of 
PEO within 1 hr. Furthermore, both mesh and layered architectures displayed 
minor surface irregularities after 1 wk (arrows point to surface defects). From a 
microstructural perspective and despite the observation of slight surface 
irregularities, no significant changes in mesh or layered PLGA fiber diameters were 
observed after 2 wk (2.23 ± 0.39 and 1.53 ± 0.39 µm, respectively).   
In line with these observations, the macrostructure of blank mesh and 
layered PLGA:PEO (1:1 and 1:3) fibers became more brittle after 72 hr due to the 
dissolution of PEO fibers from both formulation types (Figure 5.5). After 3 wk, 
mesh and layered PLGA:PEO (1:1) fibers had major ruptures and conglutination, 
while mesh and layered PLGA:PEO (1:3) fibers were completely dissolved. 
Macrostructural images of mesh PLGA:PEO (1:1) fibers are shown as 
representative for all formulations in Figure 5.5A.  
In addition to changes in fiber morphology, the overall mass loss of blank 
mesh and layered PLGA:PEO (1:1 and 1:3) fibers was assessed for up to 2 wk 
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(Figure 5.5B). For mesh PLGA:PEO (1:1 and 1:3) fibers, a 48 and 66% reduction 
in mass was observed after 1 hr, with total mass loss increasing to 53 and 75% 
after 48 hr, respectively. These values were in agreement with the general time 
frame observed for PEO dissolution. In comparison, layered PLGA:PEO (1:1 and 
1:3) fibers had 46 and 68% mass loss after 1 hr and 46 and 80% total mass loss 





Figure 5.4. SEM images of mesh and layered blank fibers after 1 hr, 48 hr, 1 wk, 
and 2 wk degradation time points. While the PEO portion of mesh fibers (1:1 and 
1:3) dissolves after 48 hr, PEO fibers in the layered (1:1) and (1:3) architecture 
dissolve after 1 and 48 hr, respectively. For both architectures, PLGA maintains its 
overall fiber structure for up to 2 wk. Arrows show surface roughening of the PLGA 




Figure 5.5. (A) Macrostructural images of blank mesh PLGA:PEO (1:1) fibers over 
the duration of the 3 wk degradation study. Similar macrostructural degradation 
was observed within mesh (1:3) and layered (1:1 and 1:3) fibers. (B) Percent of 
total mass loss, relative to starting mass, of blank mesh and layered fibers 
electrospun with different flow rate ratios (1:1 and 1:3). Mass loss values are 
shown as the mean ± standard deviation of three independent fiber batches. Scale 
bar represents 1 cm. 
In line with these observations, the macrostructure of blank mesh and 
layered PLGA:PEO (1:1 and 1:3) fibers became more brittle after 72 hr due to the 
dissolution of PEO fibers from both formulation types (Figure 5.4). After 3 wk, 
mesh and layered PLGA:PEO (1:1) fibers had major ruptures and conglutination, 
while mesh and layered PLGA:PEO (1:3) fibers were completely dissolved. 
Macrostructural images of mesh PLGA:PEO (1:1) fibers are shown as 
representative for all formulations in Figure 5.4A.  
In addition to changes in fiber morphology, the overall mass loss of blank 
mesh and layered PLGA:PEO (1:1 and 1:3) fibers was assessed for up to 2 wk 
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(Figure 5.4B). For mesh PLGA:PEO (1:1 and 1:3) fibers, a 48 and 66% reduction 
in mass was observed after 1 hr, with total mass loss increasing to 53 and 75% 
after 48 hr, respectively. These values were in agreement with the general time 
frame observed for PEO dissolution. In comparison, layered PLGA:PEO (1:1 and 
1:3) fibers had 46 and 68% mass loss after 1 hr and 46 and 80% total mass loss 
after 48 hr. After 48 hr, all fibers had negligible mass loss for the remainder of 2 
wk.  
Probiotic Release and Proliferation 
The cumulative release and proliferation of probiotics from mesh and 
layered PLGA:PEO (1:1 and 1:3) fibers were evaluated over 2 wk (Figure 5.6). 
The total probiotic concentration, accounting for probiotic release from, and 
proliferation within all mesh (Figure 5.6A) and layered (Figure 6B) fibers reached 
108 CFU/mg fiber after 48 hr and 109 CFU/mg after 6 days. After 2 wk, the total 
release and proliferation observed from different mesh fiber formulations ranged 
from 3.8 x 109 and 6.6 x 109 CFU/mg, and was similar to that observed from layered 
fibers (2.4 x 109 to 6.1 x 109 CFU/mg). Across mesh and layered architectures with 
the same Lactobacillus type or polymer composition, similar levels of probiotic 





Figure 5.6. The cumulative release and proliferation of L. crispatus (L.c.) and L. 
acidophilus (L.a.) from (A, C) mesh and (B, D) layered fibers over 2 wk. Panels C 
and D highlight different concentration ranges of release from panels A and B 
based on the time frame of release. All mesh and layered fiber formulations 
demonstrate high levels of cumulative probiotic release and proliferation, reaching 
108 and 109 CFU/mg fiber by 48 hr and 6 days, respectively. Total release and 
proliferation after 2 wk were similar between groups within each of the mesh and 
layered architectures, as a function of the area under the curve and total release 
and proliferation (P > 0.05). The only exception was observed for layered fiber 
architectures, in which L.c. PLGA:PEO (1:1) released significantly more L.c. than 
L.c. PLGA:PEO (1:3) fibers, based on total release and area under the curve 
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measurements after 2 wk (P ≤ 0.05). Across mesh and layered architectures with 
the same Lactobacillus type or polymer composition, similar levels of probiotic 
release were observed after 2 wk (P > 0.05). Release values are shown as the 
mean ± standard deviation of three independent fiber batches. Statistical 
significance between experimental groups, as calculated by one-way ANOVA, is 
represented by *P ≤ 0.05. 
For both mesh and layered architectures, no statistical significance was 
observed in total probiotic release and proliferation within mesh or layered fiber 
groups, as a function of Lactobacillus type (P > 0.05), as assessed by comparing 
both area under the curve and total cumulative release and proliferation after 2 wk. 
Similarly, as a function of PLGA:PEO composition (flow rate), fibers within mesh 
or layered fiber groups that were electrospun with different PLGA:PEO flow rates, 
displayed similar amounts of release after 2 wk, regardless of Lactobacillus type. 
The one exception was that layered L. crispatus PLGA:PEO (1:1) fibers had 
significantly higher probiotic release relative to layered L. crispatus PLGA:PEO 
(1:3) fibers after 2 wk (P ≤ 0.05). Overall, mesh and layered L. crispatus 
PLGA:PEO fibers, electrospun with equal flow rates (1:1 composition), 
demonstrated higher, albeit non-significant amounts of probiotic release, relative 
to all other formulations, with 2.1 x 109  and 2.3 x 109 CFU/mg released after 1 wk, 
and 6.6 x 109 and 6.1 x 109 CFU/mg after 2 wk.  
The mesh and layered probiotic release and proliferation curves followed a 
zero-order release trend (R2 = 0.93 to 0.99) after 48 hr, indicating a linear release 
of probiotics with respect to time. While no statistical significance was observed 
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within or across architecture types, the highest and lowest rates of release within 
mesh fibers were observed from L. crispatus PLGA:PEO (1:1) and L. acidophilus 
PLGA:PEO (1:3) formulations, with slopes of 4.1 x 108 and 2.7 x 108 
CFU/(mg·day), respectively (P > 0.05). Within layered architectures, the highest 
and lowest release/proliferation rates were obtained from L. crispatus PLGA:PEO 
(1:1) and L. crispatus PLGA:PEO (1:3) fibers, with corresponding slopes of  4.6 x 
108 and 1.8 x 108 CFU/(mg·day) (P > 0.05).  
Lactic Acid Production and pH Change 
Lactic acid production and pH changes were assessed from both blank 
mesh/layered fibers and probiotic-loaded mesh/layered fibers to compare with 
probiotic release and proliferation. The cumulative amounts of D- and L-lactic acid 
produced from mesh and layered fibers are shown in Figure 5.7 and correlate with 
the high levels of probiotic release and proliferation observed on the fiber surface. 
Mesh and layered fibers incorporating L. crispatus and L. acidophilus produced as 
much as 83 and 59 mg of D-lactic acid/mg fiber, respectively, over 2 wk, relative 
to blank fibers, which produced no lactic acid. Despite a slightly higher trend 
observed for D-, relative to L-lactic acid production for each mesh and layered 
formulation, similar cumulative amounts of D- and L-lactic acid were produced for 
each over the 2 wk duration (P > 0.05). Similarly, mesh as compared to layered 
fibers, that were electrospun with the same Lactobacillus type and flow rate 
(polymer composition), produced similar amounts of D- and L-lactic acid (P > 0.05).  
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Within mesh (Figure 5.7A-D) and layered (Figure 5.7E-H) fiber 
architectures, similar D and L-lactic acid production was observed as a function of 
Lactobacillus type or composition. Among mesh fiber formulations, the highest 
concentrations of D- and L-lactic acid were both produced from L. crispatus 
PLGA:PEO 1:3 fibers (D: 83.32 and L: 63.03 mg/mg fiber, Figure 5.7B) over 2 wk, 
while the highest amounts were produced from layered L. crispatus PLGA:PEO 
1:1 (D: 53.75 mg/mg fiber, Figure 5.7E) and L. acidophilus PLGA:PEO 1:3 (L: 
39.67 mg/mg fiber, Figure 5.7H) formulations.   
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Figure 5.7. Lactic acid production from mesh (A, B, C, and D) and layered (E, F, 
G, and H) fibers. (A, E) L. crispatus PLGA:PEO (1:1); (B, F) L. crispatus 
PLGA:PEO (1:3): (C, G) L. acidophilus PLGA:PEO (1:1); and (D, H) L. acidophilus 
PLGA:PEO (1:3) fibers. Mesh and layered fibers incorporating L. crispatus and L. 
acidophilus produced as much as 83 and 59 mg D-lactic acid/mg fiber respectively 
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over 2 wk, relative to blank fibers that produced negligible levels of D- and L-lactic 
acid (below assay detection limit of ~1.5 µg/mL). Similar lactic acid production was 
observed between mesh and layered fibers electrospun with the same 
Lactobacillus type or fiber composition, as calculated by both area under the curve 
and total lactic acid production (P > 0.05). Within mesh and layered architectures 
with the same probiotic type or fiber composition, no differences were observed in 
D- and L-lactic acid production (P > 0.05). Lactic acid production is shown as the 
mean ± standard deviation of three independent fiber batches. In some cases, 
error bars appear smaller than the symbol size. Statistical significance between 
experimental groups was determined using one-way ANOVA. 
In addition to evaluating the amount of lactic acid production, the rate of 
lactic acid produced per day was evaluated, demonstrating a linear trend for all 
mesh and layered fiber formulations (R2 = 0.93 to 0.99). Overall, similar D- and L-
lactic acid production rates (slopes) were observed between mesh and layered 
architecture fibers electrospun with the same Lactobacillus type or composition 
(flow rate) (P > 0.05). Within mesh formulations, similar rates of D- or L-lactic acid 
production were observed as a function of Lactobacillus type. Similarly in mesh 
fibers, as a function of polymer composition (1:1 or 1:3), L. acidophilus formulations 
had similar rates of D-lactic acid production, while L. crispatus PLGA:PEO (1:3) 
had a significantly higher rate of L-lactic acid production relative to L. crispatus 
PLGA:PEO (1:1) (P ≤ 0.05). The production rates of D- and L-lactic acid were 
similar across different formulations of layered fibers with either different 
Lactobacillus type or polymer composition (P > 0.05). The highest rates of  D-lactic 
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acid production were observed from mesh and layered L. crispatus PLGA:PEO 
(1:3) fibers (6.22 and 4.32 mg/mg fiber·day, respectively), while the highest rate of 
L-lactic acid production was observed from mesh L. crispatus PLGA:PEO (1:3, 
4.52 mg/mg fiber·day) and layered L. acidophilus PLGA:PEO (1:1, 3.43 mg/mg 
fiber·day) fibers. 
Corresponding with lactic acid production, a significant decrease in the 
eluate pH was observed for mesh (Figure 5.8A, B) and layered (Figure 5.8C, D) 
PLGA:PEO (1:1 and 1:3) fibers. A decrease from an initial pH of 6 to 4 or 4.5 was 
observed with 24 to 48 hr, while a subsequent decrease to 3.0 or 3.5 was observed 
after 1 wk (P ≤ 0.0001). These changes were observed regardless of probiotic type 
or polymer composition (1:1 or 1:3) (Figure 5.8). In contrast, no changes in pH 
were observed for blank PLGA:PEO (1:1 and 1:3) mesh and layered fibers, relative 
to probiotic-containing fiber groups.  
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Figure 5.8. The pH of PLGA:PEO mesh and layered fiber eluates was measured 
over 2 wk. Mesh (A) L. crispatus (L.c.) and (B) L. acidophilus (L.a.) and layered (C) 
L.c. and (D) L.a. fibers electrospun with different PLGA:PEO (1:1 and 1:3) flow rate 
ratios. The lactic acid produced by probiotics caused a significant decrease in the 
pH of all fiber eluates within the first week (P ≤ 0.0001) that persisted, regardless 
of daily media changes, over 2 wk. No changes in pH were observed in blank fiber 
eluates (P > 0.05). pH values are shown as the mean ± standard deviation of 
eluates from three independent fiber batches and error bars are smaller than the 
symbol size. Statistical significance between experimental groups, as calculated 




In Vitro Efficacy of Mesh and Layered Fibers 
To evaluate the ability of probiotic fibers to inhibit G. vaginalis, the fiber 
formulation with the highest probiotic release/proliferation and fabrication yield was 
selected for co-culture with G. vaginalis. Here, PLGA:PEO (1:1) mesh or layered 
fibers were co-cultured with G. vaginalis at equivalent concentrations (106 
CFU/mL) for up to 48 hr under anaerobic conditions at 37°C. An equivalent dose 
of mesh or layered L. crispatus PLGA:PEO (1:1) fibers (1.2 mg/mL, 106 CFU/mL, 
based on L. crispatus actual loading in PEO fibers) was administered with G. 
vaginalis (106 CFU/mL). Figure 5.9 shows the species viability as measured by 
CFU counts for free L. crispatus or free G. vaginalis; mesh or layered L. crispatus 
PLGA:PEO (1:1) fibers alone; or free L. crispatus or mesh/layered L. crispatus 
PLGA:PEO (1:1) fibers co-cultured with G. vaginalis for 4, 24, or 48 hr. For L. 
crispatus mesh PLGA:PEO (1:1) fibers, a 2.2- (P > 0.05), 8- (P ≤ 0.001), and 9.3-
log (P ≤ 0.0001) reduction in G. vaginalis viability was observed after 4, 24, and 48 
hr of co-culture, respectively. Similarly, L. crispatus layered PLGA:PEO (1:1) fibers 
completely inhibited G. vaginalis growth after 24 and 48 hr (6.5- and 9.5-log 
reduction in viability, P ≤ 0.0001), while no significant decrease in G. vaginalis 
viability was observed after 4 hr (2.3-log reduction, P > 0.05).  
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Figure 5.9. L. crispatus (L.c.) PLGA:PEO (1:1) mesh or layered fibers were co-
cultured with G. vaginalis (G.v.) at equal initial concentrations of 106 CFU/mL for 
4, 24, and 48 hr. (A) L. crispatus PLGA:PEO (1:1) mesh fibers significantly inhibited 
G. vaginalis viability after 24 (P ≤ 0.001) and 48 hr (P ≤ 0.0001). Similarly, free L. 
crispatus inhibited G. vaginalis viability after both 24 and 48 hr (P ≤ 0.0001). (B) L. 
crispatus PLGA:PEO (1:1) layered fibers significantly inhibited G. vaginalis viability 
after 24 (P ≤ 0.0001) and 48 hr (P ≤ 0.0001). Similarly, free L. crispatus inhibited 
G. vaginalis viability after both 24 (P ≤ 0.0001) and 48 hr (P ≤ 0.0001). Columns 
with zero values are represented by “+”, and the log (CFU/mL) values are 
determined from the mean ± standard deviation of eluates from three independent 
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L. crispatus fiber or free L. crispatus batches. Statistical significance between 
experimental groups, as calculated by one-way ANOVA, is represented by **P ≤ 
0.001 and ****P ≤ 0.0001. 
 Discussion 
The administration of probiotics, specifically lactobacilli, can enhance 
female reproductive health by preventing or disrupting pathogenic bacteria 
adhesion and growth. Among different Lactobacillus species, L. crispatus and L. 
acidophilus, are two of the most abundant species in a healthy vaginal environment 
that have been used for BV treatment, due to strong epithelial cell adhesion and 
the production of high lactic acid concentrations418,419.  
The intravaginal delivery of lactobacilli has shown promise to treat initial and 
recurrent BV infections, in particular, relative to oral delivery, due to the localized 
delivery of highly viable probiotic concentrations to the FRT. Different dosage 
forms including tablets337, capsules402, and suppositories420 that incorporate 
probiotics have shown efficacy against BV infection. However, rapid probiotic 
release from these delivery platforms often results in transient effects, thereby 
requiring frequent administration, which can lead to low user adherence and 
recurrent infection. To address these challenges, there is a need to develop new 
delivery platforms focused on the maintenance and restoration of vaginal health, 
via localized and prolonged lactobacilli delivery. To date, only one platform, in the 
form of pod-based IVRs, has demonstrated sustained probiotic release in vitro on 
the order of 107 CFU/ring daily over 21 days. However, the prolonged residence of 
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rings in the vaginal environment has been shown to result in bacterial matrices 
comprised of a wide variety of bacterial types and extracellular polysaccharides, 
potentially complicating the amelioration of infection407,408.  
Recently, electrospun fibers have been applied in a variety of architectures 
to prolong the release of different active agents including antiretrovirals251,346,421,422 
and antiviral proteins273 for intravaginal delivery. Furthermore, electrospun fibers 
may be a favorable dosage form by which to address challenges, such as low user 
adherence and emerging drug resistance, present with more frequently 
administered delivery platforms. Some of the benefits provided by electrospun 
fibers include the ability to integrate diverse polymer types to modulate release, 
the simplicity of the electrospinning process, and the flexibility to incorporate 
multiple types of active agents346. Recently, our group and others have extended 
the use of electrospinning to develop rapid-dissolve, “on-demand” intravaginal 
delivery platforms that incorporate probiotics with high viability and 
stability342,343,416. Given the long-standing need to develop sustained-release 
dosage forms that can maintain vaginal health and treat BV recurrence, here we 
sought to build upon rapid-dissolve fibers to create more complex architectures 
that integrate hydrophobic and hydrophilic polymers, to sustain probiotic release 
for BV treatment.  
To first evaluate the feasibility of this approach, we assessed the 
incorporation of L. crispatus and L. acidophilus in mesh and layered fibers with 
different PLGA to PEO ratios. A previous study in our group showed that L. 
acidophilus, incorporated in PEO fibers spun in water at an initial concentration of 
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5 x 107 CFU/mg fiber, had a post-spun viability of 1.7 x 107 CFU/mg fiber416. In this 
study, a similar amount of L. crispatus or L. acidophilus was incorporated in the 
PEO portion of mesh and layered fibers, and we envisioned that probiotic 
incorporation in more complex mesh and layered fibers would enable the 
hydrophilic polymer to act as a probiotic reservoir, while the hydrophobic polymer 
would serve as a structural support to enhance probiotic proliferation and retention. 
Probiotic distribution in these fiber formulations was confirmed with SEM imaging, 
showing that probiotics were well-distributed within all fiber formulations (Figure 
5.2 and Figure 5.S2). 
To evaluate the in vitro degradation of blank mesh and layered fibers, fiber 
micro- and macrostructures were evaluated after exposure to SVF. Based on SEM 
images, mesh architecture PEO fibers generally remained intact for a longer 
duration (48 hr), relative to layered architecture PEO fibers (1:3, 1 hr). These 
findings of more rapid PEO dissolution in the layered architectures may be 
attributed to the potential for increased entanglement between PEO and PLGA 
fibers in the interwoven mesh architecture, relative to discrete sections in the 
layered architecture. After 1 wk, the remaining PLGA fibers in both architectures 
had some surface roughening that remained through 2 wk. These fiber surface 
irregularities may be partially attributed to the relatively acidic environment (pH 4.5) 
of simulated vaginal fluid, which can accelerate fiber degradation. Other work, 
which studied the degradation of PLGA microspheres under different pH 
conditions, showed that an acidic environment augments polymer erosion by 
catalyzing the rupture of the ester linkage in the PLGA backbone423. Thus, while 
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these acidic conditions may contribute to the surface roughening of PLGA fibers, 
these minor irregularities did not seem to substantially contribute to fiber 
degradation. After 2 wk, PLGA:PEO (1:3) fibers displayed a more melded and 
eroded appearance, relative to PLGA:PEO (1:1) fibers, which is likely attributed to 
the higher ratio of PEO to PLGA in the PLGA:PEO (1:3) formulations. While our 
study focused on dual- and layered electrospinning of PLGA and PEO fibers, 
studies that blended PLGA with PEO (as a porogen) have been shown to 
accelerate PLGA degradation by creating a more porous structure and increasing 
surface exposure to the surrounding eluate424.  
In parallel with evaluating the micromorphology of fibers, the mass loss of 
different fiber architectures was measured after exposure to SVF. PLGA:PEO (1:1) 
mesh and layered fibers, comprised of final concentrations of ~20 wt% PEO and 
~80 wt% PLGA, had 48 and 46% weight loss after 1 hr, indicating the immediate 
nature of PEO dissolution as a primary contributor to mass loss. The same 
observation was made for PLGA:PEO (1:3) mesh and layered fibers containing 
~50 wt% PEO and ~50 wt% PLGA, which had higher mass losses (66 and 68%) 
after 1 hr, stemming from the increased PEO content. There were subsequent 
minor decreases in total mass for both mesh and layered fibers with different 
compositions for up to 48 hr, followed by a plateau in weight loss. Overall, mesh 
and layered PLGA:PEO (1:1) fibers were shown to degrade more slowly, exhibiting 
major ruptures after 3 wk, while mesh and layered PLGA:PEO (1:3) fibers were 
completely dissolved within this same time frame. 
 207 
In order to evaluate the potential of mesh and layered fibers to extend 
delivery beyond that required for on-demand applications, probiotic release and 
proliferation were assessed from different architectures. For mesh and layered 
fibers with different Lactobacillus species and polymer compositions, cumulative 
probiotic release reached ~107 CFU/mg after 24 hr. After 48 hr, a  linear trend in 
the cumulative release and proliferation of probiotic was observed, providing more 
than 108 CFU/mg probiotic daily, which is on the order of or higher than the 
required daily dose of probiotic for clinical BV treatment (108 CFU/day)425. For the 
mesh architectures, no statistical significance in probiotic release was observed as 
a function of probiotic type or polymer composition; however, in layered fibers, L. 
crispatus PLGA:PEO (1:1) released significantly higher (P ≤ 0.05) amounts of 
probiotic, relative to PLGA:PEO (1:3) fibers. In general, all tested formulations 
were able to release efficacious amount of probiotic for up to 2 wk, but it should be 
mentioned that mesh and layered PLGA:PEO (1:1) fibers better maintained their 
structures over the 2 wk study, while PLGA:PEO (1:3) were more fragile and 
susceptible to ruptures. 
Relative to this study, to our knowledge, only one other platform has 
demonstrated sustained lactobacilli release. In this previous work, L. gasseri was 
incorporated in silicone IVRs and achieved release on the order of 1.1 to 14 x 107 
CFU/ring each day for up to 21 days340. While higher probiotic release was 
observed in our study, release was conducted in MRS (pH 6.2), relative to PBS 
(pH 7.2) in the former IVR study. We acknowledge that release eluate may impact 
bacterial release and proliferation; however, in our hands, we observed minimal 
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release in the relatively low glucose (5 g/L) simulated vaginal fluid (SVF), relative 
to higher glucose-containing MRS (20 g/L), potentially indicating a lack of nutrients 
available to foster probiotic survival. In future studies, it will be important to assess 
the impact of different eluates to best represent the conditions relevant to 
intravaginal delivery and to correlate in vitro with in vivo probiotic release and 
proliferation.  
Additionally, it is important to note that differences in fiber and IVR 
morphologies may play a role in release. In fibers, probiotics were incorporated 
within the PEO fiber portion, which rapidly degrades in solution, leaving probiotics 
to intermingle and reside in the surrounding PLGA fabric. In this regard, probiotics 
are “incorporated” but not actually "encapsulated," as they are in IVRs. Hence, 
IVRs may more specifically show release, whereas probiotics may desorb from the 
fiber surface or diffuse from the matrix. Furthermore, this suggests that probiotics 
are more exposed to the surrounding eluate in fibers, thus the choice of eluate may 
play a more significant role in observing their release and viability. In upcoming in 
vivo studies, we look forward to investigating how probiotic release or diffusion 
translates to in vivo viability and colonization. These results would help to validate 
appropriate in vitro conditions by which to test these new sustained-delivery 
probiotic platforms. For fibers and other delivery vehicles, it has previously been 
acknowledged, that in vitro and in vivo release often differ197 and as such, it is 
important to establish mimetics that accurately reflect in vivo conditions and 
features of the physiological environment for intravaginal (and other) applications. 
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In addition to the ability of fibers to provide high levels of probiotic release, 
one of the observations with polymer-based delivery platforms, which in this case 
may benefit probiotic delivery and vaginal health, is the susceptibility to biofilm 
formation426. Previous work has shown that IVRs are susceptible to biofilm 
formation by a variety of bacteria, which, in some cases may limit their long-term 
use407,408. In our studies, in addition to high levels of probiotic release, we observed 
probiotic proliferation on the fiber surfaces after 72 hr, which persisted through the 
2 wk study (Figure 5.3 and Figure 5S.3). We anticipate that the presence of such 
high concentrations of probiotics and subsequent probiotic biofilms may make the 
fiber surface less prone to pathogen adherence in the context of existing infections. 
Furthermore, in terms of treating or preventing future infections, probiotic adhesion 
and growth within fibers may make the environment less amenable to sustaining 
pathogen viability. Therefore, probiotic fibers may have the ability to both release 
and localize the growth of probiotics to prevent G. vaginalis and other pathogenic 
bacteria involved in BV and more general delivery vehicle administration.  
In combination with measuring probiotic release, D- and L-lactic acid 
production and pH changes resulting from fiber administration were evaluated, due 
to the known antimicrobial and immunomodulatory effects of lactic acid. Lactic acid 
production has also been shown to restore vaginal acidity, which is another 
mechanism by which to inhibit pathogen viability and growth. It has been shown 
that both D- and L- isomers play important role in enhancing vaginal health, 
however, D- lactic acid is more protective against BV, relative to L-lactic acid, and 
only D- lactic acid can enhance α-amylase activity to support Lactobacillus 
 210 
colonization427. In our study, all fiber formulations regardless of Lactobacillus type 
or polymer composition demonstrated linear production rates of D- and L- lactic 
acid, with generally higher D-lactic acid concentrations. Based on previous studies, 
most Lactobacillus species produce both D- and L-lactic acid, and the D- to L-lactic 
acid ratio varies based on species and strain428. Generally, L. crispatus has been 
found to produce a higher amount of lactic acid relative to other species, in addition 
to a higher D- to L- lactic acid ratio429. Our results showed that there was no 
statistical significance between D- and L-lactic acid production as a function of fiber 
architecture (P > 0.05). Furthermore, all mesh and layered fibers released more 
than 3 mg/mL (~33 mM) and 2 mg/mL (~22 mM) of D- and L-lactic acid, or 5 mg/mL 
lactic acid in total, every day after 2 days. These values are within therapeutically-
relevant ranges based on the average concentration of lactic acid reported as 1.0% 
± 0.2% (w/v) or 10 mg/mL in Lactobacillus-dominated microflora, specified with a 
Nugent score of 0 to 3430. In addition to lactic acid production, a significant change 
in pH (from 6 to 3.5 or 3) was observed after 1 wk for all fiber formulations (P ≤ 
0.0001) which may be attributed to lactic acid production. These values are 
comparable to literature-reported values for the normal vaginal pH of 3.5 ± 0.3 
(range 2.8 to 4.2)430. Based on lactic acid production and corresponding pH 
changes, probiotic mesh and layered fibers show promise in their capabilities to 
restore and maintain normal vaginal health. 
Finally, the preliminary efficacy of probiotic fibers was assessed in vitro 
using a soluble co-culture assay. For each architecture, the formulation with the 
highest amount of probiotic release, L. crispatus mesh and layered PLGA:PEO 
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(1:1), was selected for in vitro efficacy studies. Both mesh and layered probiotic 
fibers completely inhibited G. vaginalis growth after 24 hr, resulting in an 8- and 
6.5-log decrease in G. vaginalis viability. This significant decrease in G. vaginalis 
viability is much higher than the minimum bactericidal criteria specified as a 3-log 
decrease in the number of pathogenic bacteria358. In addition, the efficacy of 
probiotic fibers was similar to free probiotics, showing that probiotics maintain their 
activity after the electrospinning process and exert a similar effect in short-term 
studies. While there is no other study from other groups that evaluates the efficacy 
of probiotic delivery platforms against G. vaginalis growth in vitro, there are a few 
in vitro studies that assess the ability of free probiotics to inhibit G. 
vaginalis358,431,432. One study specifically investigated the inhibitory effect of L. 
crispatus at 109 CFU/mL against G. vaginalis at 108 CFU/mL in vitro and showed 
that after 18 hr, a 5-log decrease in G. vaginalis viability was observed which is in 
agreement with our observations358. While limitations exist in co-culture type 
assays, in particular for the long-term culture of anaerobic bacteria, sustained-
release probiotic fibers may have the potential to inhibit G. vaginalis for a longer 
duration, given the amount of probiotic and lactic acid release throughout all time 
points of the study.  
Relating this platform to its potential for future clinical delivery, the polymers 
utilized to fabricate these fibers, PLGA and PEO, are FDA-approved, a feature that 
may accelerate the translation of these platforms to clinical application. When 
scaled for human applications, we estimate that probiotic release, given a 
favorable environment for probiotic proliferation, will be on the order of ~1010 CFU 
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for a 100 mg dosage form (after 48 hr) or 1010 CFU per day after 48 hr, However, 
if needed, fibers may be easily fabricated with lower probiotic doses. In addition, 
while previous in vivo studies have shown the safety and efficacy of electrospun 
fibers for intravaginal delivery34,256,433,434, preclinical trials need to be conducted to 
further evaluate the efficacy of probiotic fibers for intravaginal applications. In 
ongoing work, we plan to characterize the cellular and microbial responses 
associated with the administration of probiotic fibers in cell monolayers and 
EpiVaginalTM tissue. In parallel, the safety and efficacy of probiotic mesh and 
layered fibers will be evaluated in an established murine model of BV infection.  
Overall, this study showed for the first time that electrospun fibers have the 
potential to enable sustained probiotic release from and corresponding 
proliferation in the fibers, while producing lactic acid at concentrations relevant to 
restoring and maintaining vaginal health. Our in vitro results also suggest that 
mesh and layered fibers may offer conducive architectures to foster probiotic 
growth and integration, similar to eukaryotic cell behavior in tissue engineering 
applications. In future work, we anticipate that this platform may be utilized for 
broader, multipurpose applications to simultaneously protect women against viral 
STIs, bacterial infections, and unwanted pregnancies. With this demonstrated 
capability of probiotic delivery, this platform may facilitate more rapid restoration of 
vaginal health in the context of bacterial infections, contributing to the potential to 
address multiple unmet needs in women’s reproductive health, while providing an 




FIRST ELECTROPHYSIOLOGICAL MEASUREMENTS CONFIRM SUCCINYL 
LINKER ENHANCES PERFORMANCE OF HEPTAPEPTIDE SYNTHETIC 
CHLORIDE CHANNEL 
Introduction 
A deepening understanding of the mechanisms surrounding natural 
membrane transport has inevitably led to efforts at engineering such systems. 
Applications for such systems include highly selective filters for a specific anion or 
cation, a wide range of molecular sensors, novel antibiotics, drug delivery as well 
as DNA and RNA sequencing436,437. This study is focused on a group of chloride 
channels termed Synthetic Chloride Membrane TRansporters (SCMTR)438,439. 
The general form of the standard SCMTR is (R1)2NCOCH2OCH2CO–(Gly)x–
Pro–(Gly)x–R2440. The dialkylamine (R1)2N- group mimics the twin fatty acid chains 
of a phospholipid and serves to anchor the channel to the membrane. The linker 
of diglycolic acid has intermediate hydrophobicity and mimics the glycerol found in 
natural lipids. There is also evidence that it interacts with anions as they pass 
through the channel441. The amino acid sequence, (Gly)x–Pro–(Gly)x, functions as 
the primary anion selectivity filter and channel with the motif design driven by 
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mimicking the conserved CLC1 GxxP sequence442 and the expense of 
synthesizing the molecules443. The R2 group is also a hydrophobic moiety such as 
a phenyl or alkane and, as with the N-terminal alkyls, have been shown to act as 
a membrane anchor. The precise mechanisms that allow for such small molecules 
to organize and form discrete, sharply defined conductance states are unknown. 
There is, however, strong evidence that two or more SCMTR molecules aggregate 
to create multimers within the membrane to form the channels 444,445. 
Results and Discussion 
We investigated four types of SCMTR molecules using planar lipid bilayer 
measurements in membranes, measuring three lipid systems and two polymers. 
The geometry-equilibrated structure of SCMTR molecules used in this study and 
their chemical formulas are shown in Figure 6.1. In this group, all of the SCMTR 
molecules contain a succinyl group (-COCH2CH2CO-) as the linker between the 
N-terminal alkanes and amino acids. This structure differs from the standard form 
where the linker is derived from diglycolic anhydride439 that was chosen as it is 
structurally similar to the glycerol (-COCH2OCH2CO-) found in natural lipids and 
thus has similar polarity438,446. In addition, diglycolic acid is easily reacted with the 
diamines447 of the hydrophobic tail; however, when Pajewski et al.441, investigated 
the effect of several different linkers on the rate of chloride release from liposomes 
using fluorescent probes, they found that a succinate acid derivative (succinyl) had 
the highest chloride release rate as well as the fastest formation of ion 
 
1 There appears to be some confusion in the literature over abbreviation for the chloride channel.  Early literature 
abbreviated with a lower case “L” as in chlorine from the periodic table.  The recent trend however is to use an upper 
case “L” so it is not confused with an upper case “i”.    
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conductance pathways441.  To our knowledge, this is the first report of planar 
bilayer experiments with this linker.  
 
Figure 6.1. Molecular structure of different compounds used in the experiment. 
The chemical formula of each is listed below.  
(C18H37)2-N-OC-CH2-CH2-CO-AAAPGGG-O(CH2)6CH3  Mw=1201.75 g/mol 
(C8H17)2-N-OC-CH2-CH2-CO-GGGPGGG-O(CH2)6CH3  Mw=879.15 g/mol 
(C10H21)2-N-OC-CH2-CH2-CO-GGGPGGG-O(CH2)6CH3   Mw=935.26 g/mol 
(C12H25)2-N-OC-CH2-CH2-CO-GGGPGGG--O(CH2)6CH3  Mw=991.35 g/mol   
Each design in the set of SCMTR molecules explored here contains a 
variant of the R1 N-terminal domain; C18H37, C8H17, C10H21, and C12H25. The effects 
of such variations have been explored in the past, though only for the case of 
diglycolic acid linkers. In one of the most complete studies, the relative chloride 
release rates from liposomes with C3 to C18 N-terminated SCMTR molecules were 
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measured using chloride selective electrodes and fluorescence techniques 448. 
The result was that C8 produced the most rapid ion transport. The order of release 
rate was C8>C10>C6>C12>C3=C14=C18>C16 and the C-terminal in this case was a 
benzyl. A second study 449 explored both variation of the N- and C- terminal 
portions of the molecule using a chloride selective electrode and fluorescence 
data. Interestingly, it showed that for the case where the C-terminal was a heptyl 
instead of a benzyl, the shortest N-terminal was most active with C6>C10>C18. For 
the benzyl-terminated molecules they found that release rates were C10>C6>C18, 
which was consistent with the first study.  
The role of the C-terminal side of the molecules (R2) in chloride conduction 
was investigated in previous work 447,450 by examining structures that included 
alkanes with lengths from C2 to C18 with an ether linkage, alkanes with an amine 
linkage, diacylamides (e.g. -N[(CH2)9CH3]2) and the canonical benzyl. It was 
generally found that anion release rates from liposomes were highest for linear 
alkanes of length C7 and the didecylamide (-N[(CH2)9CH3]2). Thus, it is evident that 
both anchor chains are instrumental in channel formation. As with the N-terminal, 
it is surprising that the conductivity is maximized for chain lengths that are so much 
shorter than the fatty acid found in lipids, for example, DOPC contains 18 carbons. 
Another striking study indicated that the binding constant of the (Gly)3-Pro-(Gly)3 
is not affected by the length of alkyl groups450 and concentration studies using 
NMR implied no aggregation (no dimers or greater), however, the experiments 
were performed in CDCl3 (deuterated chloroform) and, therefore, in relatively 
different electrostatic environments.   
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All SCMTR molecules were synthesized by Dr. George Gokel’s group at the 
University of Missouri (St. Louis) via previously reported procedures438,439,447,451. 
They were then dissolved in DMSO (~0.45 mg/ml) and tested in asolectin (50 
mg/ml), DOPC: egg PE (20 mg/ml in decane) and DPhPC (20 mg/ml in decane). 
SCMTR 1 containing the amino acid sequence AAAPGGG showed the least 
activity of the molecules tested. Given that alanine has only a methyl side group, 
it is regarded as a hydrophobic amino acid.  Thus, it is not surprising that a lack of 
activity from the AAAPGGG sequence was observed since the nonpolar alanine 
interacting in the channel likely made ion passage energetically unfavorable. 
SCMTR 2 exhibited ion channel behavior in all cases except DPhPC and was most 
active in egg PC. In BLM experiments with asolectin, conductance states of 
12.2±2.5 pS and 19.3±2.6 pS at 90 mV were observed and in the egg PC system, 
two conductance states of 4.7±2.1 pS and 19.4±2.1 pS were detected at 150 mV. 
SCMTR 3 was more active than SCMTR 2. The two conductance values of 
18.2±1.4 pS and 25.6±2.8 pS were obtained at 120 mV in asolectin. 
SCMTR 4 was generally the most active ion channel tested, thus we 
observed the largest number of channel open events for a given concentration. As 
shown in Figure 6.2, at -65 mV two conductance states of 15.5±4.1 pS and 
27.8±3.1 pS were achieved in asolectin. While similar states of 18.8±1.6 and 
20.3±1.9 pS were observed in DOPC:egg PE system at 130 mV. This molecule 
was also inactive in DPhPC membranes. 
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Figure 6.2. Current vs. time with a 100 Hz low pass Bessel filter (left) and 
histogram of conductance (right) for 4 at -65 mV. Two conductance states of 
15.5±4.1 pS, 27.8±3.1 pS and the linear combination of the second state (52.0±3.8 
pS) are indicated. 
   The selectivity of SCMTR 4 was investigated by carefully replacing the 
0.5 M KCl electrolyte with 0.5 M K2SO4 at the same pH on one side of the 
membrane (trans compartment). Then the polarity of the applied voltage was 
switched from -50 mV to +50 mV to select anion flow from cis to trans 
compartments. Figure 6.3 illustrates the result of SCMTR selectivity to chloride 
ions over sulfate ions. Two conductance states were observed for both anions and 
measurements of the highest conductance state for each gives 6.9±2.0 pS for 
sulfate and 20.5±3.2 pS for chloride. Thus, the Cl- gave a 3-fold higher 
conductance than SO42-.  
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Figure 6.3. Current vs. time plot after replacing KCL with K2SO4 in trans 
compartment. The highest conductance state at positive and negative polarity is 
6.9±2.0 pS and 20.5±3.2 pS, respectively. 
   Molecules 3 and 4, i.e the most active, were tested in biomimetic 
membrane block co-polymers of poly(2-methyl-2-oxazoline) (PMOXA) and 
poly(dimethyl siloxane) (PDMS). Specifically, the diblock (PMOXA6-PDMS17) and 
the triblock (PMOXA6-PDMS35-PMOXA6) were examined as these materials have 
demonstrated reconstitution of alpha-hemolysin, alamethicin and gramicidin ion 
channels 452,453. No activity was observed in these cases. 
Three out of the four SCMTR molecules tested exhibited channel activity 
and in those cases at least two unique, well defined conductance states were 
observed. Typically, the first conductance state was between 4 and 18 pS while 
the second lay between 18 and 28 pS. The activity increased as the N-terminal 
alkanes reached 12 carbons with C12>C10>C8. This contrasts with previous reports 
of molecules having diglycolic acid (-COCH2OCH2CO-) as a linker that showed 
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activities following the sequence C6>C10>C18 instead of the succinyl (-
COCH2CH2CO-). The values showed weak dependence on the membrane 
composition and there was no clear indication of voltage dependent gating. It was 
further noteworthy that the activity of the samples seemed to degrade rapidly after 
being solvated in DMSO with samples losing all trace of channel behavior after 
about 2 weeks when stored at 4°C.  
While the exact mechanism for the formation of conductance channels by 
small molecules such as the SCMTR analogs remains an open question, recent 
work modifying the β-barrel436 of alpha-hemolysin to shorten the transmembrane 
section below the thickness of the lipid membrane have shown that it is still 
possible to obtain channel behavior. It is suggested436 that pores in such cases are 
formed by buckling of the lipids around the protein to form a hydrophilic ring.  
Further, molecular dynamics simulations of canonical SCMTR molecules by 
Burkhardt et al.454 support the hypothesis of membrane reorganization for the 
formation of water channels through the membrane and predicts conductance 
states with values between 55 and 126 pS.       
Appreciation is expressed for the financial support of this work from the J. 
B. Speed College of Engineering, University of Louisville. We also acknowledge 




OVERALL DISCUSSION AND CONCLUSION 
One-third of the global health issues and disease burden for women of age 
15-44 years is attributed to poor sexual and reproductive health outcomes455. 
These health burdens are mostly attributed to female reproductive viral and 
bacterial infections, such as HIV-1, HSV-2, and BV. These infections can enhance 
virus shedding in patients, stimulate immune cell infiltration to the localized region, 
and promote microscopic tears that enable epithelial and immune cells to be more 
susceptible to infection, thereby increasing the risk of HIV and HSV-2 co-infections. 
Given the diversity and magnitude of these unmet reproductive health needs, there 
is an urgent need to develop novel topical delivery platforms with multipurpose 
prevention that simultaneously target a diversity of sexually transmitted 
pathogens4. 
The overall goal of this work was to develop novel strategies to enhance the 
delivery and efficacy of active agents, including live probiotic cells, from 
intravaginal delivery platforms.  In addition, these dosage forms including NPs, NP-
fiber composites, and dual-electrospun mesh and layered fibers were designed 
and developed to help overcome challenges associated with current topical 
delivery platforms which include: transient release, inefficient loading, frequent 
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application, and low user adherence. Finally, these studies have shown that 
these delivery platforms can offer a safe and efficacious alternative to women with 
the potential to encapsulate a variety of agents ranging from small molecules to 
large proteins and even live probiotic cells.  
Combination therapy is one of the most promising strategies to decrease 
the global prevalence of STIs. A variety of ARVs have been developed to prevent 
HIV infection either before or after HIV exposure. While approximately 25 anti-HIV 
drugs currently exist, only a few of them, such as valaciclovir, foscarnet, and 
raltegravir, are dually efficacious against HSV-2 infection. One of the challenges 
with ARVs, currently used in treatment regimens, is the increased risk of drug-
resistance and the corresponding long-term side effects of administration. One 
option to help overcome these challenges is in the discovery and development of 
efficacious biological molecules, that have a demonstrated safety profile and are 
known to exert functional effect via different mechanisms of action. One of these 
candidates, GRFT, is as an antiviral lectin that has been shown to prevent both 
HIV-1 and HSV-2 infections and is currently in Phase I clinical trials against HIV-1 
infection456. Additionally, GRFT exhibits an excellent safety profile, with negligible 
induction of pro-inflammatory cytokines231,457 and has demonstrated synergy with 
other antiretrovirals222, suggesting the benefits of future co-administration 
strategies.  
In this work, we sought to develop new multipurpose formulations, 
comprised of Q-GRFT (an oxidation-resistant variant of GRFT) and an ARV (e.g. 
TFV, RAL, or DAP) to enhance the efficacy of active agents in preventing against 
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HIV-1 infection. These ARVs were selected due to their distinct chemical 
properties and different mechanisms of action and Q-GRFT was used as a 
promising biological candidate with potent antiviral properties. First, we showed 
that all active agents were successfully encapsulated in PLGA NPs with loading 
efficiency values in the range of 15 to 100%. In addition, all NP formulations 
provided ~20% release over two weeks in SVF. Next, each ARV, in free and 
encapsulated forms, was co-administered with Q-GRFT or Q-GRFT NPs to 
evaluate the impact of co-administration on prophylactic efficacy against HIV-1 in 
vitro. The in vitro efficacy of free versus encapsulated agents was subsequently 
evaluated against HIV-1 pseudovirus infection, showing that Q-GRFT NPs were 
4.1-fold more efficacious, relative to free Q-GRFT, while ARV-encapsulated NPs 
had similar IC50 values to the administration of each free ARV alone. In parallel, 
the potential of Q-GRFT and ARV co-administration in both free and encapsulated 
forms were evaluated. When free Q-GRFT was co-administered with each free 
ARV, synergistic interactions were observed for all co-administration groups with 
a 3.7 to 6.3-fold decrease in the IC50 of free Q-GRFT and a 2.8 to 5.6-fold reduction 
in the IC50 values of free ARVs. When Q-GRFT and ARVs were each encapsulated 
in NPs, synergistic interactions were observed for all formulation combinations. 
Specifically, the synergy between Q-GRFT- and DAP-encapsulated NPs 
significantly improved, relative to free Q-GRFT and free DAP co-administration, 
with 6 and 8.6-fold increases in efficacy, respectively.  
Based on these results, we selected the most synergistic co-administered 
formulations, Q-GRFT NPs and DAP NPs, and aimed to investigate the impact of 
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incorporating Q-GRFT and DAP in NP-fiber composites. DAP, a small hydrophobic 
molecule, showed a burst release followed by minimal release that was still within 
the in vitro IC50 range previously observed with DAP administration to TZM-bl cells. 
In comparison, the release profile of Q-GRFT, a large generally hydrophilic protein, 
followed an “S” shape, indicating two distinct release phases on day 1 and days 
42 through 60, each of which was followed by more gradual release. While the 
release profiles of these specific agents, provided by this platform, were less than 
ideal for prolonged delivery applications, it was worthwhile to investigate the 
incorporation and release of active agents with different hydrophilicities and sizes 
in a NP-fiber composite. In future work, the release profiles may be optimized by 
changing the NP content, outer layer polymer composition and thickness, and fiber 
diameter. 
In order to obtain a better understanding of the potential for polymeric 
dosage forms to incorporate ARVs, we used computational modeling to study 
intermolecular interactions between PLGA and TFV, RAL, and DAP. Molecular 
dynamic and molecular mechanic simulations indicated that hydrogen bonding 
between TFV and PLGA in the presence of water was weaker than between TFV 
and water in the same system, causing the drug to leach into the aqueous phase 
in the process of NP fabrication and causing low encapsulation efficacy. However, 
hydrogen bonding between the oxygen atom in the carbonyl group of PLGA and 
the hydrogen atom connected to the oxygen atom in RAL was stronger than RAL 
and the oxygen atom in water, resulting in high encapsulation efficacy for RAL 
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NPs. These results are in agreement with experimental loading values for TFV and 
RAL which were 15 and 100%. 
In parallel with concerns of viral reproductive infections, bacterial infections, 
such as BV, present the most frequent vaginal infection affecting around 33% of 
women, domestically and globally6,334,458 and have been shown to increase the risk 
of HIV-1 acquisition by up to 60%. Clinical studies have shown that BV may be 
responsible for a significant increase in reported HIV-1 infections in Africa7 and 
that women infected with BV have a higher risk of infecting their male partner. 
Balancing and restoring the vaginal flora using probiotic delivery may both treat 
BV and lessen female-to-male HIV-1 transmission. Therefore, two studies in this 
dissertation focused on developing novel probiotic dosage forms to potentially 
prevent and treat BV infection and recurrence. 
Traditional therapies such as oral and topical antibiotics have been used for 
BV treatment, showing an initially high treatment efficacy of 80%. However, there 
are challenges associated with antibiotic therapies including the risk of BV 
recurrence and the development of antibiotic-resistant bacteria. One promising 
approach is to use probiotics, such as Lactobacillus, to reduce BV symptoms and 
improve the endogenous vaginal microflora326-328, thereby “priming” the FRT for 
beneficial bacteria colonization and proliferation. Probiotic delivery for BV 
treatment has been preliminary explored with the focus on relatively transient 
therapy, that requires daily administration.  Current dosage forms, including gels, 
films, and tablets, used to deliver probiotics to the FRT are associated with low 
intravaginal residence time, which may result in transient protection, messiness 
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via leakage, and unfavorable discharge that can adversely impact user adherence 
and efficacy. Next-generation delivery platforms seek to address these challenges 
by providing long-term prophylactic and therapeutic alternatives. 
In these studies, we first demonstrated the safety and functional impact of 
blank and antibiotic rapid-dissolve PEO fibers for treatment in a murine model of 
BV infection. In vivo experiments showed that PEO fibers were relatively inert in 
the mouse vagina and did not adversely affect the tissue. Moreover, fibers that 
incorporated 100 µg/mg fiber metronidazole were capable of both preventing and 
treating G. vaginalis infection in a mouse model. From a materials perspective, the 
effect of different parameters including electrospinning solution, polymer type, and 
the incorporation of fresh or lyophilized probiotics on post-spin viability was 
assessed. Results showed that electrospinning solution and polymer type have 
minimal impact on probiotic viability, whereas the choice of fresh or lyophilized 
bacteria exerted a significant impact on probiotic viability. Overall, using fresh 
bacteria resulted in 4-logs higher viability, relative to the incorporation of lyophilized 
bacteria. In addition to evaluating post-spun probiotic viability, the long-term 
viability of probiotic fibers in different storage conditions was examined for up to 
90 d. When fibers were stored at room temperature, L. acidophilus viability 
decreased dramatically over the first few days, resulting in negligible viability after 
one month. Among all formulations, the highest L. acidophilus viability after 3 
months was observed in PEO fibers that were electrospun in MRS with glycerol 
and stored at -20°C. Lastly, for the first time, we showed that L. acidophilus PEO 
and PVA fibers administered at 107 and 108 CFU/mL (~2 and 20 mg of fiber per 
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mL media based on actual loading) can fully inhibit G. vaginalis growth (108 
CFU/mL) after 24 hr co-culture. Moreover, fibers at both concentrations completely 
inhibited G. vaginalis adherence to HeLa cells after 16 hr. 
Based on the promising results of this study, we sought to build upon these 
rapid-dissolve formulations to fabricate more complex fiber architectures 
composed of both hydrophilic and hydrophobic polymers to modulate probiotic 
release. Both mesh and layered architectures incorporating L. crispatus or L. 
acidophilus demonstrated high, therapeutically-relevant levels of probiotic release 
and lactic acid production for up to 14 d, resulting in a significant reduction in pH. 
In addition, soluble co-culture experiments showed that both mesh and layered 
fibers incorporating probiotics completely inhibit G. vaginalis growth after 48 hr. 
These results suggest that mesh fibers may offer a viable long-term probiotic 
alternative to daily antibiotic administration to maintain vaginal health, treat BV, 
and prevent BV recurrence. 
Conclusion and Future Work 
All of the presented studies showed promise to enhance the intravaginal 
delivery of agents to the FRT; however, moving forward, there are a variety of 
directions to pursue in future work. Regarding the NP delivery platforms developed 
for HIV-1 prevention, all of the selected ARVs were co-administered with Q-GRFT 
at equipotent ratios and demonstrated synergy. However, other ratios may be 
explored in future work to further increase synergy, in particular for NP-
encapsulated agents which may require loading and releaseoptimization as well. 
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In addition to the ratio of Q-GRFT:ARV, different administration times may be 
explored to optimize the efficacy of these active agents for utility in both prevention 
and treatment applications. In this study, the active agents were administered or 
co-administered 1 hr prior to virus administration which indicates their potential 
utility for prevention. However, due to the different mechanisms of action of these 
ARVs, administration of NPs simultaneous to or after virus infection may also 
demonstrate therapeutic effect against HIV-1 infection. Therefore, in future 
experiments, different temporal regimens may be evaluated to similarly assess 
efficacy and synergistic interactions between Q-GRFT and different ARVs. In 
addition to these in vitro experiments, in vivo experiments, which explore the 
impact of co-administration, may be conducted to determine release, distribution, 
retention, and corresponding efficacy of these active agents and delivery platforms 
as translated to an initial murine model of HIV-1 infection.  
In addition to NP co-administration, we demonstrated the potential of NP-
fiber composites to alter Q-GRFT and DAP release profiles; however, the in vitro 
efficacy was not explored. Therefore, the efficacy of NP-fiber composites that 
incorporate both Q-GRFT and DAP against HIV-1 infection may be explored in 
future work. Furthermore, the release profile for these and other active agents may 
be optimized by changing the NP content and altering the outer layer fiber 
thickness and polymer type.  
As we showed in our studies, PLGA NPs encapsulate ARVs and proteins 
with moderate loading. However, there are some challenges regarding the 
encapsulation of small hydrophilic molecules such as TFV. Molecular dynamic 
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simulations demonstrated that due to the stronger hydrogen bonding between TFV 
and water molecules, PLGA NPs cannot encapsulate TFV. Therefore, adding more 
reactive moieties to PLGA chains may improve the intermolecular interactions 
between the polymer and the drug, leading to higher loading. In the future, the 
effect of adding different functional groups, such as polyethylene glycol, to the 
polymer chain may be evaluated to tailor the interactions between TFV and PLGA, 
and to improve the loading of NPs.  
In addition to HIV-1 prevention, we aimed to develop a new delivery platform 
to treat BV infection. The first-generation rapid release PEO and PVA fibers 
incorporated probiotics with relatively high viability and stability under refrigerated 
and freezer conditions. However, probiotic viability and stability under different 
storage conditions may be further improved by incorporating other and more 
concentrated nutrient sources such as inulin, skim milk, and lactulose. Due to the 
preliminary in vitro efficacy observed with rapid-dissolve hydrophilic fibers, we 
evaluated more complex fiber architectures to provide a prolonged probiotic 
release to treat BV recurrence.  
While rapid-release fibers demonstrated initial promise in providing on-
demand protection against G. vaginalis infection, sustained-release probiotic fibers 
consisting of hydrophilic and hydrophobic polymers are anticipated to provide long-
term treatment for BV and may provide a new option to help restore the balance 
of beneficial bacteria to the FRT. Furthermore, one may envision that these fibers 
may be used prophylactically to help maintain female reproductive health in 
women who are considered at-risk for recurrent BV infections. In this work, both 
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mesh and layered fibers, comprised of PLGA and PEO were successfully 
fabricated to incorporate high concentrations of probiotics and to promote the 
sustained-release and localized proliferation of probiotics through two weeks. 
Electrospun fibers such as these, may offer women an alternative delivery platform 
that can provide localized delivery for a prolonged period of time, prompting less 
frequent administration by patients, which may enhance user adherence. 
Moreover, this delivery platform provided the opportunity to consider other 
technologies that may be suitable to even longer time frames of probiotic release, 
potentially offering women more alternatives.  
One potential direction of future work is to investigate the feasibility of fibers 
as multipurpose delivery platforms to deliver both probiotics and antiviral agents 
simultaneously to protect women against both BV recurrence and HIV-1 infection. 
Mention the possibility of antibiotic then antiviral phased administration – in this or 
another platform design.  From a release perspective, even though the delivery 
platform we developed demonstrated promise in sustaining probiotic release, other 
polymer compositions such as PCL and fiber architectures such as coaxial fibers 
may be explored to further enhance this delivery platform. Furthermore, due to the 
promising in vitro results regarding the efficacy of probiotic-containing fibers, we 
plan to examine their safety and efficacy in vaginal epithelial cells, EpiVaginalTM 
tissue, and in a more complex in vivo model. By doing so, we anticipate attaining 
a more in-depth understanding of host, microbe, and vehicular interactions via the 
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